### NUCLEIC ACIDS AND PROTEINS FROM STREPTOCOCCUS PNEUMONIAE

The present invention relates to proteins derived from *Streptococcus pneumoniae*, nucleic acid molecules encoding such proteins, the use of the nucleic acid and/or proteins as antigens/immunogens and in detection/diagnosis, as well as methods for screening the proteins/nucleic acid sequences as potential anti-microbial targets.

5

10

15

20

Streptococcus pneumoniae, commonly referred to as the pneumococcus, is an important pathogenic organism. The continuing significance of Streptoccocus pneumoniae infections in relation to human disease in developing and developed countries has been authoritatively reviewed (Fiber, G.R., Science, 265: 1385-1387 (1994)). That indicates that on a global scale this organism is believed to be the most common bacterial cause of acute respiratory infections, and is estimated to result in 1 million childhood deaths each year, mostly in developing countries (Stansfield, S.K., Pediatr. Infect. Dis., 6: 622 (1987)). In the USA it has been suggested (Breiman et al., Arch. Intern. Med., 150: 1401 (1990)) that the pneumococcus is still the most common cause of bacterial pneumonia, and that disease rates are particularly high in young children, in the elderly, and in patients with predisposing conditions such as asplenia, heart, lung and kidney disease, diabetes, alcoholism, or with immunosupressive disorders, especially AIDS. These groups are at higher risk of pneumococcal septicaemia and hence meningitis and therefore have a greater risk of dying from pneumococcal infection. The pneumococcus is also the leading cause of otitis media and sinusitis, which remain prevalent infections in children in developed countries, and which incur substantial costs.

The need for effective preventative strategies against pneumococcal infection is highlighted by the recent emergence of penicillin-resistant pneumococci. It has been reported that 6.6% of pneumoccal isolates in 13 US hospitals in 12 states were found to be resistant to penicillin and some isolates were also resistant to other antibiotics including third generation cyclosporins (Schappert, S.M., Vital and Health Statistics of

the Centres for Disease Control/National Centre for Health Statistics, 214:1 (1992)). The rates of penicillin resistance can be higher (up to 20%) in some hospitals (Breiman et al, J. Am. Med. Assoc., 271: 1831 (1994)). Since the development of penicillin resistance among pneumococci is both recent and sudden, coming after decades during which penicillin remained an effective treatment, these findings are regarded as alarming.

For the reasons given above, there are therefore compelling grounds for considering improvements in the means of preventing, controlling, diagnosing or treating pneumococcal diseases.

Various approaches have been taken in order to provide vaccines for the prevention of pneumococcal infections. Difficulties arise for instance in view of the variety of serotypes (at least 90) based on the structure of the polysaccharide capsule surrounding the organism. Vaccines against individual serotypes are not effective against other serotypes and this means that vaccines must include polysaccharide antigens from a whole range of serotypes in order to be effective in a majority of cases. An additional problem arises because it has been found that the capsular polysaccharides (each of which determines the serotype and is the major protective antigen) when purified and used as a vaccine do not reliably induce protective antibody responses in children under two years of age, the age group which suffers the highest incidence of invasive pneumococcal infection and meningitis.

A modification of the approach using capsule antigens relies on conjugating the polysaccharide to a protein in order to derive an enhanced immune response, particularly by giving the response T-cell dependent character. This approach has been used in the development of a vaccine against *Haemophilus influenzae*, for instance. There are, however, issues of cost concerning both the multi-polysaccharide vaccines and those based on conjugates.

A third approach is to look for other antigenic components which offer the potential to be vaccine candidates. This is the basis of the present invention. Using a specially developed bacterial expression system, we have been able to identify a group of protein antigens from pneomococcus which are associated with the bacterial envelope or which are secreted.

Thus, in a first aspect the present invention provides a *Streptococcus pneumoniae* protein or polypeptide having a sequence selected from those shown in table 1.

In a second aspect, the present invention provides a *Streptococcus pneumoniae* protein or polypeptide having a sequence selected from those shown in table 2.

A protein or polypeptide of the present invention may be provided in substantially pure form. For example, it may be provided in a form which is substantially free of other proteins.

As discussed herein, the proteins and polypeptides of the invention are useful as antigenic material. Such material can be "antigenic" and/or "immunogenic". Generally, "antigenic" is taken to mean that the protein or polypeptide is capable of being used to raise antibodies or indeed is capable of inducing an antibody response in a subject. "Immunogenic" is taken to mean that the protein or polypeptide is capable of eliciting a protective immune response in a subject. Thus, in the latter case, the protein or polypeptide may be capable of not only generating an antibody response but, in addition, a non-antibody based immune response.

25

15

20

5

The skilled person will appreciate that homologues or derivatives of the proteins or polypeptides of the invention will also find use in the context of the present invention, ie as antigenic/immunogenic material. Thus, for instance proteins or polypeptides which include one or more additions, deletions, substitutions or the like are encompassed by the

present invention. In addition, it may be possible to replace one amino acid with another of similar "type". For instance replacing one hydrophobic amino acid with another.

One can use a program such as the CLUSTAL program to compare amino acid sequences. This program compares amino acid sequences and finds the optimal alignment by inserting spaces in either sequence as appropriate. It is possible to calculate amino acid identity or similarity (identity plus conservation of amino acid type) for an optimal alignment. A program like BLASTx will align the longest stretch of similar sequences and assign a value to the fit. It is thus possible to obtain a comparison where several regions of similarity are found, each having a different score. Both types of identity analysis are contemplated in the present invention.

In the case of homologues and derivatives, the degree of identity with a protein or polypeptide as described herein is less important than that the homologue or derivative should retain the antigenicity or immunogenicity of the original protein or polypeptide. However, suitably, homologues or derivatives having at least 60% similarity (as discussed above) with the proteins or polypeptides described herein are provided. Preferably, homologues or derivatives having at least 70% similarity, more preferably at least 80% similarity are provided. Most preferably, homologues or derivatives having at least 90% or even 95% similarity are provided.

20

5

10

15

In an alternative approach, the homologues or derivatives could be fusion proteins, incorporating moieties which render purification easier, for example by effectively tagging the desired protein or polypeptide. It may be necessary to remove the "tag" or it may be the case that the fusion protein itself retains sufficient antigenicity to be useful.

25

In an additional aspect of the invention there are provided antigenic/immunogenic fragments of the proteins or polypeptides of the invention, or of homologues or derivatives thereof.

For fragments of the proteins or polypeptides described herein, or of homologues or derivatives thereof, the situation is slightly different. It is well known that is possible to screen an antigenic protein or polypeptide to identify epitopic regions, ie those regions which are responsible for the protein or polypeptide's antigenicity or immunogenicity. Methods for carrying out such screening are well known in the art. Thus, the fragments of the present invention should include one or more such epitopic regions or be sufficiently similar to such regions to retain their antigenic/immunogenic properties. Thus, for fragments according to the present invention the degree of identity is perhaps irrelevant, since they may be 100% identical to a particular part of a protein or polypeptide, homologue or derivative as described herein. The key issue, once again, is that the fragment retains the antigenic/immunogenic properties.

5

10

15

20

Thus, what is important for homologues, derivatives and fragments is that they possess at least a degree of the antigenicity/immunogenicity of the protein or polypeptide from which they are derived.

Gene cloning techniques may be used to provide a protein of the invention in substantially pure form. These techniques are disclosed, for example, in J. Sambrook *et al Molecular Cloning* 2nd Edition, Cold Spring Harbor Laboratory Press (1989). Thus, in a third aspect, the present invention provides a nucleic acid molecule comprising or consisting of a sequence which is:

- (i) any of the DNA sequences set out in Table 1 or their RNA equivalents;
- 25 (ii) a sequence which is complementary to any of the sequences of (i);
  - (iii) a sequence which codes for the same protein or polypeptide, as those sequences of (i) or (ii);

- (iv) a sequence which has substantial identity with any of those of (i), (ii) and (iii);
- (v) a sequence which codes for a homologue, derivative or fragment of aprotein as defined in Table 1.

In a fourth aspect the present invention provides a nucleic acid molecule comprising or consisting of a sequence which is:

10 (i) any of the DNA sequences set out in Table 2 or their RNA equivalents;

15

25

30

- (ii) a sequence which is complementary to any of the sequences of (i);
- (iii) a sequence which codes for the same protein or polypeptide, as those sequences of (i) or (ii);
  - (iv) a sequence which has substantial identity with any of those of (i), (ii) and (iii); or
- 20 (v) a sequence which codes for a homologue, derivative or fragment of a protein as defined in Table 2.

The nucleic acid molecules of the invention may include a plurality of such sequences, and/or fragments. The skilled person will appreciate that the present invention can include novel variants of those particular novel nucleic acid molecules which are exemplified herein. Such variants are encompassed by the present invention. These may occur in nature, for example because of strain variation. For example, additions, substitutions and/or deletions are included. In addition, and particularly when utilising microbial expression systems, one may wish to engineer the nucleic acid sequence by making use of known preferred codon usage in the particular organism being used for

expression. Thus, synthetic or non-naturally occurring variants are also included within the scope of the invention.

The term "RNA equivalent" when used above indicates that a given RNA molecule has a sequence which is complementary to that of a given DNA molecule (allowing for the fact that in RNA "U" replaces "T" in the genetic code).

When comparing nucleic acid sequences for the purposes of determining the degree of homology or identity one can use programs such as BESTFIT and GAP (both from the Wisconsin Genetics Computer Group (GCG) software package) BESTFIT, for example, compares two sequences and produces an optimal alignment of the most similar segments. GAP enables sequences to be aligned along their whole length and finds the optimal alignment by inserting spaces in either sequence as appropriate. Suitably, in the context of the present invention when discussing identity of nucleic acid sequences, the comparison is made by alignment of the sequences along their whole length.

Preferably, sequences which have substantial identity have at least 50% sequence identity, desirably at least 75% sequence identity and more desirably at least 90 or at least 95% sequence identity with said sequences. In some cases the sequence identity may be 99% or above.

Desirably, the term "substantial identity" indicates that said sequence has a greater degree of identity with any of the sequences described herein than with prior art nucleic acid sequences.

25

5

10

15

20

It should however be noted that where a nucleic acid sequence of the present invention codes for at least part of a novel gene product the present invention includes within its scope all possible sequence coding for the gene product or for a novel part thereof.

The nucleic acid molecule may be in isolated or recombinant form. It may be incorporated into a vector and the vector may be incorporated into a host. Such vectors and suitable hosts form yet further aspects of the present invention.

- Therefore, for example, by using probes based upon the nucleic acid sequences provided herein, genes in *Streptococcus pneumoniae* can be identified. They can then be excised using restriction enzymes and cloned into a vector. The vector can be introduced into a suitable host for expression.
- Nucleic acid molecules of the present invention may be obtained from *S.pneumoniae* by the use of appropriate probes complementary to part of the sequences of the nucleic acid molecules. Restriction enzymes or sonication techniques can be used to obtain appropriately sized fragments for probing.
- Alternatively PCR techniques may be used to amplify a desired nucleic acid sequence. Thus the sequence data provided herein can be used to design two primers for use in PCR so that a desired sequence, including whole genes or fragments thereof, can be targeted and then amplified to a high degree.
- Typically primers will be at least 15-25 nucleotides long.

As a further alternative chemical synthesis may be used. This may be automated. Relatively short sequences may be chemically synthesised and ligated together to provide a longer sequence.

25

30

There is another group of proteins from *S.pneumoniae* which have been identified using the bacterial expression system described herein. These are known proteins from *S.pneumoniae*, which have not previously been identified as antigenic proteins. The amino acid sequences of this group of proteins, together with DNA sequences coding for them are shown in Table 3. These proteins, or homologues, derivatives and/or

fragments thereof also find use as antigens/immunogens. Thus, in another aspect the present invention provides the use of a protein or polypeptide having a sequence selected from those shown in Tables 1-3, or homologues, derivatives and/or fragments thereof, as an immunogen/antigen.

5

10

25

30

In yet a further aspect the present invention provides an immunogenic/antigenic composition comprising one or more proteins or polypeptides selected from those whose sequences are shown in Tables 1-3, or homologues or derivatives thereof, and/or fragments of any of these. In preferred embodiments, the immunogenic/antigenic composition is a vaccine or is for use in a diagnostic assay.

In the case of vaccines suitable additional excipients, diluents, adjuvants or the like may be included. Numerous examples of these are well known in the art.

It is also possible to utilise the nucleic acid sequences shown in Tables 1-3 in the preparation of so-called DNA vaccines. Thus, the invention also provides a vaccine composition comprising one or more nucleic acid sequences as defined herein. DNA vaccines are described in the art (see for instance, Donnelly *et al*, *Ann. Rev. Immunol.*, **15**:617-648 (1997)) and the skilled person can use such art described techniques to produce and use DNA vaccines according to the present invention.

As already discussed herein the proteins or polypeptides described herein, their homologues or derivatives, and/or fragments of any of these, can be used in methods of detecting/diagnosing *S.pneumoniae*. Such methods can be based on the detection of antibodies against such proteins which may be present in a subject. Therefore the present invention provides a method for the detection/diagnosis of *S.pneumoniae* which comprises the step of bringing into contact a sample to be tested with at least one protein, or homologue, derivative or fragment thereof, as described herein. Suitably, the sample is a biological sample, such as a tissue sample or a sample of blood or saliva obtained from a subject to be tested.

In an alternative approach, the proteins described herein, or homologues, derivatives and/or fragments thereof, can be used to raise antibodies, which in turn can be used to detect the antigens, and hence *S.pneumoniae*. Such antibodies form another aspect of the invention. Antibodies within the scope of the present invention may be monoclonal or polyclonal.

Polyclonal antibodies can be raised by stimulating their production in a suitable animal host (e.g. a mouse, rat, guinea pig, rabbit, sheep, goat or monkey) when a protein as described herein, or a homologue, derivative or fragment thereof, is injected into the animal. If desired, an adjuvant may be administered together with the protein. Well-known adjuvants include Freund's adjuvant (complete and incomplete) and aluminium hydroxide. The antibodies can then be purified by virtue of their binding to a protein as described herein.

15

10

5

Monoclonal antibodies can be produced from hybridomas. These can be formed by fusing myeloma cells and spleen cells which produce the desired antibody in order to form an immortal cell line. Thus the well-known Kohler & Milstein technique (*Nature* **256** (1975)) or subsequent variations upon this technique can be used.

20

Techniques for producing monoclonal and polyclonal antibodies that bind to a particular polypeptide/protein are now well developed in the art. They are discussed in standard immunology textbooks, for example in Roitt *et al*, *Immunology* second edition (1989), Churchill Livingstone, London.

25

30

In addition to whole antibodies, the present invention includes derivatives thereof which are capable of binding to proteins etc as described herein. Thus the present invention includes antibody fragments and synthetic constructs. Examples of antibody fragments and synthetic constructs are given by Dougall *et al* in *Tibtech* **12** 372-379 (September 1994).

Antibody fragments include, for example, Fab, F(ab')<sub>2</sub> and Fv fragments. Fab fragments (These are discussed in Roitt *et al* [*supra*]). Fv fragments can be modified to produce a synthetic construct known as a single chain Fv (scFv) molecule. This includes a peptide linker covalently joining V<sub>h</sub> and V<sub>1</sub> regions, which contributes to the stability of the molecule. Other synthetic constructs that can be used include CDR peptides. These are synthetic peptides comprising antigen-binding determinants. Peptide mimetics may also be used. These molecules are usually conformationally restricted organic rings that mimic the structure of a CDR loop and that include antigen-interactive side chains.

10

15

20

25

30

5

Synthetic constructs include chimaeric molecules. Thus, for example, humanised (or primatised) antibodies or derivatives thereof are within the scope of the present invention. An example of a humanised antibody is an antibody having human framework regions, but rodent hypervariable regions. Ways of producing chimaeric antibodies are discussed for example by Morrison *et al* in PNAS, **81**, 6851-6855 (1984) and by Takeda *et al* in Nature. **314**, 452-454 (1985).

Synthetic constructs also include molecules comprising an additional moiety that provides the molecule with some desirable property in addition to antigen binding. For example the moiety may be a label (e.g. a fluorescent or radioactive label). Alternatively, it may be a pharmaceutically active agent.

Antibodies, or derivatives thereof, find use in detection/diagnosis of *S.pneumoniae*. Thus, in another aspect the present invention provides a method for the detection/diagnosis of *S.pneumoniae* which comprises the step of bringing into contact a sample to be tested and antibodies capable of binding to one or more proteins described herein, or to homologues, derivatives and/or fragments thereof.

In addition, so-called "Affibodies" may be utilised. These are binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain

(Nord et al, ) Thus, Small protein domains, capable of specific binding to different target proteins can be selected using combinatorial approaches.

It will also be clear that the nucleic acid sequences described herein may be used to detect/diagnose *S.pneumoniae*. Thus, in yet a further aspect, the present invention provides a method for the detection/diagnosis of *S.pneumoniae* which comprises the step of bringing into contact a sample to be tested with at least one nucleic acid sequence as described herein. Suitably, the sample is a biological sample, such as a tissue sample or a sample of blood or saliva obtained from a subject to be tested. Such samples may be pre-treated before being used in the methods of the invention. Thus, for example, a sample may be treated to extract DNA. Then, DNA probes based on the nucleic acid sequences described herein (ie usually fragments of such sequences) may be used to detect nucleic acid from *S.pneumoniae*.

## 15 In additional aspects, the present invention provides:

5

10

20

- (a) a method of vaccinating a subject against *S.pneumoniae* which comprises the step of administering to a subject a protein or polypeptide of the invention, or a derivative, homologue or fragment thereof, or an immunogenic composition of the invention;
- (b) a method of vaccinating a subject against *S.pneumoniae* which comprises the step of administering to a subject a nucleic acid molecule as defined herein;
- 25 (c) a method for the prophylaxis or treatment of *S.pneumoniae* infection which comprises the step of administering to a subject a protein or polypeptide of the invention, or a derivative, homologue or fragment thereof, or an immunogenic composition of the invention;
- 30 (d) a method for the prophylaxis or treatment of S.pneumoniae infection which

comprises the step of administering to a subject a nucleic acid molecule as defined herein;

(e) a kit for use in detecting/diagnosing *S.pneumoniae* infection comprising one or more proteins or polypeptides of the invention, or homologues, derivatives or fragments thereof, or an antigenic composition of the invention; and

5

10

15

20

(f) a kit for use in detecting/diagnosing *S.pneumoniae* infection comprising one or more nucleic acid molecules as defined herein.

Given that we have identified a group of important proteins, such proteins are potential targets for anti-microbial therapy. It is necessary, however, to determine whether each individual protein is essential for the organism's viability. Thus, the present invention also provides a method of determining whether a protein or polypeptide as described herein represents a potential anti-microbial target which comprises antagonising, inhibiting or otherwise interfering with the function or expression of said protein and determining whether *S.pneumoniae* is still viable.

A suitable method for inactivating the protein is to effect selected gene knockouts, ie prevent expression of the protein and determine whether this results in a lethal change. Suitable methods for carrying out such gene knockouts are described in Li et al, P.N.A.S., 94:13251-13256 (1997) and Kolkman et al, 178:3736-3741 (1996).

- In a final aspect the present invention provides the use of an agent capable of antagonising, inhibiting or otherwise interfering with the function or expression of a protein or polypeptide of the invention in the manufacture of a medicament for use in the treatment or prophylaxis of *S. pneumoniae* infection.
- As mentioned above, we have used a bacterial expression system as a means of

identifying those proteins which are surface associated, secreted or exported and thus, would find use as antigens.

The information necessary for the secretion/export of proteins has been extensively studied in bacteria. In the majority of cases, protein export requires a signal peptide to be present at the N-terminus of the precursor protein so that it becomes directed to the translocation machinery on the cytoplasmic membrane. During or after translocation, the signal peptide is removed by a membrane associated signal peptidase. Ultimately the localization of the protein (i.e. whether it be secreted, an integral membrane protein or attached to the cell wall) is determined by sequences other than the leader peptide itself.

We are specifically interested in surface located or exported proteins as these are likely to be antigens for use in vaccines, as diagnostic reagents or as targets for therapy with novel chemical entities. We have therefore developed a screening vector-system in *Lactococcus lactis* that permits genes encoding exported proteins to be identified and isolated. We provide below a representative example showing how given novel surface associated proteins from *Streptococcus pneumoniae* have been identified and characterized. The screening vector incorporates the staphylococcal nuclease gene *nuc* lacking its own export signal as a secretion reporter. Staphylococcal nuclease is a naturally secreted heat-stable, monomeric enzyme which has been efficiently expressed and secreted in a range of Gram positive bacteria (Shortle, *Gene*, 22:181-189 (1983); Kovacevic *et al.*, *J. Bacteriol.*, 162:521-528 (1985); Miller *et al.*, *J. Bacteriol.*, 169:3508-3514 (1987); Liebl *et al.*, *J. Bacteriol.*, 174:1854-1861 (1992); Le Loir *et al.*, *J. Bacteriol.*, 176:5135-5139 (1994); Poquet *et al.*, *J. Bacteriol.*, 180:1904-1912 (1998)).

Recently, Poquet *et al.* ((1998), *supra*) have described a screening vector incorporating the *nuc* gene lacking its own signal leader as a reporter to identify exported proteins in Gram positive bacteria, and have applied it to *L. lactis*. This

vector (pFUN) contains the pAMβ1 replicon which functions in a broad host range of Gram-positive bacteria in addition to the ColE1 replicon that promotes replication in Escherichia coli and certain other Gram negative bacteria. Unique cloning sites present in the vector can be used to generate transcriptional and translational fusions between cloned genomic DNA fragments and the open reading frame of the truncated nuc gene devoid of its own signal secretion leader. The nuc gene makes an ideal reporter gene because the secretion of nuclease can readily be detected using a simple and sensitive plate test: Recombinant colonies secreting the nuclease develop a pink halo whereas control colonies remain white (Shortle, (1983), supra; Le Loir et al.,

10 (1994), supra).

> Thus, the invention will now be described with reference to the following representative example, which provides details of how the proteins, polypeptides and nucleic acid sequences described herein identified as antigenic targets.

15

5

We describe herein the construction of three reporter vectors and their use in L. lactis to identify and isolate genomic DNA fragments from Streptococcus pneumoniae encoding secreted or surface associated proteins.

The invention will now be described with reference to the examples, which should not 20 be construed as in any way limiting the invention. The examples refer to the figures in which:

Figure 1: shows the results of a number of DNA vaccine trials; and

Figure 2: shows the results of further DNA vaccine trials.

## **EXAMPLE 1**

(i) Construction of the pTREP1-nuc series of reporter vectors

30

25

## (a) Construction of expression plasmid pTREP1

The pTREP1 plasmid is a high-copy number (40-80 per cell) theta-replicating gram positive plasmid, which is a derivative of the pTREX plasmid which is itself a derivative of the previously published pIL253 plasmid. pIL253 incorporates the broad Gram-positive host range replicon of pAMβ1 (Simon and Chopin, *Biochimie*, **70**:559-567 (1988)) and is non-mobilisable by the *L lactis* sex-factor. pIL253 also lacks the *tra* function which is necessary for transfer or efficient mobilisation by conjugative parent plasmids exemplified by pIL501. The Enterococcal pAMβ1 replicon has previously been transferred to various species including *Streptococcus*, *Lactobacillus* and *Bacillus* species as well as *Clostridium acetobutylicum*, (Oultram and Klaenhammer, *FEMS Microbiological Letters*, **27**:129-134 (1985); Gibson *et al.*, (1979); LeBlanc *et al.*, *Proceedings of the National Academy of Science USA*, **75**:3484-3487 (1978)) indicating the potential broad host range utility. The pTREP1 plasmid represents a constitutive transcription vector.

The pTREX vector was constructed as follows. An artificial DNA fragment containing a putative RNA stabilising sequence, a translation initiation region (TIR), a multiple cloning site for insertion of the target genes and a transcription terminator was created by annealing 2 complementary oligonucleotides and extending with Tfl DNA polymerase. The sense and anti-sense oligonucleotides contained the recognition sites for NheI and BamHI at their 5' ends respectively to facilitate cloning. This fragment was cloned between the XbaI and BamHI sites in pUC19NT7, a derivative of pUC19 which contains the T7 expression cassette from pLET1 (Wells *et al., J. Appl. Bacteriol.*, 74:629-636 (1993)) cloned between the EcoRI and HindIII sites. The resulting construct was designated pUCLEX. The complete expression cassette of pUCLEX was then removed by cutting with HindIII and blunting followed by cutting with EcoRI before cloning into EcoRI and SacI (blunted) sites of pIL253 to generate the vector pTREX (Wells and Schofield, *In Current advances in metabolism, genetics and applications-NATO ASI Series*, H 98:37-62 (1996)). The putative RNA stabilising

sequence and TIR are derived from the *Escherichia coli* T7 bacteriophage sequence and modified at one nucleotide position to enhance the complementarity of the Shine Dalgarno (SD) motif to the ribosomal 16s RNA of *Lactococcus lactis* (Schofield *et al.* pers. coms. University of Cambridge Dept. Pathology.).

5

10

A Lactococcus lactis MG1363 chromosomal DNA fragment exhibiting promoter activity which was subsequently designated P7 was cloned between the EcoRI and BglII sites present in the expression cassette, creating pTREX7. This active promoter region had been previously isolated using the promoter probe vector pSB292 (Waterfield *et al*, Gene, 165:9-15 (1995)). The promoter fragment was amplified by PCR using the Vent DNA polymerase according to the manufacturer.

The pTREP1 vector was then constructed as follows. An artificial DNA fragment

15

20

25

which included a transcription terminator, the forward pUC sequencing primer, a promoter multiple -cloning site region and a universal translation stop sequence was created by annealing two overlapping partially complementary synthetic oligonucleotides together and extending with sequenase according to manufacturers instructions. The sense and anti-sense (pTREPF and pTREPR) oligonucleotides contained the recognition sites for EcoRV and BamHI at their 5' ends respectively to facilitate cloning into pTREX7. The transcription terminator was that of the Bacillus penicillinase gene, which has been shown to be effective in Lactococcus (Jos et al., Applied and Environmental Microbiology, 50:540-542 (1985)). This was considered necessary as expression of target genes in the pTREX vectors was observed to be leaky and is thought to be the result of cryptic promoter activity in the origin region (Schofield et al. pers. coms. University of Cambridge Dept. Pathology.). The forward pUC primer sequencing was included to enable direct sequencing of cloned DNA fragments. The translation stop sequence which encodes a stop codon in 3 different frames was included to prevent translational fusions between vector genes and cloned DNA fragments. The pTREX7 vector was first digested with EcoRI and blunted using the 5' - 3' polymerase activity of T4 DNA polymerase (NEB) according to

30

manufacturer's instructions. The EcoRI digested and blunt ended pTREX7 vector was then digested with Bgl II thus removing the P7 promoter. The artificial DNA fragment derived from the annealed synthetic oligonucleotides was then digested with EcoRV and Bam HI and cloned into the EcoRI(blunted)-Bgl II digested pTREX7 vector to generate pTREP. A *Lactococcus lactis* MG1363 chromosomal promoter designated P1 was then cloned between the EcoRI and BglII sites present in the pTREP expression cassette forming pTREP1. This promoter was also isolated using the promoter probe vector pSB292 and characterised by Waterfield *et al.*, (1995), *supra*. The P1 promoter fragment was originally amplified by PCR using vent DNA polymerase according to manufacturers instructions and cloned into the pTREX as an EcoRI-BglII DNA fragment. The EcoRI-BglII P1 promoter containing fragment was removed from pTREX1 by restriction enzyme digestion and used for cloning into pTREP (Schofield *et al.*, pers. coms. University of Cambridge, Dept. Pathology.).

## (b) PCR amplification of the S. aureus nuc gene.

The nucleotide sequence of the *S. aureus nuc* gene (EMBL database accession number V01281) was used to design synthetic oligonucleotide primers for PCR amplification. The primers were designed to amplify the mature form of the nuc gene designated nucA which is generated by proteolytic cleavage of the N-terminal 19 to 21 amino acids of the secreted propeptide designated Snase B (Shortle, (1983), *supra*). Three sense primers (nucS1, nucS2 and nucS3, Appendix 1) were designed, each one having a blunt-ended restriction endonuclease cleavage site for EcoRV or SmaI in a different reading frame with respect to the nuc gene. Additionally BgIII and BamHI were incorporated at the 5' ends of the sense and anti-sense primers respectively to facilitate cloning into BamHI and BgIII cut pTREP1. The sequences of all the primers are given in Appendix 1. Three nuc gene DNA fragments encoding the mature form of the nuclease gene (NucA) were amplified by PCR using each of the sense primers combined with the anti-sense primer described above. The nuc gene fragments were amplified by PCR using *S. aureus* genomic DNA template, Vent DNA Polymerase

(NEB) and the conditions recommended by the manufacturer. An initial denaturation step at 93 °C for 2 min was followed by 30 cycles of denaturation at 93 °C for 45 sec, annealing at 50 °C for 45 seconds, and extension at 73 °C for 1 minute and then a final 5 min extension step at 73 °C. The PCR amplified products were purified using a Wizard clean up column (Promega) to remove unincorporated nucleotides and primers.

## (c) Construction of the pTREP1-nuc vectors

5

25

10 The purified nuc gene fragments described in section b were digested with Bgl II and BamHI using standard conditions and ligated to BamHI and BglII cut and dephosphorylated pTREP1 to generate the pTREP1-nuc1, pTREP1-nuc2 and pTREP1-nuc3 series of reporter vectors. General molecular biology techniques were carried out using the reagents and buffer supplied by the manufacture or using 15 standard conditions(Sambrook and Maniatis, (1989), supra). In each of the pTREP1nuc vectors the expression cassette comprises a transcription terminator, lactococcal promoter P1, unique cloning sites (BgIII, EcoRV or SmaI) followed by the mature form of the nuc gene and a second transcription terminator. Note that the sequences required for translation and secretion of the nuc gene were deliberately excluded in 20 this construction. Such elements can only be provided by appropriately digested foreign DNA fragments (representing the target bacterium) which can be cloned into the unique restriction sites present immediately upstream of the *nuc* gene.

In possessing a promoter, the pTREP1-nuc vectors differ from the pFUN vector described by Poquet *et al.* (1998), *supra*, which was used to identify *L. lactis* exported proteins by screening directly for Nuc activity directly in *L. lactis*. As the pFUN vector does not contain a promoter upstream of the *nuc* open reading frame the cloned genomic DNA fragment must also provide the signals for transcription in addition to those elements required for translation initiation and secretion of Nuc. This limitation

may prevent the isolation of genes that are distant from a promoter for example genes which are within polycistronic operons. Additionally there can be no guarantee that promoters derived from other species of bacteria will be recognised and functional in *L. lactis*. Certain promoters may be under stringent regulation in the natural host but not in *L. lactis*. In contrast, the presence of the P1 promoter in the pTREP1-nuc series of vectors ensures that promoterless DNA fragments (or DNA fragments containing promoter sequences not active in *L. lactis*) will still be transcribed.

## (d) Screening for secreted proteins in S. pneumoniae

10

15

20

25

5

Genomic DNA isolated from S. pneumoniae was digested with the restriction enzyme Tru9I. This enzyme which recognises the sequence 5'- TTAA -3' was used because it cuts A/T rich genomes efficiently and can generate random genomic DNA fragments within the preferred size range (usually averaging 0.5 - 1.0 kb). This size range was preferred because there is an increased probability that the P1 promoter can be utilised to transcribe a novel gene sequence. However, the P1 promoter may not be necessary in all cases as it is possible that many Streptococcal promoters are recognised in L. lactis. DNA fragments of different size ranges were purified from partial Tru9I digests of S. pneumoniae genomic DNA. As the Tru 9I restriction enzyme generates staggered ends the DNA fragments had to be made blunt ended before ligation to the EcoRV or Smal cut pTREP1-nuc vectors. This was achieved by the partial fill-in enzyme reaction using the 5'-3' polymerase activity of Klenow enzyme. Briefly Tru9I digested DNA was dissolved in a solution (usually between 10-20 µl in total) supplemented with T4 DNA ligase buffer (New England Biolabs; NEB) (1X) and 33 µM of each of the required dNTPs, in this case dATP and dTTP. Klenow enzyme was added (1 unit Klenow enzyme (NEB) per µg of DNA) and the reaction incubated at 25°C for 15 minutes. The reaction was stopped by incubating the mix at 75°C for 20 minutes. EcoRV or Smal digested pTREP-nuc plasmid DNA was then added (usually between 200-400 ng). The mix was then supplemented with 400 units of T4 DNA ligase (NEB) and T4 DNA ligase buffer (1X) and incubated overnight at 16°C. The ligation mix was precipitated directly in 100% Ethanol and 1/10 volume of 3M sodium acetate (pH 5.2) and used to transform L. lactis MG1363 (Gasson, 1983). Alternatively, the gene cloning site of the pTREP-nuc vectors also contains a BgIII site which can be used to clone for example Sau3AI digested genomic DNA fragments.

L. lactis transformant colonies were grown on brain heart infusion agar and nuclease secreting (Nuc<sup>+</sup>) clones were detected by a toluidine blue-DNA-agar overlay (0.05 M Tris pH 9.0, 10 g of agar per litre, 10 g of NaCl per liter, 0.1 mM CaCl2, 0.03% wt/vol. salmon sperm DNA and 90 mg of Toluidine blue O dye) essentially as described by Shortle, 1983, supra and Le Loir et al., 1994, supra). The plates were then incubated at 37°C for up to 2 hours. Nuclease secreting clones develop an easily identifiable pink halo. Plasmid DNA was isolated from Nuc+ recombinant L. lactis clones and DNA inserts were sequenced on one strand using the NucSeq sequencing primer described in Appendix 1, which sequences directly through the DNA insert.

15

20

10

5

# **Isolation of Genes Encoding Exported Proteins from** S. pneumoniae

A large number of gene sequences putatively encoding exported proteins in S. pneumoniae have been identified using the nuclease screening system. These have now been further analysed to remove artefacts. The sequences identified using the screening system have been analysed using a number of parameters.

1. All putative surface proteins were analysed for leader/signal peptide 25 sequences using the software programs Sequencher (Gene Codes Corporation) and DNA Strider (Marck, Nucleic Acids Res., 16:1829-1836 (1988)). Bacterial signal peptide sequences share a common design. They are characterised by a short positively charged N-terminus (N region) immediately preceding a stretch of hydrophobic residues (central portion-h region) followed by a more polar C-terminal portion which contains the cleavage site (c-region). Computer software is available

30

which allows hydropathy profiling of putative proteins and which can readily identify the very distinctive hydrophobic portion (h-region) typical of leader peptide sequences. In addition, the sequences were checked for the presence of or absence of a potential ribosomal binding site (Shine-Dalgarno motif) required for translation initiation of the putative nuc reporter fusion protein.

- 2. All putative surface protein sequences were also matched with all of the protein/DNA sequences using the publicly databases [OWL-proteins inclusive of SwissProt and GenBank translations]. This allows us to identify sequences similar to known genes or homologues of genes for which some function has been ascribed. Hence it has been possible to predict a function for some of the genes identified using the LEEP system and to unequivocally establish that the system can be used to identify and isolate gene sequences of surface associated proteins. We should also be able to confirm that these proteins are indeed surface related and not artifacts. The LEEP system has been used to identify novel gene targets for vaccine and therapy.
- 3. Some of the genes identified proteins did not possess a typical leader peptide sequence and did not show homology with any DNA/protein sequences in the database. Indeed these proteins may indicate the primary advantage of our screening method, i.e. the isolation of atypical surface-related proteins, which may have been missed in all previously described screening protocols or approaches based on sequence homology searches.

In all cases, only partial gene sequences were initially obtained. Full length genes were obtained in all cases by reference to the TIGR *S.pneumoniae* database (www@tigr.org). Thus, by matching the originally obtained partial sequences with the database, we were able to identify the full length gene sequences. In this way, as described herein, three groups of genes were clearly identified, ie a group of genes encoding previously unidentified *S.pneumoniae* proteins, a second group exhibiting some homology with known proteins from a variety of sources and a third group which encoded known *S.pneumoniae* proteins, which were, however, not known as antigens.

# **Example 2: Vaccine trials**

## pcDNA3.1+ as a DNA vaccine vector

## pcDNA3.1+

5

30

35

The vector chosen for use as a DNA vaccine vector was pcDNA3.1 (Invitrogen) (actually pcDNA3.1+, the forward orientation was used in all cases but may be 10 referred to as pcDNA3.1 here on). This vector has been widely and successfully employed as a host vector to test vaccine candidate genes to give protection against pathogens in the literature (Zhang, et al., Kurar and Splitter, Anderson et al.). The vector was designed for high-level stable and non-replicative transient expression in mammalian cells. pcDNA3.1 contains the ColE1 origin of replication which allows convenient high-copy number replication and growth in E. coli. This in turn allows 15 rapid and efficient cloning and testing of many genes. The pcDNA3.1 vector has a large number of cloning sites and also contains the gene encoding ampicillin resistance to aid in cloning selection and the human cytomegalovirus (CMV) immediate-early promoter/enhancer which permits efficient, high-level expression of 20 the recombinant protein. The CMV promoter is a strong viral promoter in a wide range of cell types including both muscle and immune (antigen presenting) cells. This is important for optimal immune response as it remains unknown as to which cells types are most important in generating a protective response in vivo. A T7 promoter upstream of the multiple cloning site affords efficient expression of the modified 25 insert of interest and which allows in vitro transcription of a cloned gene in the sense orientation.

Zhang, D., Yang, X., Berry, J. Shen, C., McClarty, G. and Brunham, R.C. (1997) "DNA vaccination with the major outer-membrane protein genes induces acquired immunity to *Chlamydia trachomatis* (mouse pneumonitis) infection". *Infection and Immunity*, **176**, 1035-40.

Kurar, E. and Splitter, G.A. (1997) "Nucleic acid vaccination of *Brucella abortus* ribosomal *L7/L12* gene elicits immune response". *Vaccine*, **15**, 1851-57.

Anderson, R., Gao, X.-M., Papakonstantinopoulou, A., Roberts, M. and Dougan, G. (1996) "Immune response in mice following immunisation with DNA encoding fragment C of tetanus toxin". *Infection and Immunity*, **64**, 3168-3173.

## 40 **Preparation of DNA vaccines**

Oligonucleotide primers were designed for each individual gene of interest derived using the LEEP system. Each gene was examined thoroughly, and where possible,

primers were designed such that they targeted that portion of the gene thought to encode only the mature portion of the gene protein. It was hoped that expressing those sequences that encode only the mature portion of a target gene protein, would facilitate its correct folding when expressed in mammalian cells. For example, in the majority of cases primers were designed such that putative N-terminal signal peptide sequences would not be included in the final amplification product to be cloned into the pcDNA3.1 expression vector. The signal peptide directs the polypeptide precursor to the cell membrane via the protein export pathway where it is normally cleaved off by signal peptidase I (or signal peptidase II if a lipoprotein). Hence the signal peptide does not make up any part of the mature protein whether it be displayed on the surface of the bacteria surface or secreted. Where an N-terminal leader peptide sequence was not immediately obvious, primers were designed to target the whole of the gene sequence for cloning and ultimately, expression in pcDNA3.1.

- Having said that, however, other additional features of proteins may also affect the expression and presentation of a soluble protein. DNA sequences encoding such features in the genes encoding the proteins of interest were excluded during the design of oligonucleotides. These features included:
- 20 1. LPXTG (SEQ ID NO: 182) cell wall anchoring motifs.
  - 2. LXXC (SEQ ID NO: 197) ipoprotein attachment sites.
  - 3. Hydrophobic C-terminal domain.
  - 4. Where no N-terminal signal peptide or LXXC (SEQ ID NO: 197) was present the start codon was excluded.
- 5. Where no hydrophobic C-terminal domain or LPXTG (SEQ ID NO: 182) motif was present the stop codon was removed.

Appropriate PCR primers were designed for each gene of interest and any and all of the regions encoding the above features was removed from the gene when designing 30 these primers. The primers were designed with the appropriate enzyme restriction site followed by a conserved Kozak nucleotide sequence (in most cases(NB except in occasional instances for example ID59) GCCACC was used. The Kozak sequence facilitates the recognition of initiator sequences by eukaryotic ribosomes) and an ATG start codon upstream of the insert of the gene of interest. For example the forward 35 primer using a BamH1 site the primer would begin GCGGGATCCGCCACCATG (SEQ ID NO: 183) followed by a small section of the 5' end of the gene of interest. The reverse primer was designed to be compatible with the forward primer and with a Not1 restriction site at the 5' end in most cases (this site is TTGCGGCCGC) (SEQ ID NO: 184) (NB except in occasional instances for example ID59 where a Xho1 site was 40 used instead of Not1).

## **PCR** primers

The following PCR primers were designed and used to amplify the truncated genes of interest.

ID5

5

Forward Primer (SEQ ID NO: 185)
5' CGGATCCGCCACCATGGGTCTAATTGAAGACTTAAAAAATCAA 3'

Reverse Primer (SEQ ID NO: 186)

10 5' TTGCGGCCGCCAATGCTAGACTAAACACAAGACTCA 3'

**ID59** 

Forward Primer (SEQ ID NO: 187)

15 5' CGCGGATCCATGAAAAAAATCTATTCATTTTTAGCA 3'

Reverse Primer (SEQ ID NO: 188)

5' CCCTCGAGGGCTACTTCCGATACATTTTAAACTGTAGG 3'

20 ID51

Forward Primer (SEQ ID NO: 189)

5' CGGATCCGCCACCATGAGTCATGTCGCTGCAAATG 3'

Reverse Primer (SEQ ID NO: 190)

25 5' TTGCGGCCGCATACCAAACGCTGACATCTACG 3'

**ID29** 

Forward Primer (SEQ ID NO: 191)

30 5' CGGATCCGCCACCATGCAAAAAGAGCGGTATGGTTATG 3'

Reverse Primer (SEO ID NO: 192)

5' TTGCGGCCGCACCCCCATTCTTAATCCCTT 3'

ID50

35

40

Forward Primer (SEQ ID NO: 193)

5' CGGATCCGCCACCATGGAGGTATGTGAAATGTCACGTAAA 3'

Reverse Primer (SEQ ID NO: 194)

5' TTGCGGCCGCTTTTACAAAGTCAAGCAAAGCC 3'

Cloning

The insert along with the flanking features described above was amplified using PCR against a template of genomic DNA isolated from type 4 S. pneumoniae strain 11886

obtained from the National Collection of Type Cultures. The PCR product was cut with the appropriate restriction enzymes and cloned in to the multiple cloning site of pcDNA3.1 using conventional molecular biological techniques. Suitably mapped clones of the genes of interested were cultured and the plasmids isolated on a large scale (>1.5 mg) using Plasmid Mega Kits (Qiagen). Successful cloning and maintenance of genes was confirmed by restriction mapping and sequencing ~700 base pairs through the 5' cloning junction of each large scale preparation of each construct.

## 10 Strain validation

5

15

20

25

A strain of type 4 was used in cloning and challenge methods which is the strain from which the *S. pneumoniae* genome was sequenced. A freeze dried ampoule of a homogeneous laboratory strain of type 4 *S. pneumoniae* strain NCTC 11886 was obtained from the National Collection of Type Strains. The ampoule was opened and the cultured re suspended with 0.5 ml of tryptic soy broth (0.5% glucose, 5% blood). The suspension was subcultured into 10 ml tryptic soy broth (0.5% glucose, 5% blood) and incubated statically overnight at 37°C. This culture was streaked on to 5% blood agar plates to check for contaminants and confirm viability and on to blood agar slopes and the rest of the culture was used to make 20% glycerol stocks. The slopes were sent to the Public Health Laboratory Service where the type 4 serotype was confirmed.

A glycerol stock of NCTC 11886 was streaked on a 5% blood agar plate and incubated overnight in a CO2 gas jar at 37°C. Fresh streaks were made and optochin sensitivity was confirmed.

## Pneumococcal challenge

A standard inoculum of type 4 *S. pneumoniae* was prepared and frozen down by passaging a culture of pneumococcus 1x through mice, harvesting from the blood of infected animals, and grown up to a predetermined viable count of around 10<sup>9</sup> cfu/ml in broth before freezing down. The preparation is set out below as per the flow chart.

Streak pneumococcal culture and confirm identity




Grow over-night culture from 4-5 colonies on plate above



40

35



specific target-gene sequence of interest. A total of 100 µg of DNA in Dulbecco's PBS (Sigma) was injected intramuscularly into the tibialis anterior muscle of both legs (50 µl in each leg). A boost was carried using the same procedure 4 weeks later. For

comparison, control groups were included in all vaccine trials. These control groups were either unvaccinated animals or those administered with non-recombinant pcDNA3.1+ DNA (sham vaccinated) only, using the same time course described above. 3 weeks after the second immunisation, all mice groups were challenged intranasally with a lethal dose of S. pneumoniae serotype 4 (strain NCTC 11886). The number of bacteria administered was monitored by plating serial dilutions of the inoculum on 5% blood agar plates. A problem with intranasal immunisations is that in some mice the inoculum bubbles out of the nostrils, this has been noted in results table and taken account of in calculations. A less obvious problem is that a certain amount of the inoculum for each mouse may be swallowed. It is assumed that this amount will be the same for each mouse and will average out over the course of inoculations. However, the sample sizes that have been used are small and this problem may have significant effects in some experiments. All mice remaining after the challenge were killed 3 or 4 days after infection. During the infection process, challenged mice were monitored for the development of symptoms associated with the onset of S. pneumoniae induced-disease. Typical symptoms in an appropriate order included piloerection, an increasingly hunched posture, discharge from eyes, increased lethargy and reluctance to move. The latter symptoms usually coincided with the development of a moribund state at which stage the mice were culled to prevent further suffering. These mice were deemed to be very close to death, and the time of culling was used to determine a survival time for statistical analysis. Where mice were found dead, the survival time was taken as the last time point when the mouse was monitored alive.

## **Interpretation of Results**

5

10

15

20

25

30

35

A positive result was taken as any DNA sequence that was cloned and used in challenge experiments as described above which gave protection against that challenge. Protection was taken as those DNA sequences that gave statistically significant protection (to a 95% confidence level (p<0.05)) and also those which were marginal or close to significant using Mann-Whitney or which show some protective features for example there were one or more outlying mice or because the time to the first death was prolonged. It is acceptable to allow marginal or non-significant results to be considered as potential positives when it is considered that the clarity of some of the results may be clouded by the problems associated with the administration of intranasal infections.

Results Trials 1-6 (see figure 1)

Mouse number	Mean survival times (hours)								
	Unvacc control (1)	pcDNA 3.1+ (1)	ID5 (1)	Unvacc control (2)	ID59 (2)	Unvacc control (5)	]		
1	47.5	61.0	61.0	49.0	55.0	58.0	Ť		
2	57.0	47.5	61.0	51.0	55.0	75.0			
3	47.5	50.5	57.0	49.0	55.0	48.0			
4	47.5	50.5	72.0	55.0	69.5	46.7			
5	77.0	72.0	47.5	49.0	74.0	58.0			
6	57.0	50.5	mouse died	49.0	mouse died	75.0			
Mean	55.6	55.3	59.7	50.3	61.7	60.1	Γ		
sd	11.5	9.4	8.8	2.4	9.3	12.5			
p value 1	-	-	0.1722	-	0.0064	-	Γ		
p value 2	-	-	0.2565	-	-	-	Γ		

<sup>\* -</sup> bubbled when dosed so may not have received full inoculum.

T - terminated at end of experiment having no symptoms of infection.

Numbers in brackets - survival times disregarded assuming incomplete dosing p value 1 refers to significance tests compared to unvaccinated controls p value 2 refers to significance tests compared to pcDNA3.1+ vaccinated controls

## 10 Statistical Analyses.

- Trial 1 None of the other groups had significantly longer survival times than the controls. The survival times of the unvaccinated and pcDNA3.1 control groups were not significantly different. One of the mice from ID5 was an outlying result and the mean survival times for ID5 were extended but not significantly so.
- 15 Trial 2 The group vaccinated with ID59 had significantly longer survival times than the unvaccinated control group.
  - Trial 5 The group vaccinated with ID59 again survived for an average of almost 10 hours longer than the controls but the results were not quite statistically significant.

Trial 6 - The group vaccinated with ID51 did not have survival times significantly higher than unvaccinated controls (p=<36.0), however, there were 2 outlying mice in the vaccinated group.

## 5 Vaccine trials 7 and 8 (See figure 2)

	Mean survival times (hours)					
Mouse number	Unvacc control (7)	ID29 (7)	Unvacc control (8)	ID50 (8)		
1	59.6	73.1	45.1	60.6		
2	47.2	54.8	50.8	60.6		
3	59.6	59.3	60.4	51.1		
4	70.9	54.8*	55.2	60.6		
5	68.6*	59.3	45.1	60.6		
6	76.0	54.8	45.1	60.6		
Mean	63.6	59.35	50.2	59.1		
sd	10.3	7.1	6.4	3.9		
p value 1	-	<39.0	-	0.0048		

<sup>\* -</sup> bubbled when dosed so may not have received full inoculum.

Numbers in brackets - survival times disregarded assuming incomplete dosing p value 1 refers to significance tests compared to unvaccinated controls

## Statistical Analyses.

15

Trial 7 - The ID29 vaccinated group showed prolonged times to the first death. T Trial 8 - The group vaccinated with ID50 survived significantly longer than

unvaccinated controls.

T - terminated at end of experiment having no symptoms of infection.

## Appendix I - Oligonucleotide primers

nucS1

Bgl II Eco RV

5 5'- cgagatctgatatctcacaaacagataacggcgtaaatag -3' (SEQ ID NO: 171)

nucS2

Bgl II Sma I

5'- gaagatetteceegggateacaaacagataacggegtaaatag -3' (SEQ ID NO: 172)

10

nucS3

Bgl II Eco RV

5'- cgagatctgatatccatcacaaacagataacggcgtaaatag -3' (SEQ ID NO: 173)

15 nucR

Bam HI

5'- cgggatccttatggacctgaatcagcgttgtc -3' (SEQ ID NO: 174)

NucSeq

5'- ggatgctttgtttcaggtgtatc -3' (SEQ ID NO: 175)

pTREPF

5'- catgatatcggtacctcaagctcatatcattgtccggcaatggtgtgggctttttttgttttagcggataa caatttcacac -3' (SEQ ID NO: 176)

25

pTREPR

5'- gcggatccccgggcttaattaatgtttaaacactagtcgaagatctcgcgaattctcctgtgtgaaatt gttatccgcta -3' (SEQ ID NO: 177)

30 pUCF

5'- cgccagggttttcccagtcacgac -3' (SEQ ID NO: 178)

 $V_R$ 

5'- tcagggggggggggcctatg -3' (SEQ ID NO: 179)

35

 $V_1$ 

5'- tcgtatgttgtgtggaattgtg -3' (SEQ ID NO: 180)

 $v_2$ 

5'- tccggctcgtatgttgtgtggaattg -3' (SEQ ID NO: 181)

### TABLE 1

### ID4 1200 bp

5 (SEQ ID NO: 1)

ATGAGAAATATGTGGGTTGTAATCAAGGAAACCTATCTTCGACATGTCGAGTCATGGAGTTTCTTCTTTATGGTGAT TTCGCCGTTCCTCTTTTAGGAATCTCTGTAGGAATTGGGCATCTCCAAGGTTCTTCTATGGCTAAAAATAATAAAG TGGCAGTAGTGACAACAGTGCCATCTGTAGCAGAAGGACTGAAGAATGTAAATGGTGTTAACTTCGACTATAAAG

- 10 ACGAAGCAAGTGCCAAAGAAGCAATTAAAGAAGAAAAATTAAAAGGTTATTTGACCATTGATCAAGAAGATAGTG TTCTAAAGGCAGTTTATCATGGCGAAACATCGCTTGAAAATGGAATTAAATTTGAGGTTACAGGTACACTCAATGA ACTGCAAAATCAGCTTAATCGTTCAACTGCTTCCTTGTCTCAAGAGCAGGAAAAACGCTTAGCGCAGACAATTCAA TTCACAGAAAAGATTGATGAAGCCAAGGAAAATAAAAAGTTTATTCAAACAATTGCAGCAGGTGCCTTAGGATTCT
- TTCTTTATATGATTCTGATTACCTATGCGGGTGTAACAGCTCAGGAAGTTGCCAGTGAAAAAGGCACCAAAATTAT 15 GGAAGTCGTTTTTTCTAGCATAAGGGCAAGTCACTATTTCTATGCGCGGATGATGGCTCTGTTTCTAGTGATTTTAA CGCATATTGGGATCTATGTTGTAGGTGGTCTGGCTGCCGTTTTGCTCTTTAAAGATTTGCCATTCTTGGCTCAGTCTG GTATTTTGGATCACTTGGGAGATGCTATCTCACTGAATACCTTGCTCTTTATTTTGATCAGTCTTTTCATGTACGTAG TCTTGGCAGCCTTCCTAGGATCTATGGTTTCTCGTCCTGAGGACTCAGGGAAAGCCTTGTCGCCTTTGATGATTTTTG ATTATGGGTGGTTTTTTTGGAGTGACAGCTCTAGGTGCAGCTGGTGACAATCTCCTCTTGAAGATTGGTTCTTATAT
- 20 TCCCTTTATTTCGACCTTCTTTATGCCGTTTCGAACGATTAATGACTATGCGGGGGGGAGCAGAAGCATGGATTTCAC TTGCTATTACAGTGATTTTTGCGGTGGTAGCAACAGGATTTATCGGACGCATGTATGCTAGTCTCGTTCTTCAAACG

(SEO ID NO: 2)

- 25 MRNMWVVIKETYLRHVESWSFFFMVISPFLFLGISVGIGHLQGSSMAKNNKVAVVTTVPSVAEGLKNVNGVNFDYKDE ASAKEAIKEEKLKGYLTIDQEDSVLKAVYHGETSLENGIKFEVTGTLNELQNQLNRSTASLSQEQEKRLAQTIQFTEKIDE AKENKKFIQTIAAGALGFFLYMILITYAGVTAQEVASEKGTKIMEVVFSSIRASHYFYARMMALFLVILTHIGIYVVGGLA AVLLFKDLPFLAQSGILDHLGDAISLNTLLFILISLFMYVVLAAFLGSMVSRPEDSGKALSPLMILIMGGFFGVTALGAAG DNLLLKIGSYIPFISTFFMPFRTINDYAGGAEAWISLAITVIFAVVATGFIGRMYASLVLQTDDLGIWKTFKRALSYK 30
  - ID5 1125 bp

(SEQ ID NO: 3)

- 35 GAAAGTCTTCTCGTATCCATTGTAATCAGTGCATACAATGAAGAAAAATATCTGCCTGGTCTAATTGAAGACTTAA AAAATCAAACCTATCCTAAAGAGGATATTGAAATTCTATTTATAAATGCTATGTCCACAGATGGGACCACAGCTAT CATTCAGCAATTTATAAAGGAAGATACAGAGTTTAACTCAATTAGATTGTATAACAATCCTAAGAAAAATCAAGCT AGTGGTTTTAACCTGGGAGTTAAACATTCTGTAGGGGACCTTATTTTAAAAATTGATGCTCATTCAAAAGTTACTGA
- GACTTTTGTAATGAACAATGTGGCTATTATTCAACAAGGTGAATTTGTCTGTGGGGGGCCTAGACCGACGATTGTC 40 GAAGGAAAAGGAAAATGGGCAGAGACCTTGCATCTTGTTGAGGAAAATATGTTTGGCAGTAGCATTGCCAATTAT CGAAATAGTTCTGAGGATAGATATGTTTCTTCTATTTTTCATGGAATGTATAAACGAGGGTTTTCCAGAAGGTTGG TTTAGTAAATGAGCAACTTGGCCGAACTGAAGATAATGATATTCATTATAGAATTCGAGAATATGGTTATAAAATC CGCTATAGCCCAAGTATTCTATCTTATCAGTATATTCGACCAACATTCAAGAAAATGCTGCATCAAAAGTATTCAA
- ATGGTTTGTGGATTGGCTTGACAAGTCATGTTCAGTTTAAGTGTTTATCATTATTTCACTATGTTCCTTGTTTATTTG 45 TTTTGAGTCTTGTGTTTAGTCTAGCATTGTTACCGATCACATTCGTATTCATAACTTTACTATTAGGTGCCTATTTTCT TTCCATTCACTTTGCTTATGGCCTTGGGACGATTGTAGGTTTAATTAGAGGATTTAAATGGAAGAAGGAGTACAAG AGAACAATAATTTATTTGGATAAAATAAGCCAAATAAATCAAAATATGCTATAA
- 50 (SEQ ID NO: 4)

PGKVLKIMIEWWKEKFRRVVVTQNVESLLVSIVISAYNEEKYLPGLIEDLKNQTYPKEDIEILFINAMSTDGTTAIIQQFIK EDTEFNSIRLYNNPKKNQASGFNLGVKHSVGDLILKIDAHSKVTETFVMNNVAIIQQGEFVCGGPRPTIVEGKGKWAETL HLVEENMFGSSIANYRNSSEDRYVSSIFHGMYKREVFOKVGLVNEOLGRTEDNDIHYRIREYGYKIRYSPSILSYOYIRPT FKKMLHOKYSNGLWIGLTSHVQFKCLSLFHYVPCLFVLSLVFSLALLPITFVFITLLLGAYFLLLSLLTLLTLLKHKNGFLI 55

VMPFILFSIHFAYGLGTIVGLIRGFKWKKEYKRTIIYLDKISQINQNML

### ID11 696 bp

(SEO ID NO: 5)

60 ATGATGAAAGAACAAAATACGATAGAAATCGATGTATTTCAATTAGTTAAAAGCTTGTGGAAACGCAAGCTAATG ATTITAATAGTGGCACTTGTGACAGGTGCGGGGGCTTTTGCATATAGCACTTTTATTGTTAAGCCAGAATATACGAG AACTTATCTGGTAAAAGACTACCGTGAGATTATCCTTTCGCAGGATGTTTTGGAGGAAGTTGTTTCTGATTTGAAAC TAGATTTGACGCCAAAAGGTTTGGCTAATAAAATTAAAGTGACAGTACCAGTTGATACCCGTATTGTCTCTATTTCA 65 GTTAATGATCGAGTTCCTGAAGAGGCAAGCCGTATCGCTAACTCTTTGAGAGAGTAGCTGCTCAAAAAATTATCA

GTATTACTCGTGTTTCTGACGTGACAACACTGGAGGAGGCAAGGCCGGCGATATCCCCGTCTTCGCCAAATATTAA ACGCAATACACTAATTGGTTTTTTTGGCAGGGGTGATTGGAACTAGTGTTATAGTTCTTCATCTTGAACTTTTTGGATA CTCGTGTGAAACGTCCGGAAGATATCGAAAATACATTGCAGATGACACTTTTGGGAGTTGTGCCAAACTTGGGTAA GTTGAAATAG

5

(SEQ ID NO: 6)
MMKEQNTIEIDVFQLVKSLWKRKLMILIVALVTGAGAFAYSTFIVKPEYTSTTRIYVVNRNQGDKPGLTNQDLQAGTYL
VKDYREIILSQDVLEEVVSDLKLDLTPKGLANKIKVTVPVDTRIVSISVNDRVPEEASRIANSLREVAAQKIISITRVSDVTT
LEEARPAISPSSPNIKRNTLIGFLAGVIGTSVIVLHLELLDTRVKRPEDIENTLQMTLLGVVPNLGKLK

10

### ID19 555 bp

(SEQ ID NO: 7)

20 ATGTCTTTGGTAAAAATCAGTAA

(SEQ ID NO: 8)
MVKVAVILAQGFEEIEALTVVDVLRRANITCDMVGFEEQVTGSHAIQVRADHVFDGDLSDYDMIVLPGGMPGSAHLRD
NQTLIQELQSFEQEGKKLAAICAAPIALNQAEILKNKRYTCYDGVQEQILDGHYVKETVVVDGQLTTSRGPSTALAFAYE
LVEOLGGDAESLRTGMLYRDVFGKNO

#### ID27 306 bp

(SEO ID NO: 9)

35

25

(SEQ ID NO: 10)
MVGMVEPNLESLIKDLYNHARHDLSEDLVAALLETTKKLPTTNEQLQAVRLSGLVNRELLLNPKHPAPELLNLARFVKR
EEAKYRGTATSALMYEELFKML

40 <u>ID29 945 bp</u>

(SEQ ID NO: 11)

55 GATCTAATATCCACACCAAGCAGACGTTGA

(SEQ ID NO: 12)

MFLKKEREVISMRKWTKGFLIFGVVTTVIGFILLFVGIQSDGIKSLLSMSKEPVYDSRTEKLTFGKEVENLEITLHQHTLTI
TDSFDDQIHISYHPSLSAHHDLITNQNDRTLSLTDKKLSETPFLSSGIGGILHIASSYSSRFEEVILRLPKGRTLKGINISANR
GQTTIINASLENATLNTNSYILRIEGSRIKNSKLTTPNIVNIFDTVLTDSQLESTENHFHAENIQVHGKVELTAKDYLRIILD
QKESQRINWDISSNYGSIFQFTREKPESRGTELSNPYKTEKTDVKDQLIARSDDNIDLISTPSRR

### ID30 879 bp

65 (SEQ ID NO: 13)

(SEQ ID NO: 14)
MKQEWFESNDFVKTTSKNKPEEQAQEVADKAEETIADLDTPIEKNTQLEEEVPQAEVELESQQEEKIEAPEDSEARTEIEE
KKASNSTEEEPDLSKETEKVTIAEESQEALPQQKATTKEPLLISKSLESPYIPDQAPKSRDKWKEQVLDFWSWLVEAIKSP
TSKLETSITHSYTAFLLLILFSASSFFFSIYHIKHAYYGHIASINSRFPEQLAPLTLFSIISILVATTLFFFSFLLGSFVVRRFIHO

EKDWTLDKVLQQYSQLLAIPISSLLLLVSLLSLIAYDLQPSCV

## 20 ID105 990 bp

15

40

50

(SEQ ID NO: 15) ATGCAACTCGCTTCTTCGGTCTACTCATTGTTCGTCTGGTACAATTTGTTCTTAAAAAAGGAAAGGAGAGGTAATCAG CATGCGTAAATGGACAAAAGGATTTCTCATCTTTGGTGTGGTGACTACCGTTATCGGCTTTATCCTGCTTTTTGTAG GTATCCAATCTGACGGGATTAAGAGCCTACTTTCCATGTCCAAAGAACCTGTCTATGATAGCCGTACGGAAAAGCT 25 AACCTTTGGCAAGGAAGTCGAAAACCTAGAAATTACTCTCCACCAACACACGCTCACCATCACAGACTCTTTCGAT GATCAAATCCACATTTCTTACCATCCATCTCTTTCTGCTCACCATGATCTTATCACCAATCAGAACGATAGAACTCT GAGTCTCACTGATAAGAAACTGTCTGAAACTCCGTTTCTCTCTTCTGGAATTGGTGGGATTCTTCATATCGCAAGTA GCTACTCTAGTCGTTTTGAAGAAGTTATTCTCCGACTACCAAAAGGGAGAACTCTAAAAGGGATCAACATCTCAGC CAATCGCGGACAAACCACCATCATAAATGCTAGCCTTGAAAATGCGACCCTCAATACAAACAGCTATATCCTCCGA 30 ATTGAAGGAAGTCGTATCAAAAACAGTAAACTCACAACGCCCAATATCGTTAATATCTTTGATACAGTTCTTACAG CAAAGATTATCTCAGAATCATCCTAGACCAGAAAGAAAGCCAACGAATTAACTGGGACATCTCAAGCAACTATGG TTCTATCTTCCAATTCACAAGAGAAAAGCCTGAATCAAGAGGTACGGAATTAAGCAACCCTTACAAAACTGAAAA AACCGATGTCAAGGATCAACTCATTGCGAGATCTGATGATAATATTGATCTAATATCCACACCAAGCAGACGTTGA 35

(SEQ ID NO: 16)

MQLASSVYSLFVWYNLFLKKEREVISMRKWTKGFLIFGVVTTVIGFILLFVGIQSDGIKSLLSMSKEPVYDSRTEKLTFGK
EVENLEITLHQHTLTITDSFDDQIHISYHPSLSAHHDLITNQNDRTLSLTDKKLSETPFLSSGIGGILHIASSYSSRFEEVILRL
PKGRTLKGINISANRGQTTIINASLENATLNTNSYILRIEGSRIKNSKLTTPNIVNIFDTVLTDSQLESTENHFHAENIQVHG
KVELTAKDYLRIILDQKESQRINWDISSNYGSIFQFTREKPESRGTELSNPYKTEKTDVKDQLIARSDDNIDLISTPSRR

### ID107 -78bp

(SEQ ID NO: 17)

(SEQ ID NO: 18) MICKMKQGGSRACWGWRVGEGRCYFN

## ID109 714 bp

(SEQ ID NO: 19)

(SEQ ID NO: 20)

DKEALSNLNLQIENGEIMGLIGHNGAGKSTTIKSLVSIISPSSGRILVDGQELSENRLAIKRKIGYVADSPDLFLRLTANEF WELIASSYDLSRSDLEASLARLLNVFDFAENRYQVIETLSHGMRQKVFVIGALLSDPDIWVLDEPLTGLDPQAAFDLKQ MMKEHAQKGKTVLFSTHVLEVAEQVCDRIAILKKGHLIYCGKVEDLRKDHPDQSLESIYLSLAGRKEEVADASQGH

## 5 ID112 360 bp

(SEQ ID NO: 21)

(SEO ID NO: 22)

MALFSERGAVRKTPMASPIMRPMMVPTIEIKRVIPAPRKSCCQFSERILATWLKKLLLVSSVVVASAGCSLIIRSIKATWSS FEMVSMLALIWLIRLSFLRSPIAIAVSSSPVLKPGST

#### ID 128 - 3.43

(SEQ ID NO: 23)

- TGAGCAAATTGTAATCAAAATTACAGATCAGGGCTATGTAACGTCACACG
  GTGACCACTATCATTACTATAATGGGAAAGTTCCTTATGATGCCCTCTTT
  AGTGAAGAACTCTTGATGAAGGATCCAAACTATCAACTTAAAGACGCTGA
  TATTGTCAATGAAGTCAAGGGTGGTTAATCATCAAGGTCGATGGAAAAT
  ATTATGTCTACCTGAAAGATGCAGCTCATGCTGATAATGTTCGAACTAAA
  GATGAAATCAATCGTCAAAAACAAGAACATGTCAAAAGATAATGAGAAGGT

- 45 TAGTCTAGCAACACCTTCTCCATCTCTTCCAATCAATCCAGGAACTTCAC
  ATGAGAAACATGAAGAAGATGGATACGGATTTGATGCTAATCGTATTATC
  GCTGAAGATGAATCAGGTTTTGTCATGAGTCACGGAGACCACAATCATTA
  TTTCTTCAAGAAGGACTTGACAGAAGAGCAAATTAAGGTGCGCAAAAACA
  TTTAG

50 (SEQ ID NO: 24)

MKFSKKYIAAGSAVIVSLSLCAYALNQHRSQENKDNNRVSYVDGSQSSQK SENLTPDQVSQKEGIQAEQIVIKITDQGYVTSHGDHYHYYNGKVPYDALF SEELLMKDPNYQLKDADIVNEVKGGYIIKVDGKYYVYLKDAAHADNVRTK

- 55 DEINRQKQEHVKDNEKVNSNVAVARSQGRYTTNDGYVFNPADIIEDTGNA
  YIVPHGGHYHYIPKSDLSASELAAAKAHLAGKNMQPSQLSYSSTASDNNT
  QSVAKGSTSKPANKSENLQSLLKELYDSPSAQRYSESDGLVFDPAKIISR
  TPNGVAIPHGDHYHFIPYSKLSALEEKIARMVPISGTGSTVSTNAKPNEV
  VSSLGSLSSNPSSLTTSKELSSASDGYIFNPKDIVEETATAYIVRHGDHF
- 60 HYIPKSNQIGQPTLPNNSLATPSPSLPINPGTSHEKHEEDGYGFDANRII AEDESGFVMSHGDHNHYFFKKDLTEEQIKVRKNI\*

# TABLE 2

### ID2 840 bp

- (SEQ ID NO: 26)
  MGIALENVNFTYQEGTPLASAALSDVSLTIEDGSYTALIGHTGSGKSTILQLLNGLLVPSQGSVRVFDTLITSTSKNKDIRQ
  IRKQVGLVFQFAENQIFEETVLKDVAFGPQNFGVSEEDAVKTAREKLALVGIDESLFDRSPFELSGGQMRRVAIAGILAM
  EPAILVLDEPTAGLDPLGRKELMTLFKKLHQSGMTIVLVTHLMDDVAEYANQVYVMEKGRLVKGGKPSDVFQDVVFM
  EEVQLGVPKITAFCKRLADRGVSFKRLPIKIEEFKESLNG

# ID 3 6360 bp

25 (SEQ ID NO: 27) TACCCGGTAGTCTTAGCAGACACATCTAGCTCTGAAGATGCTTTAAACATCTCTGATAAAGAAAAAGTAGCAGAAA ATAAAGAGAAACATGAAAATATCCATAGTGCTATGGAAACTTCACAGGATTTTAAAGAGAAGAAAACAGCAGTCA TTAAGGAAAAAGAAGTTGTTAGTAAAAATCCTGTGATAGACAATAACACTAGCAATGAAGAAGCAAAAATCAAAG 30 AAGAAAATTCCAATAAATCCCAAGGAGATTATACGGACTCATTTGTGAATAAAAACACAGAAAAATCCCAAAAAAG AAGATAAAGTTGTCTATATTGCTGAATTTAAAGATAAAGAATCTGGAGAAAAAGCAATCAAGGAACTATCCAGTCT TAAGAATACAAAAGTTTTATATACTTATGATAGAATTTTTTAACGGTAGTGCCATAGAAACAACTCCAGATAACTTG GACAAAATTAAACAAATAGAAGGTATTTCATCGGTTGAAAGGGCACAAAAAGTCCAACCCATGATGAATCATGCC AGAAAGGAAATTGGAGTTGAGGAAGCTATTGATTACCTAAAGTCTATCAATGCTCCGTTTGGGAAAAATTTTGATG 35 GTAGAGGTATGGTCATTTCAAATATCGATACTGGAACAGATTATAGACATAAGGCTATGAGAATCGATGATGATGC CAAAGCCTCAATGAGATTTAAAAAAGAAGACTTAAAAAGGCACTGATAAAAAATTATTGGTTGAGTGATAAAAATCCC TCATGCGTTCAATTATTATAATGGTGGCAAAATCACTGTAGAAAAATATGATGATGGAAGGGATTATTTTGACCCA CATGGGATGCATATTGCAGGGATTCTTGCTGGAAATGATACTGAACAAGACATCAAAAACTTTAACGGCATAGATG GAATTGCACCTAATGCACAAATTTTCTCTTACAAAATGTATTCTGACGCAGGATCTGGGTTTTGCGGGTGATGAAAC 40 AATGTTTCATGCTATTGAAGATTCTATCAAACACAACGTTGATGTTTTCGGTATCATCTGGTTTTACAGGAACAG GTCTTGTAGGTGAGAAATATTGGCAAGCTATTCGGGCATTAAGAAAAGCAGGCATTCCAATGGTTGTCGCTACGGG TAACTATGCGACTTCTGCTTCAAGTTCTTCATGGGATTTAGTAGCAAATAATCATCTGAAAATGACCGACACTGGA AATGTAACACGAACTGCAGCACATGAAGATGCGATAGCGGTCGCTTCTGCTAAAAATCAAACAGTTGAGTTTTGATA AAGTTAACATAGGTGGAGAAAGTTTTAAATACAGAAATATAGGGGCCTTTTTCGATAAGAGTAAAATCACAACAA 45 GTTTGGATCTTAGGGGCAAAATTGCAGTAATGGATAGAATTTATACAAAGGATTTAAAAAAATGCTTTTAAAAAAAGC TATGGATAAGGGTGCACGCGCCATTATGGTTGTAAATACTGTAAATTACTACAATAGAGATAATTGGACAGAGCTT CCAGCTATGGGATATGAAGCGGATGAAGGTACTAAAAGTCAAGTGTTTTCAATTTCAGGAGATGATGGTGTAAAGC TATGGAACATGATTAATCCTGATAAAAAAACTGAAGTCAAAAGAAATAATAAAGAAGATTTTAAAGATAAATTGG 50 AGCAATACTATCCAATTGATATGGAAAGTTTTAATTCCAACAAACCGAATGTAGGTGACGAAAAAGAGATTGACTT TAAGTTTGCACCTGACACAGACAAGAACTCTATAAAGAAGATATCATCGTTCCAGCAGGATCTACATCTTGGGGG CCAAGAATAGATTTACTTTTAAAACCCGATGTTTCAGCACCTGGTAAAAATATTAAATCCACGCTTAATGTTATTAA TGGCAAATCAACTTATGGCTATATGTCAGGAACTAGTATGGCGACTCCAATCGTGGCAGCTTCTACTGTTTTGATTA GACCGAAATTAAAGGAAATGCTTGAAAGACCTGTATTGAAAAATCTTAAGGGAGATGACAAAATAGATCTTACAA 55 CTTTGCATCACCTAGACACAGGGGGGCGCCTAATTAATGTGGCCAATGCTTTGAGAAATGAAGTTGTAGCAACT TTCAAAAACACTGATTCTAAAGGTTTGGTAAACTCATATGGTTCCATTTCTCTTAAAGAAATAAAAGGTGATAAAA AATACTTTACAATCAAGCTTCACAATACATCAAACAGACCTTTGACTTTTAAAGTTTCAGCATCAGCGATAACTACA GATTCTCTAACTGACAGATTAAAACTTGATGAAACATATAAAGATGAAAAATCTCCAGATGGTAAGCAAATTGTTC 60 CAGAAATTCACCCAGAAAAAGTCAAAGGAGCAAATATCACATTTGAGCATGATACTTTCACTATAGGCGCAAATTC TTTGAGTCAGTGGAAGCGATGGAAGCTCTAAACTCCAGCGGGAAGAAAATAAACTTCCAACCTTCTTTGTCGATGC CTCTAATGGGATTTGCTGGGAATTGGAACCACGAACCATCCTTGATAAATGGGCTTGGGAAGAAGGGTCAAGATC AAAAACACTGGGAGGTTATGATGATGATGGTAAACCGAAAATTCCAGGAACCTTAAATAAGGGAATTGGTGGAGA 65 ACATGGTATAGATAAATTTAATCCAGCAGGAGTTATACAAAATAGAAAAGATAAAAATACAACATCCCTGGATCA AAATCCAGAATTATTTGCTTTCAATAACGAAGGGATCAACGCTCCATCATCAAGTGGTTCTAAGATTGCTAACATTT

ATCCTTTAGATTCAAATGGAAATCCTCAAGATGCTCAACTTGAAAGAGGATTAACACCTTCTCCACTTGTATTAAGA AGTGCAGAAGAAGGATTGATTTCAATAGTAAATACAAATAAAGAGGGAGAAAATCAAAGAGACTTAAAAGTCATT TCGAGAGAACACTTTATTAGAGGAATTTTAAATTCTAAAAGCAATGATGCAAAGGGAATCAAATCATCTAAACTAA AAGTTTGGGGTGACTTGAAGTGGGATGGACTCATCTATAATCCTAGAGGTAGAGAAAAAAGCACCAGAAAGTA 5 AGGATAATCAAGATCCTGCTACTAAGATAAGAGGTCAATTTGAACCGATTGCGGAAGGTCAATATTTCTATAAATT TAAATATAGATTAACTAAAGATTACCCATGGCAGGTTTCCTATATTCCTGTAAAAATTGATAACACCGCCCCTAAG ATTGTTTCGGTTGATTTTTCAAATCCTGAAAAAATTAAGTTGATTACAAAGGATACTTATCATAAGGTAAAAGATCA TTGGTATGCTGGCGCCGCTCTTGTTAATGAAGATGGAGAGGTTGAAAAAAATCTTGAAGTAACTTACGCAGGTGAG 10 GGTCAAGGAAGAAATAGAAAACTTGATAAAGACGGAAATACCATTTATGAAATTAAAGGTGCGGGAGATTTAAGG GGAAAAATCATTGAAGTCATTGCATTAGATGGTTCTAGCAATTTCACAAAGATTCATAGAATTAAATTTGCTAATC AGGCTGATGAAAAGGGGATGATTTCCTATTATCTAGTAGATCCTGATCAAGATTCATCTAAATATCAAAAGCTTGG AGAACATCATCAAGAAAATGAAGAGTCTATTAAAGAAAAATCTAGTTTTACTATTGATAGAAATATTTCAACA 15 ATTAGAGACTTTGAAAATAAAGACTTAAAGAAACTCATTAAAAAGAAATTTAGAGAAGTTGATGATTTTACAAGTG AAACTGGTAAGAGAATGGAGGAATACGATTATAAATACGATGATAAAGGAAATATAATAGCCTACGATGATGGGA CTGATCTAGAATATGAAACTGAGAAACTTGACGAAATCAAATCAAAATTTATGGTGTTCTAAGTCCGTCTAAAGA TGGACACTTTGAAATTCTTGGAAAGATAAGTAATGTTTCTAAAAATGCCAAGGTATATTATGGGAATAACTATAAA TCTATAGAAATCAAAGCGACCAAGTATGATTTCCACTCAAAAACGATGACATTTGATCTATACGCTAATATTAATG 20 ATATTGTGGATGGATTAGCTTTTGCAGGAGATATGAGATTATTTGTTAAAGATAATGATCAGAAAAAAGCTGAAAT TAAAATTAGAATGCCTGAAAAAATTAAGGAAACTAAATCAGAATATCCCTATGTATCAAGTTATGGGAATGTCATA GAATTAGGGGAAGGAGATCTTTCAAAAAACAAACCAGACAATTTAACTAAAATGGAATCTGGTAAAATCTATTCT GATTCAGAAAAACAACAATATCTGTTAAAGGATAATATCATTCTAAGAAAAGGCTATGCACTAAAAGTGACTACCT ATAATCCTGGAAAAACGGATATGTTAGAAGGAAATGGAGTCTATAGCAAGGAAGATATAGCAAAAATACAAAAG 25 GCCAATCCTAATCTAAGAGCCCTTTCAGAAACAACAATTTATGCTGATAGTAGAAAATGTTGAAGATGGAAGAAGTA CCCAATCTGTATTAATGTCGGCTTTGGACGGCTTTAACATTATAAGGTATCAAGTGTTTACATTTAAAATGAACGAT AAAGGGGAAGCTATCGATAAAGACGGAAATCTTGTGACAGATTCTTCTAAACTTGTATTATTTGGTAAGGATGATA ACCAGTAAACCTTTCAATGGATAAGAACTACTTTAATCCATCTAAATCTAATAAAATTTATGTACGAAATCCAGAA 30 TTTTATTTAAGAGGTAAGATTTCTGATAAGGGTGGTTTTAACTGGGAATTGAGAGTTAATGAATCGGTTGTAGATA ATTATTTAATCTACGGAGATTTACACATTGATAACACTAGAGATTTTAATATTAAGCTGAATGTTAAAGACGGTGA TTATCTTCAAACTGGCTATAGCGATTTGAATGCTAAAGCAGTTGGAGTCCACTATCAGTTTTTATATGATAATGTTA AACCCGAAGTAAACATTGATCCTAAGGGAAATACTAGTATCGAATATGCTGATGGAAAATCTGTAGTCTTTAACAT 35 CAATGATAAAAGAAATAATGGATTCGATGGTGAGATTCAAGAACAACATATTTATATAAATGGAAAAGAATATAC ATCATTTAATGATATTAAACAAATAATAGACAAGACACTAAACATTAAGATTGTTGTAAAAGATTTTGCAAGAAAT ACAACCGTAAAAGAATTCATTTTAAATAAAGATACGGGAGAGGTAAGTGAATTAAAACCTCATAGGGTAACTGTG ACCATTCAAAATGGAAAAGAAATGAGTTCAACGATAGTGTCGGAAGAAGATTTTATTTTACCTGTTTATAAGGGTG AATTAGAAAAAGGATACCAATTTGATGGTTGGGAAATTTCTGGTTTCGAAGGTAAAAAAGACGCTGGCTATGTTAT 40 TACTTTTGATGTATCGAAAAAGAAAGATAACCCACAAGTAAACCATAGTCAATTAAATGAAAGTCACAGAAAAGA GGATTTACAAAGAGAAGAGCATTCACAAAAATCTGATTCAACTAAGGATGTTACAGCTACAGTTCTTGATAAAAAC AATATCAGTAGTAAATCAACTACTAACAATCCTAATAAGTTGCCAAAAACTGGAACAGCAAGCGGAGCCCAGACA 45 (SEQ ID NO: 28) YPVVLADTSSSEDALNISDKEKVAENKEKHENIHSAMETSQDFKEKKTAVIKEKEVVSKNPVIDNNTSNEEAKIKEENSN

KSQGDYTDSFVNKNTENPKKEDKVVYIAEFKDKESGEKAIKELSSLKNTKVLYTYDRIFNGSAIETTPDNLDKIKQIEGIS SVERAQKVQPMMNHARKEIGVEEAIDYLKSINAPFGKNFDGRGMVISNIDTGTDYRHKAMRIDDDAKASMRFKKEDLK GTDKNYWLSDKIPHAFNYYNGGKITVEKYDDGRDYFDPHGMHIAGILAGNDTEQDIKNFNGIDGIAPNAQIFSYKMYSD AGSGFAGDETMFHAIEDSIKHNVDVVSVSSGFTGTGLVGEKYWQAIRALRKAGIPMVVATGNYATSASSSSWDLVANN HLKMTDTGNVTRTAAHEDAIAVASAKNQTVEFDKVNIGGESFKYRNIGAFFDKSKITTNEDGTKAPSKLKFVYIGKGQD QDLIGLDLRGKIAVMDRIYTKDLKNAFKKAMDKGARAIMVVNTVNYYNRDNWTELPAMGYEADEGTKSQVFSISGDD GVKLWNMINPDKKTEVKRNNKEDFKDKLEQYYPIDMESFNSNKPNVGDEKEIDFKFAPDTDKELYKEDIIVPAGSTSWG PRIDLLLKPDVSAPGKNIKSTLNVINGKSTYGYMSGTSMATPIVAASTVLIRPKLKEMLERPVLKNLKGDDKIDLTSLTKI ALQNTARPMMDATSWKEKSQYFASPRQQGAGLINVANALRNEVVATFKNTDSKGLVNSYGSISLKEIKGDKKYFTIKL HNTSNRPLTFKVSASAITTDSLTDRLKLDETYKDEKSPDGKQIVPEIHPEKVKGANITFEHDTFTIGANSSFDLNAVINVGE

50

55

60

65

AKNKNKFVESFIHFESVEAMEALNSSGKKINFQPSLSMPLMGFAGNWNHEPILDKWAWEEGSRSKTLGGYDDDGKPKIP
GTLNKGIGGEHGIDKFNPAGVIQNRKDKNTTSLDQNPELFAFNNEGINAPSSSGSKIANIYPLDSNGNPQDAQLERGLTPS
PLVLRSAEEGLISIVNTNKEGENQRDLKVISREHFIRGILNSKSNDAKGIKSSKLKVWGDLKWDGLIYNPRGREENAPESK
DNQDPATKIRGQFEPIAEGQYFYKFKYRLTKDYPWQVSYIPVKIDNTAPKIVSVDFSNPEKIKLITKDTYHKVKDQYKNE
TLFARDQKEHPEKFDEIANEVWYAGAALVNEDGEVEKNLEVTYAGEGQGRNRKLDKDGNTIYEIKGAGDLRGKIIEVIA
LDGSSNFTKIHRIKFANQADEKGMISYYLVDPDQDSSKYQKLGEIAESKFKNLGNGKEGSLKKDTTGVEHHHQENEESIK
EKSSFTIDRNISTIRDFENKDLKKLIKKKFREVDDFTSETGKRMEEYDYKYDDKGNIIAYDDGTDLEYETEKLDEIKSKIY
GVLSPSKDGHFEILGKISNVSKNAKVYYGNNYKSIEIKATKYDFHSKTMTFDLYANINDIVDGLAFAGDMRLFVKDNDQ
KKAEIKIRMPEKIKETKSEYPYVSSYGNVIELGEGDLSKNKPDNLTKMESGKIYSDSEKQQYLLKDNIILRKGYALKVTT

YNPGKTDMLEGNGVYSKEDIAKIQKANPNLRALSETTIYADSRNVEDGRSTQSVLMSALDGFNIIRYQVFTFKMNDKGE AIDKDGNLVTDSSKLVLFGKDDKEYTGEDKFNVEAIKEDGSMLFIDTKPVNLSMDKNYFNPSKSNKIYVRNPEFYLRGKI SDKGGFNWELRVNESVVDNYLIYGDLHIDNTRDFNIKLNVKDGDIMDWGMKDYKANGFPDKVTDMDGNVYLQTGYS DLNAKAVGVHYQFLYDNVKPEVNIDPKGNTSIEYADGKSVVFNINDKRNNGFDGEIQEQHIYINGKEYTSFNDIKQIIDK TLNIKIVVKDFARNTTVKEFILNKDTGEVSELKPHRVTVTIQNGKEMSSTIVSEEDFILPVYKGELEKGYQFDGWEISGFE GKKDAGYVINLSKDTFIKPVFKKIEEKKEEENKPTFDVSKKKDNPQVNHSQLNESHRKEDLQREEHSQKSDSTKDVTAT VLDKNNISSKSTTNNPNKLPKTGTASGAQTLLAAGIMFIVGIFLGLKKKNQD

## ID6 597 bp

(SEQ ID NO: 29)

5

25

15 CAGATACGGACTTAGCCAAACGTGCTCGTAAGATTGCCCGTGTTGGTGGTGCTAATAACTTTTCTGAAGAGCAACT
TCAATATTTTATGAAAAATCTGCCAGCTGAGTTTGCCCGTTACAGTGAGCAACAAGTCAGCGACTACCTAGCTCTC
AATGCAGGTTTGGTTGCCATGAACTTGGTTCTTGCATTGACAGACCAAGGAATTGGTTCTAACATTATTCTTGGTTT
TGACAAATCAAAAGTTAATGAAGTTTTGGAAATCGAAGACCGTTTCCGCCCAGAACTCTTGATCACAGTGGGTTAT
ACAGACGAAAAATTGGAACCAAGCTACCGCTTGCCAGTAGATGAAATCATCGAGAAAAGATAG

20 (SEQ ID NO: 30)

LELNKKRHATKHFTDKLVDPKDVRTAIEIATLAPSAHNSQPWKFVVVREKNAELAKLAYGSNFEQVSSAPVTIALFTDT DLAKRARKIARVGGANNFSEEQLQYFMKNLPAEFARYSEQQVSDYLALNAGLVAMNLVLALTDQGIGSNIILGFDKSK VNEVLEIEDRFRPELLITVGYTDEKLEPSYRLPVDEIIEKR

#### ID7 1401 bp

(SEO ID NO: 31)

- TTACTATGGTTTGAAAATCATCAAAGAATTGGGTCTTCCAACTTCTAAGAAAGTTCGCTTCATCGTTGGAACAGACG
  AAGAATCAGGCTGGGCAGACATGGACTACTACTTTGAGCACGTAGGACTTGCCAAACCAGATTTCGGTTTCTCACC
  AGATGCTGAATTTCCAATCATCAATGGTGAAAAAAGGAAATATCACGGAATACCTCCACTTTGCAGGAGAAAATAC
  AGGTGTTGCCCGTCTTCACAGCTTTACAGGTGGTTTACGTGAAAATATGGTACCAGAATCAGCAACAGCAGTCGTT
  TCAGGTGACTTGGCTGACTTGCAAGCTAAACTAGATGCCTTTTGTTGCAGAACACAAACTTAGAGGAGAACTCCAAG
- 45 AGGTCATGAACAAGTCATCGGTGGTAGAACCTTTGGTCGCTTGCTAGAACGCGGAGTTGCCTACGGTGCTATGTTC
  CCAGACTCGATTGATACCATGCACCAAGCCAATGAATTTATCGCCTTGGATGATCTTTTCCGAGCAGCAGCAATTTA
  TGCCGAAGCTATTTACGAATTGATCAAATAA

(SEO ID NO: 32)

- 50 MTAIDFTAEVEKRKEDLLADLFSLLEINSERDDSKADAQHPFGPGPVKALEKFLEIADRDGYPTKNVDNYAGHFEFGDG EEVLGIFAHMDVVPAGSGWDTDPYTPTIKDGRLYARGASDDKGPTTACYYGLKIIKELGLPTSKKVRFIVGTDEESGWA DMDYYFEHVGLAKPDFGFSPDAEFPIINGEKGNITEYLHFAGENTGVARLHSFTGGLRENMVPESATAVVSGDLADLQA KLDAFVAEHKLRGELQEEAGKYKVTIIGKSAHGAMPASGVNGATYLALFLSQFGFAGPAKDYLDIAGKILLNDHEGENL KIAHVDEKMGALSMNAGVFHFDETSADNTIALNIRYPKGTSPEQIKSILENLPVVSVSLSEHGHTPHYVPMEDPLVQTLL NIYEKQTGFKGHEQVIGGGTFGRLLERGVAYGAMFPDSIDTMHQANEFIALDDLFRAAAIYAEAIYELIK
  - ID8 1617 bp

(SEQ ID NO: 33)

TTAACTAACCAAAATGAAGCTTTTTTAAAATCTAGTGAGACTATATTGAATGGATFTGATGTGTTAGCGTCCTTGAA TCTTTTATATGTATTGCCTAAGAAAATTAAAGAAGCAGGAATTTTATTAAAGATGGTTATACAAAGAAGAAGACAACT CTTGCAATAAAAGGAATAGTGAAAATTGGTACTATTGAAGCAATAGGAGCACTAACAGGTGTTATTTTTACAGCGC 5 TAGGTGAATTAGGAGGTCAATTATCCTCTATTATTGGTACGAAGCCTATTTTTTTAAAATTGTATTCAATTAATCCA ATTGAGTCAAATAAAATGAATGATATCGAACCAAATGAGGTGAATAGAGATTTTCCGTTATATGAAGCAAAAAAT ATTTGCTATAAGTATGGAGATAAAGAAATATTAAAAAACTTAAATTTTTGTTTTCAACGTAATGAAAAGTATTTAAT TTGCGATTCTGCGGGGATGATATAAAAAAAAACCTCCTATTTAAATATGGTTTCGAATGTTCTATATGTAGATCAAAA 10 AGCTTATTTGTTTGAAGGTACGATTAGAGATAATATTTTATTGGAAGAAAATTATACTGATGAAGAAATACTACAG TCTTTAGAGCAAGTTGGTTTGAGTGTAAAAGATTTTCCTAATAACATTTTAGATTATTATGTTGGTGATGATGGGAG ATTACTGTCAGGAGGGCAGAAACAAAAATTACTTTAGCTAGAGGGCCTAATTAGAAATAAGAAAATAGTATTAAT ACTGTCATTATTGTTACCCATGCTCCGCATCCGGAACTTAAACAATATTTTACTAAGATATATCAATTTCCAAAGGA

15 ттттатттаа

(SEQ ID NO: 34)

MYTIIKSNIKKFSLLTIFIVAGQLLLIYAATINALVLNELIAMNLERFLKLSIYQMIVWCGIIFLDWVVKNYQVEVIQEFNLE IRNRVATDISNSTYQEFHSKSSGTYLSWLNNDVQTLNDQAFKQLFLVIKGISGTIFAVVTLNHYHWSLTVATLFSLMIML LVPKIFASKMREVSLNLTNQNEAFLKSSETILNGFDVLASLNILLYVLPKKIKEAGILLKMVIQRKTTVETLAGAISFFLNIF FQISLVFLTGYLAIKGIVKIGTIEAIGALTGVIFTALGELGGQLSSIIGTKPIFLKLYSINPIESNKMNDIEPNEVNRDFPLYEA KNICYKYGDKEILKNLNFCFQRNEKYLILGESGSGKSTLLKLLNGFLRDYSGELRFCGDDIKKTSYLNMVSNVLYVDQK AYLFEGTIRDNILLEENYTDEEILQSLEQVGLSVKDFPNNILDYYVGDDGRLLSGGQKQKITLARGLIRNKKIVLIDEGTSA IDRRTSLAIERKILDREDLTVIIVTHAPHPELKQYFTKIYQFPKDFI

ID9 705 bp

(SEO ID NO: 35)

**AGTCATCAAGCCTTAA** 

- 40 (SEQ ID NO: 36)
  ITVKQIMDEIAVSDMTARRYLQELADKDLLIRVHGGAEKLRTNSLLTNERSNIEKQALQTAEKQEIAHFAGSLVEERETIF
  IGPGTTLEFFARELPIDNIRVVTNSLPVFLILSERKLTDLILIGGNYRDITGAFVGTLTLQNLSNLQFSKAFVSCNGIQNGAL
  ATFSEEEGEAQRIALNNSNKKYLLADHSKFNKFDFYTFYNVSNLDTIVSDSKLSDSILFKLSKHIKVIKP
- 45 ID10 483 bp

55

60

(SEQ ID NO: 37)

ATGACTGAGTTTTCGTTAGATCTTCTTCTAGAAGCCATTAAACTAGCTCGTTGGACCTACTACTATCACTTGAAACA
GCTAGACAAAACAGATAAAGACCAAGAGCTTAAAACTGAAATTCAATCCATCTTTATCGAACACAAGGGAAATTA
TGCTTATCGCCGGGTTCATTTAGAACTAAGAAATCGTGGTTATCTGGTAAATCATAAAAGAGTTCAAGGCTTGaTGA
AAGTACTCAATTTACAAGCTAAAATGCGAAAGAAACGAAAATATTCTTCTCATAAAGGAGACGTTGGTAAGAAGG
CAGAGAATCTCATTCAAGCCCAATTTGAAGGCTCTAAAACAATGGAAAAGTGCTACACAGATGTGACTGAATTTGC
CATTCCAGCAAGTACTCAAAAGCTTTACTTATCACCAGTTTTTAGATGGCTTTAACAGCGAAATTATTGCTTTTTATC
TTTCTTGTTCGCCTAATTTAGAATAA

(SEQ ID NO: 38)

 $\label{thm:mass} MTEFSLDLLLEAIKLARWTYYYHLKQLDKTDKDQELKTEIQSIFIEHKGNYAYRRVHLELRNRGYLVNHKRVQGLMKV\\ LNLQAKMRKKRKYSSHKGDVGKKAENLIQAQFEGSKTMEKCYTDVTEFAIPASTQKLYLSPVLDGFNSEIIAFNLSCSPN\\ LE$ 

ID14 1266 bp

(SEQ ID NO: 39)

ATTGAGCCTGCTAAAACCTTTATCACTCGTGCCTTGGAAGCTGGAAAACACGTTGTTACTGCTAACAAGGACCTTTT AGCTGTCCATGGCGCAGAATTGCTAGAAATCGCTCAAGCTAACAAGGTAGCACTTTACTACGAAGCAGCAGTTGCT GGTGGGATTCCAATTCTTCGTACTTTAGCAAATTCCTTGGCTTCTGATAAAATTACGCGCGTGCTTGGAGTAGTCAA CGGAACTTCCAACTTCATGGTGACCAAGATGGTGGAAGAAGGCTGGTCTTACGATGATGCTCTTGCGGAAGCACAA 5 CGTCTAGGATTTGCAGAAAGCGATCCGACGAATGACGTAGATGGGATTGATGCAGCCTACAAGATGGTTATTTTGA GCCAATTTGCCTTTGGCATGAAGATTGCCTTTGATGATGTAGCCCACAAGGGAATCCGCAATATCACACCAGAAGA CAGAAGTGACTCCAACCTTCCTACCTAAAGCGCACCCACTTGCTAGTGTGAATGGCGTAATGAACGCTGTCTTTGT AGAATCTATCGGTATTGGTGAGTCTATGTACTACGGACCAGGTGCGGGTCAAAAACCAACTGCAACAAGTGTTGTA 10 GCTGATATTGTCCGTATCGTTCGTCGTTTGAATGATGGTACTATTGGCAAAGACTTCAACGAATATAGCCGTGACTT GGTCTTGGCAAATCCTGAAGATGTCAAAGCAAACTACTATTTCTCAATCTTGGCTCTAGACTCAAAAGGTCAGGTC TTGAAGTTGGCTGAAATCTTCAATGCTCAAGATATTTCCTTTAAGCAAAATCCTTCAAGATGGCAAAGAGGGTGACA AGGCCCTGTCGTTATCATCACACACACAGATTAATAAAGCCCAGCTTGAAAATGTCTCAGCTGAATTGAAGAAGGT TTCAGAATTCGACCTCTTGAATACCTTCAAGGTGCTAGGAGAATAA

15

PGFGTVASGVPFLLKENGGKINQSAHSDIKVAKVLVKDEDEKNRLLAAGNDFNFVTNVDDILSDQDITIVVELMGRIEPA KTFITRALEAGKHVVTANKDLLAVHGAELLEIAQANKVALYYEAAVAGGIPILRTLANSLASDKITRVLGVVNGTSNFM VTKMVEEGWSYDDALAEAQRLGFAESDPTNDVDGIDAAYKMVILSQFAFGMKIAFDDVAHKGIRNITPEDVAVAQELG YVVKLVGSIEETSSGIAAEVTPTFLPKAHPLASVNGVMNAVFVESIGIGESMYYGPGAGQKPTATSVVADIVRIVRRLND GTIGKDFNEYSRDLVLANPEDVKANYYFSILALDSKGQVLKLAEIFNAQDISFKQILQDGKEGDKARVVIITHKINKAQLE NVSAELKKVSEFDLLNTFKVLGE

#### ID16 1725 bp

25

(SEO ID NO: 41)

ATGAAACACCTATTATCTTACTTCAAACCCTACATCAAGGAATCAATTTTAGCCCCCCTTGTTCAAGCTGTTAGAAGC TGTTTTTGAGCTCTTGGTTCCCATGGTGATTGCTGGGATTGTTGACCAATCTTTACCTCAGGGAGATCAAGGTCATC TCTGGATGCAGATTGGCCTGCTCCTTATCTTTGCAGTAATTGGCGTTTTTAGTGGCCTTGATAGCTCAATTTTACTCAG 30 CAAAGGCAGCAGTAGGTTCTGCTAAGGAATTGACAAACGATCTTTATCGTCATATTCTTTCCTTGCCCAAGGACAG AATTCCTGCGTCTCTTTTTACGAGCGCCCATTATCGTTTTTTGGTGCCATTTTTATGGCTTATCGAATCTCAGCTGAGT TGACTITCTGGTTCTTAGTCTTGGCTGCCATTTTGACCATTGTCATTGTAGGGTTATCTCGATTGGTCAATCCTTTCT ACAGTAGTCTCAGAAAGAAAACGGACCAACTGGTTCAGGAAACGCGCCAGCAATTGCAAGGGATGCGGGTTATTC 35 GTGCTTTTGGTCAAGAAAACGAGAGTTACAGATTTTTCAAACCCTTAACCAAGTTTATGCTAGATTACAAGAAAA GACAGGTTTCTGGTCTAGTTTATTAACACCTCTGACCTATCTGATTGTCAATGGAACTCTTCTCGTTATTATCTGGCA AGGCTATATTTCAATTCAAGGAGGAGTGCTCAGTCAAGGTGCTCTCATTGCTCTTATCAATTACCTCTTACAGATTT TGGTGGAATTGGTCAAGCTAGCCATGTTGATCAATTCCCTCAACCAGTCCTATATCTCAGTCAAGCGAATCGAGGA 40 GTCCAAGAATTGACCTTTACCTATCCTGATGCGGCCCAGCCTTCTCTGAGATACATTTCCTTTGATATGACTCAAGG ACAAATTCTAGGTATCATCGGGGGAACTGGTTCTGGTAAATCAAGCTTGGTGCAACTCTTACTTGGACTTTATCCAG TAGACAAGGGGAACATTGACCTTTATCAAAATGGACGTAGTCCTCTTAATTTTGGAGCAGTGGCGGTCTTGGATTGC 

50 (SEO ID NO: 42)

MKHLLSYFKPYIKESILAPLFKLLEAVFELLVPMVIAGIVDQSLPQGDQGHLWMQIGLLLIFAVIGVLVALIAQFYSAKAA VGSAKELTNDLYRHILSLPKDSRDRLTTSSLVTRLTSDTYQIQTGINQFLRLFLRAPIIVFGAIFMAYRISAELTFWFLVLVA ILTIVIVGLSRLVNPFYSSLRKKTDQLVQETRQQLQGMRVIRAFGQEKRELQIFQTLNQVYARLQEKTGFWSSLLTPLTYL IVNGTLLVIIWQGYISIQGGVLSQGALIALINYLLQILVELVKLAMLINSLNQSYISVKRIEEVFVEAPEDIHSELEQKQATR DKVLQVQELTFTYPDAAQPSLRYISFDMTQGQILGIIGGTGSGKSSLVQLLLGLYPVDKGNIDLYQNGRSPLNLEQWRSW IAYVPQKVELFKGTIRSNLTLGFNQEVSDQELWQALEIAQAKDFVSEKEGLLDALVEAGGRNFSGGQKQRLSIARAVLR QAPFLILDDATSALDTITESKLLKAIRENFPNTSLILISQRTSTLQMADQILLLEKGELLAVGKHDDLMKSSQVYCEINASQ HGKED

#### ID18 1224 bp

(SEQ ID NO: 43)

ATGAAACGTTCTCCGACTCAAGAGTCGATTACAGTTTGCTCTTGCCAGTATTTTTTCTACTGGTCATCGGTGTGGT
GGCTATCTATATAGCCGTTAGTCATGATTATCCCAATAATATTCTGCCCATTTTAGGGCAGCAGGTCGCCTGGATTG
CCTTGGGGCTTGTGATTGGTTTTGTGGTCATGCTCTTTAATACAGAATTTCTTTGGAAGGTGACCCCCTTTCTATATA

- 15 (SEQ ID NO: 44)

  MKRSLDSRVDYSLLLPVFFLLVIGVVAIYIAVSHDYPNNILPILGQQVAWIALGLVIGFVVMLFNTEFLWKVTPFLYILGL
  GLMILPIVFYNPSLVASTGAKNWVSINGITLFQPSEFMKISYILMLARVIVQFTKKHKEWRRTVPLDFLLIFWMILFTIPVL
  VLLALQSDLGTALVFVAIFSGIVLLSGVSWKIIIPVFVTAVTGVAGFLAIFISKDGRAFLHQIGMPTYQINRILAWLNPFEFA
  QTTTYQQAQGQIAIGSGGLFGQGFNASNLLIPVRESDMIFTVIAEDFGFIGSVLVIALYLMLIYRMLKITLKSNNQFYTYIS
  TGLIMMLLFHIFENIGAVTGLLPLTGIPLPFISQGGSAIISNLIGVGLLLSMSYQTNLAEEKSGKVPFKRKKVVLKQIK

#### ID22 987 bp

- (SEO ID NO: 45) 25 ATGGTGGCTAAGAAAAAATCTTATTTTTATGTGGTCTTTTTCTCTTGGAGGTGGTGCAGAGAAGATTCTATCAAC CATTGTTTCAAATCTGGATCCAGAAAAGTATGATATTGATATTCTTGAAAATGGAGCACTTTGACAAGGGATATGAA TCTGTTCCAAAGCATGTACGCATTTTAAAATCCCTTCAAGATTATCGCCAAACCAGATGGTTACGAGCTTTTTTGTG GAGAATGAGAATTTATTTTCCAAGACTGACTCGTCGTTTGCTTGTAAAAGATGATTATGATGTTGAAGTTTCTTTTA 30 AGAACTTCTTAAGGATAGCTCTAAAAGAGAATCACATAGAAGCCAGTTGGATGCTGCGAATACAATTGTAGGGATT TCAAAAAAGACCAGCAATTCTATCAAGGAAGTTTATCCAGATTATACTTCTAAATTACAGACAATCTACAATGGAT ATGATTTTCAGACTATTCTAGAAAAATCTCAAGAGAAGATCGATATCGAGATTGCTCCTCAAAGTATCTGTACTATC GGACGGATTGAGGAAAATAAGGGTTCTGACCGTGTAGTGGAAGTGATACGATTATTACACCAAGAGGGAAAAAAC TATCATCTCTATTTTATCGGGGCTGGTGATATGGAAGAGGGAACTGAAAAAACGAGTCAAAGAGTATGGGATTGAG 35 AAACAAGAAGGTTTTCCTGGAGTGTATGTGGAGGCCTTGAGTCTGGGACTCCCTTTTATCTCTACGGACGTTGGAG GGGCTGAGGAATTATCCCAAGAAGGACGATTTGGACAAATCATTGAGAGCAATCAAGAGGCAGCTCAGGCGATTA CTAATTACATGACTTCTGCCTCAAACTTTGATGTCGATGAGGCTAGCCAATTCATCAACAATTTACAATTACAAAA CAAATCGAACAAGTAGAAAAACTATTAGAGGAGTAG
- 40
  (SEQ ID NO: 46)
  MVAKKKILFFMWSFSLGGGAEKILSTIVSNLDPEKYDIDILEMEHFDKGYESVPKHVRILKSLQDYRQTRWLRAFLWRM
  RIYFPRLTRRLLVKDDYDVEVSFTIMNPPLLFSKRREVKKISWIHGSIEELLKDSSKRESHRSQLDAANTIVGISKKTSNSIK
  EVYPDYTSKLQTIYNGYDFQTILEKSQEKIDIEIAPQSICTIGRIEENKGSDRVVEVIRLLHQEGKNYHLYFIGAGDMEEEL
  KKRVKEYGIEDYVHFLGYQKNPYQYLSQTKVLLSMSKQEGFPGVYVEALSLGLPFISTDVGGAEELSQEGRFGQIIESNQ
  EAAQAITNYMTSASNFDVDEASQFIQQFTITKQIEQVEKLLEE

### ID23 1434 bp

- 50 (SEO ID NO: 47) ATGGAAACTGCATTAATTAGTGTGATTGTGCCAGTCTATAATGTGGCGCAGTACCTAGAAAAATCGATAGCTTCCA TTCAGAAGCAGACCTATCAAAATCTGGAAATTATTCTTGTTGATGATGGTGCAACAGATGAAAGTGGTCGCTTGTG TGATTCAATCGCTGAACAAGATGACAGGGTGTCAGTGCTTCATAAAAAGAACGAAGGATTGTCGCAAGCACGAAA 55 AGAGCTTATATGAGCAATTAGTTCAAGAAGATGCGGATGTTTCGAGCTGTGGTGTCATGAATGTCTATGCTAATGA TGAAAGCCCACAGTCAGCCAATCAGGATGACTATTTTGTCTGTGATTCTCAAACATTTCTAAAGGAATACCTCATA GGTGAAAAAATACCTGGGACGATTTGCAATAAGCTAATCAAGAGACAGATTGCAACTGCCCTATCCTTTCCTAAGG GGTTGATTTACGAAGATGCCTATTACCATTTTGATTTAATCAAGTTGGCCAAGAAGTATGTGGTTAATACTAAACCC TATTACTATTCCATAGAGGGGATAGTATTACGACCAAACCCTATGCAGAGAAGGATTTAGCCTATATTGATAT 60 CTACCAAAAGTTTTATAATGAAGTTGTGAAAAACTATCCTGACTTGAAAAGAGGTCGCTTTTTTTCAGATTGGCCTATG CCCACTTCTTTATTCTGGATAAGATGTTGCTAGATGATCAGTATAAACAGTTTGAAGCCTATTCTCAGATTCATCGT TTTTTAAAAGGCCATGCCTTTGCTATTTCTAGGAATCCAATTTTCCGTAAGGGGAGAAGAATTAGTGCTTTGGCCCT ATTCATAAATATTTCCTTATATCGATTCTTATTACTGAAAAATATTGAAAAAATCTAAAAAATTACATTAG
- 65 (SEO ID NO: 48)

METALISVIVPYYNVAQYLEKSIASIQKQTYQNLEIILVDDGATDESGRLCDSIAEQDDRVSVLHKKNEGLSQARNDGMK QAHGDYLIFIDSDDYIHPEMIQSLYEQLVQEDADVSSCGVMNVYANDESPQSANQDDYFVCDSQTFLKEYLIGEKIPGTI CNKLIKRQIATALSFPKGLIYEDAYYHFDLIKLAKKYVVNTKPYYYYFHRGDSITTKPYAEKDLAYIDIYQKFYNEVVKN YPDLKEVAFFRLAYAHFFILDKMLLDDQYKQFEAYSQIHRFLKGHAFAISRNPIFRKGRRISALALFINISLYRFLLLKNIE KSKKLH

# ID24 735bp

5

(SEQ ID NO: 50)
MRIKEKTNNINGGIKNVSKHYGHSIILKDINFALNKGEIVGLAGRNGVGKSTLMKILVQNNQPTSGNIISSDNVGYLIEEP
KLFLSKTGLENLKYLSNLYGVDYNQERFRCLIQELDLTQSINKKVKTYSLGTKQKLALLLTLVTEPDILILDEPTNGLDIES
SQIVLAVLKKLALHENVGILISSHKLEDIEEICERVLFLENGLLTFQKVGKDSHNFLFEIAFSSATDRDIFITKQEFWDIV

### ID25 1704bp

(SEO ID NO: 51) 30 ATGACTGAATTAGATAAACGTCACCGCAGTAGCATTTATGACAGCATGGTTAAATCACCTAACCGTGCTATGCTTC GTGCGACTGGTATGACAGATAAGGACTTTGAAACATCGATTGTGGGAGTGATTTCGACTTGGGCGGAAAATACACC ATGTAACATTCACTTGCATGATTTCGGGAAACTGGCTAAAGAAGGTGTCAAATCTGCAGGCGCTTGGCCTGTACAG TTTGGAACCATTACCGTAGCGGACGGGATCGCTATGGGAACGCCTGGTATGCGTTTCTCTAACATCTCGTGACAT CATCGCGGACTCCATCGAGGCGGCTATGAGTGGTCACAACGTGGATGCCTTCGTCGCTATCGGTGGCTGTGACAAG 35 AACATGCCTGGATCTATGATTGCTATTGCTAATATGGATATCCCAGCTATTTTCGCCTATGGTGGAACTATTGCACC GGGAAATCTTGATGGTAAAGATATCGACTTGGTTTCTGTCTTTGAAGGTATCGGAAAATGGAACCACGGTGACATG ATACCATGGCAACTGCTATCGAAGTTCTAGGGATGAGTTTGCCAGGGTCATCCTCTCACCCAGCTGAATCAGCTGA TAAGAAGAAGATATCGAAGCAGCAGGACGTGCTGTTGTTAAGATGTTGGAACTTGGTCTCAAACCATCAGATATC 40 TTGACTCGTGAAGCCTTTGAAGATGCTATCACTGTAACGATGGCTCTCGGTGGTTCTACAAACGCCACTCTTCACTT GCTCGCCATTGCCCATGCCGCAAATGTTGACTTGTCACTTGAGGACTTCAATACGATTCAAGAACGTGTGCCTCACT TGGCCGACTTGAAACCATCTGGTCAGTATGTCTTCCAAGACCTCTACGAAGTCGGTGGTGTCCCTGCGGTTATGAA GTATTTGTTGGCAAATGGTTTCCTTCACGGAGATCGCATCACATGTACTGGTAAGACTGTAGCTGAAAACTTGGCTG ACTTTGCAGACTTGACTCCAGGCCAAAAAGTTATCATGCCACTTGAAAATCCAAAACGTGCGGATGGTCCGCTTAT 45 CATCTTGAACGGGAACCTTGCTCCTGACGGTGCAGTTGCCAAGGTATCAGGTGTTAAAGTGCGTCGTCACGTTGGG CCAGCTAAGGTCTTTGACTCAGAAGAAGATGCGATTCAGGCCGTTCTGACAGATGAAATCGTTGATGGCGATGTAG TCGTTGTTCGTTTTGTTGGACCTAAAGGTGGTCCTGGTATGCCTGAGATGCTATCACTTTCTTCAATGATTGTTGGTA TATCGCTCCTGAAGCTCAGGATGGTGGACCAATTGCCTATCTCCGTACCGGCGATATCGTTACGGTTGACCAAGAT 50 ACCAAAGAAATTTCTATGGCCGTATCCGAAGAAGAACTTGAAAAAACGCAAGGCAGAAACAACCTTGCCACCACTT

(SEQ ID NO: 52)
 MTELDKRHRSSIYDSMVKSPNRAMLRATGMTDKDFETSIVGVISTWAENTPCNIHLHDFGKLAKEGVKSAGAWPVQFG
TITVADGIAMGTPGMRFSLTSRDIIADSIEAAMSGHNVDAFVAIGGCDKNMPGSMIAIANMDIPAIFAYGGTIAPGNLDGK
DIDLVSVFEGIGKWNHGDMTAEDVKRLECNACPGPGGCGGMYTANTMATAIEVLGMSLPGSSSHPAESADKKEDIEAA
GRAVVKMLELGLKPSDILTREAFEDAITVTMALGGSTNATLHLLAIAHAANVDLSLEDFNTIQERVPHLADLKPSGQYVF
QDLYEVGGVPAVMKYLLANGFLHGDRITCTGKTVAENLADFADLTPGQKVIMPLENPKRADGPLIILNGNLAPDGAVA
KVSGVKVRRHVGPAKVFDSEEDAIQAVLTDEIVDGDVVVVRFVGPKGGPGMPEMLSLSSMIVGKGQGDKVALLTDGR
FSGGTYGLVVGHIAPEAQDGGPIAYLRTGDIVTVDQDTKEISMAVSEEELEKRKAETTLPPLYSRGVLGKYAHIVSSASR
GAVTDFWNMDKSGKK

TACAGCCGTGGTGTCCTCGGTAAATATGCCCACATCGTATCATCTGCTTCACGCGGAGCCGTGACAGACTTCTGGA

#### ID26 274bp

65

(SEQ ID NO: 53)

ATATGGACAAGTCAGGTAAAAAATAA

ATGTTATAAAAAATAAAGAATTTAAGGAGAAATACAATATGTCAATTTTTATTGGAGGAGCATGGCCATATGCA AACGGTTCGTTACATATTGGTCACGCGGCAGCGCTTTTACCGGGGGATATTCTTGCAAGATACTATCGTCAGAAGGGAGAGGAAGTTTTATATGTTTCTGGAAGTGATTGTAATGGAACCCCTATTTCTATCAGAGCTAAAAAAAGAAAATAA GTCTGTGAAAGAAATTGCTGATTTTTATCATAAGGAATTTAATCCA

5 (SEO ID NO: 54)

CYNKNKEFKEKYNMSIFIGGAWPYANGSLHIGHAAALLPGDILARYYROKGEEVLYVSGSDCNGTPISIRAKKENKSVK **EIADFYHKEFNP** 

#### 10 ID28 1065bp

(SEO ID NO: 55)

ATGACAACATTATTTTCAAAAAATTAAAGAAGTAACAGAACTTGCTGCAGTCTCAGGTCATGAAGCGCCTGTCCGTG CTTATCTTCGTGAAAAGTTGACACCGCATGTGGATGAAGTGGTGACAGATGGCTTGGGTGGTATTTTTGGTATCAA 15 ACATTCAGAAGCTGTGGATGCACCGCGCGTCTTGGTCGCTTCTCATATGGACGAAGTTGGTTTTATGGTCAGCGAA ATCAAGCCAGATGGTACCTTCCGTGTCGTAGAAATCGGTGGCTGGAACCCCATGGTGGTTAGCAGCCAACGTTTCA AACTCTTGACTCGTGATGGTCATGAAATTCCTGTGATTTCAGGTTCTGTTCCTCCGCATTTGACTCGTGGAAAGGGG GGACCAACCATGCCAGCCATTGCCGATATCGTTTTTGATGGTGGTTTTTGCGGACAAGGCTGAGGCAGAAAGTTTTG 

20 GAACTCTATCTGGGTTCTAACGTCCAAGAAGAAGTTGGTCTGCGTGGCGCTCATACCTCTACAACCAAGTTTGACC CAGAAGTCTTCCTCGCAGTTGATTGCTCACCAGCAGGTGATGTCTACGGTGGTCAAGGCAAGATTGGAGATGGAAC CTTGATTCGTTTCTATGATCCAGGTCACTTGCTTCTCCCAGGGATGAAGGATTTCCTTTTGACAACGGCTGAAGAAG CTGGTATCAAGTACCAATACTGTGGTAAAGGCGGAACAGATGCAGGTGCAGCTCATCTGAAAAATGGTGGTGT

25 CCCATCAACAACTATCGGTGTCTGCGCTCGTTATATCCATTCTCACCAAACCCTCTATGCAATGGATGACTTCCTAG AAGCGCAAGCTTTCTTACAAGCCTTGGTGAAGAAATTGGATCGTTCAACGGTTGATTTGATTAAACATTATTAA

(SEQ ID NO: 56)

MTTLFSKIKEVTELAAVSGHEAPVRAYLREKLTPHVDEVVTDGLGGIFGIKHSEAVDAPRVLVASHMDEVGFMVSEIKP 30 DGTFRVVEIGGWNPMVVSSORFKLLTRDGHEIPVISGSVPPHLTRGKGGPTMPAIADIVFDGGFADKAEAESFGIRPGDTI VPDSSAILTANEKNIISKAWDNRYGVLMVSELAEALSGQKLGNELYLGSNVQEEVGLRGAHTSTTKFDPEVFLAVDCSP AGDVYGGQGKIGDGTLIRFYDPGHLLLPGMKDFLLTTAEEAGIKYQYYCGKGGTDAGAAHLKNGGVPSTTIGVCARYI **HSHOTLYAMDDFLEAOAFLOALVKKLDRSTVDLIKHY** 

#### 35 ID31 1182bp

(SEQ ID NO: 57)

ATGGAATTTTCTATGAAATCAGTCAAAGGACTACTCTTTATCATAGCTAGTTTTATCTTGACTCTTTTGACTTTGATG AACACTTCTCCCCAATTCATGATTCCAGGACTAGCTTTAACAAGCCTATCTCTGACTTTTATCCTAGCCACTCGTCTC 40 CCACTACTAGAAAGCTGGTTTCACAGTTTGGAGAAGGTCTACACCGTCCACAAATTCACAGCCTTTCTCAAATCAT CCTACTAATCTTTCATAACTTTAGTATGGGCGGTTTGTGGGGGCTCTCGCTTAGCTGCTCAGTTTGGCAATCTTGCCAT CTATATCTTTGCCAGCATCATCCTTGTCGCCTATTTAGGCAAATACATCCAATACGAAGCTTGGCGATGGATTCACC GCCTGGTTTACCTAGCCTATATTTTAGGACTCTTTCACATCTACATGATAATGGGCAATCGTCTCCTTACATTTAATC

TTCTAAGTTTTCTTGTTGGTAGCTATGCCCTTTTAGGCTTACTAGCTGGTTTTTATATCATTTTTCTATATCAAAAGAT 45 TTCCTTCCCCTATCTAGGGAAAATTACCCATCTCAAACGCTTAAATCACGATACTAGAGAAAATTCAAATCCATCTTA GCAGACCTTTCAACTATCAATCAGGACAATTTGCCTTTCTAAAGATTTTCCAAGAAGGCTTTGAAAGTGCTCCGCAT CCCTTTTCTATCTCAGGAGGTCATGGTCAAACTCTTTACTTTACTGTTAAAACTTCAGGCGACCATACCAAGAATAT CTATGATAATCTTCAAGCCGGCAGCAAAGTAACCCTAGACAGAGCTTACGGACACATGATCATAGAAGAAGGACG AGAAAATCAGGTTTGGATTGCTGGAGGTATTGGGATCACCCCCTTCATCTCTTACATCCGTGAACATCCTATTTTAG

50 ATAAACAGGTTCACTTCTACTATAGCTTCCGTGGAGATGAAAATGCAGTCTACCTAGATTTACTCCGTAACTATGCT CAGAAAAATCCTAATTTTGAACTCCATCTAATCGACAGTACGAAAGACGGCTATCTTAATTTTGAACAAAAAGAAG TGCCCGAACATGCAACCGTCTATATGTGTGGTCCTATTTCTATGATGAAGGCACTTGCCAAACAGATTAAGAAACA AAATCCAAAAACAGAGCATATTTAC

55

60

MEFSMKSVKGLLFIIASFILTLLTWMNTSPOFMIPGLALTSLSLTFILATRLPLLESWFHSLEKVYTVHKFTAFLSIILLIFHN FSMGGLWGSRLAAQFGNLAIYIFASIILVAYLGKYIQYEAWRWIHRLVYLAYILGLFHIYMIMGNRLLTFNLLSFLVGSY ALLGLLAGFYIIFLYQKISFPYLGKITHLKRLNHDTRÉIQIHLSRPFNYQSGQFAFLKIFQEGFESAPHPFSISGGHGQTLYFT VKTSGDHTKNIYDNLOAGSKVTLDRAYGHMIIEEGRENOVWIAGGIGITPFISYIREHPILDKOVHFYYSFRGDENAVYL DLLRNYAQKNPNFELHLIDSTKDGYLNFEQKEVPEHATVYMCGPISMMKALAKQIKKQNPKTEHIY

# ID32 900bp

(SEO ID NO: 59)

65 ATGACTTTTAAATCAGGCTTTGTAGCCATTTTAGGACGTCCCAATGTTGGGAAGTCAACCTTTTTAAATCACGTTAT GGGGCAAAAGATTGCCATCATGAGTGACAAGGCGCAGACAACGCGCAATAAAATCATGGGAATTTACACGACTGA

(SEQ ID NO: 60)
MTFKSGFVAILGRPNVGKSTFLNHVMGQKIAIMSDKAQTTRNKIMGIYTTDKEQIVFIDTPGIHKPKTALGDFMVESAYS
TLREVDTVLFMVPADEARGKGDDMIIERLKAAKVPVILVVNKIDKVHPDQLLSQIDDFRNQMDFKEIVPISALQGNNVSR
LVDILSENLDEGFQYFPSDQITDHPERFLVSEMVREKVLHLTREEIPHSVAVVVDSMKRDEETDKVHIRATIMVERDSQK
GIIIGKGGAMLKKIGSMARRDIELMLGDKVFLETWVKVKKNWRDKKLDLADFGYNEREY

# ID33 855bp

15

- (SEQ ID NO: 62)

  MLLVFTEGGLMPELPEVETVCRGLEKLIIGKKISSIEIRYPKMIKTDLEEFQRELPSQIIESMGRRGKYLLFYLTDKVLISHL RMEGKYFYYPDQGPERKHAHVFFHFEDGGTLVYEDVRKFGTMELLVPDLLDVYFISKKLGPEPSEQDFDLQVFQSALA KSKKPIKSHLLDQTLVAGLGNIYVDEVLWRAQVHPARPSQTLTAEEATAIHDQTIAVLGQAVEKGGSTIRTYTNAFGED GSMQDFHQVYDKTGQECVRCGTIIEKIQLGGRGTHFCPNCQRRD

# 40 <u>ID34 633bp</u>

(SEQ ID NO: 63)

AAAGGAGGACTGA

(SEQ ID NO: 64)

MSKLSKEGLMGKIIGITGGIASGKSTVTNFLRQQGFQVVDADAVVHQLQKPGGRLFEALVQHFGQEIILENGELNRPLLA SLIFSNPDEREWSKQIQGEIIREELATLREQLAQTEEIFFMDIPLLFEQDYSDWFAETWLVYVDRDAQVERLMKRDQLSK DEAESRLAAQWPLEKKKDLASQVLDNNGNQNQLLNQVHILLEGGRQDDRD

# ID35 1269bp

60 (SEO ID NO: 65)

65

(SEO ID NO: 66)

MIIMAIRTSFLIKCISFLREVGKMTEINWKDNLRIAWFGNFLTGASISLVVPFMPIFVENLGVGSQQVAFYAGLAISVSAIS
AALFSPIWGILADKYGRKPMMIRAGLAMTITMGGLAFVPNIYWLIFLRLLNGVFAGFVPNATALIASQVPKEKSGSALGT
LSTGVVAGTLTGPFIGGFIAELFGIRTVFLLVGSFLFLAAILTICFIKEDFQPVAKEKAIPTKELFTSVKYPYLLLNLFLTSFVI
QFSAQSIGPILALYVRDLGQTENLLFVSGLIVSSMGFSSMMSAGVMGKLGDKVGNHRLLVVAQFYSVIIYLLCANASSPL
QLGLYRFLFGLGTGALIPGVNALLSKMTPKAGISRVFAFNQVFFYLGGVVGPMAGSAVAGQFGYHAVFYATSLCVAFS
CLFNLIQFRTLLKVKEI

### ID36 1311bp

(SEQ ID NO: 67)

(SEQ ID NO: 68)

MALPTIAIVGRPNVGKSTLFNRIAGERISIVEDVEGVTRDRIYATGEWLNRSFSMIDTGGIDDVDAPFMEQIKHQAEIAME
EADVIVFVVSGKEGITDADEYVARKLYKTHKPVILAVNKVDNPEMRNDIYDFYALGLGEPLPISSVHGIGTGDVLDAIVE
NLPNEYEEENPDVIKFSLIGRPNVGKSSLINAILGEDRVIASPVAGTTRDAIDTHFTDTDGQEFTMIDTAGMRKSGKVYEN
TEKYSVMRAMRAIDRSDVVLMVINAEEGIREYDKRIAGFAHEAGKGMIIVVNKWDTLEKDNHTMKNWEEDIREQFQY
LPYAPIIFVSALTKQRLHKLPEMIKQISESQNTRIPSAVLNDVIMDAIAINPTPTDKGKRLKIFYATQVATKPPTFVIFVNEE
ELMHFSYLRFLENQIRKAFVFEGTPIHLIARKRK

# ID37 714bp

50

(SEO ID NO: 69)

- 65 (SEO ID NO: 70)

MTETIKLMKAHTSVRRFKEQEIPQVDLNEILTAAQMASSWKNFQSYSVIVVRSQEKKDALYELVPQEAIRQSAVFLLFVG DLNRAEKGARLHTDTFQPQGVEGLLISSVDAALAGQNALLAAESLGYGGVIIGLVRYKSEEVAELFNLPDYTYSVFGMA LGVPNQHHDMKPRLPLENVVFEEEYQEQSTEAIQAYDRVQADYAGARATTSWSQRLAEQFGQAEPSSTRKNLEQKKLL

# 5 ID38 729bp

(SEQ ID NO: 71)

- ATGACAGAAÁTTAGACTAGAGCACGTCAGTTATGCCTATGGTCAGGAGAGGATTTTAGAGGATATCAACCTACAG
  GTGACTTCAGGCGAAGTGGTTTCCATCCTAGGCCCAAGTGGTGTTGGAAAGACCACCCTCTTTAATCTAATCGCTG
  GGATTITAGAAGTTCAGTCAGGGAGAATTGTCCTTGATGGTGAAGAAAATCCCAAGGGGCGCGTGAGTTATATGTT
  GCAAAAGGATCTGCTCTTGGAGCACAAGACGGTGCTTGGAAAATATCATTCTGCCCCTCTTGATTCAAAAGGTGGAT
  AAGGCAGAAGCTATTTCCCGAGCGGATAAAATTCTTGCGACCTTCCAGCTGACAGCTGAAGAAGCAAGATATCCTC
  ATGAACTTAGCGGTGGGATGAGCATAGACAAAGATGGAACTCCACGCTTGGTATCTTGAGAGCAGT
  TGCAGCTAACAACCCTGGATCATCACGCATAGTATTGAGGAGCCCTCAATCTTCAGCGACCGTATCTATATCTTGAA
  AAATCGCCCTGGGCAGATTGTTTCAGAAATTAAACTAGATTGGTCTGAAGATGAGACAAGGAAGTCCAAAAGAT
- TGCCTACAAACGTCAAATTTTGGCGGAATTAGGCTTAGATAAGTAG

  (SEQ ID NO: 72)
  MTEIRLEHVSYAYGQERILEDINLQVTSGEVVSILGPSGVGKTTLFNLIAGILEVQSGRIVLDGEENPKGRVSYMLQKDLL
- MTEIRLEHVSYAYGQERILEDINLQVTSGEVVSILGPSGVGKTTLFNLIAGILEVQSGRIVLDGEENPKGRVSYMLQKDLL
  LEHKTVLGNIILPLLIQKVDKAEAISRADKILATFQLTAVRDKYPHELSGGMRQRVALLRTYLFGHKLFLLDEAFSALDE
  MTKMELHAWYLEIHKQLQLTTLIITHSIEEALNLSDRIYILKNRPGQIVSEIKLDWSEDEDKEVQKIAYKRQILAELGLDK

# ID39 2433bp

25

(SEQ ID NO: 73)

- ATGGGCATGCCGCAGACTCCTAGTGGTGGTCTCGAGGATTATACGCATGATTTGACAGAGCAAGCGCGTTCTGGCA
  AGTTAGAACCAGTCATCGGTCGGGACAAGGAAATCTCACGTATGATTCAAATCTTGAGCCGGAAGACTAAGAACA
  ACCCTGTCTTGGTTGGGGATGCTGGTGTCGGGAAAACAGCTCTGGCGCTTTGGTCTTGCCCAGCGTATTGCTAGTGGT
  GACGTGCCTGCGGAAATGGCTAAGATGCGCGTGTTAGAACTTGATTTGATGAATGTCGTTGCAGGGACACGCTTCC
  GTGGTGACTTTGAAGAACAGCATGAATAATATCATCAAGGATATTGAAGAAGATGGCCAAGTCATCCTCTTTATCGA
- 45
  AAGCAAAGCATGTAAAAGCAGACGATTCAGATTTGAGTCCAGCTGACAAGGCCAGCACAAGAGCAAGAGAAGCAGATGGAAA
  45
  CAGGCAGCCCAGCTAATCGCAAAAGAAGAAGAAGTACCTGTCTACAAAGACTTGGTGACAGAGTCTGATATTTTG
  ACCACCTTGAGTCGCTTGTCAGGAATCCCAGTTCAAAAACTGACTCAAACGGATGCTAAGAAGTATTTAAATCTTG
  AAGCAGAACTCCATAAACGGGTTATCGGTCAAGATCAAGCTGTTTCAAGCATTAGCCGTGCCATTCGCCGCAACCA
  GTCAGGGATTCGCAGTCATAAGCGTCCGATTGGTTCCTTTTATGTTCCTAGGGCCTACAGGTGTCGGGAAAACTGAA
- CCAGGAAAATATGGAAAAACGCATGTTTGAAGAACTGAAAAAAGCTTATAGACCGGAATTCATCAACCGTATTGA
  TGAGAAGGTGGTCTTCCATAGCCTATCTAGTGATCATATGCAGGAAGTGGTGAAGATTATGGTCAAGCCTTTAGTG
  GCAAGTTTGACTGAAAAAGGCATTGACTTGAAATTACAAGCTTCAGCTCTGAAATTGTTAGCAAAATCAAGGATATG
  ACCCAGAGATGGGAGCTCGCCACTTCGCAGAACCCTGCAAACAGAAGTGGAGGACAAGTTGGCAGAACTTCTTC
  TCAAGGGAGATTTAGTGGCAGGCAGCACACTTAAGATTGGTGCAAAGCAGGCCAGTTAAAATTTGATATTGCATA

60 (SEO ID NO: 74)

MNYSKALNECIESAYMVAGHFGARYLESWHLLIAMSNHSYSVAGATLNDYPYEMDRLEEVALELTETDYSQDETFTEL PFSRRLQVLFDEAEYVASVVHAKVLGTEHVLYAILHDSNALATRILERAGFSYEDKKDQVKIAALRRNLEERAGWTRED LKALRQRHRTVADKQNSMANMMGMPQTPSGGLEDYTHDLTEQARSGKLEPVIGRDKEISRMIQILSRKTKNNPVLVGD AGVGKTALALGLAQRIASGDVPAEMAKMRVLELDLMNVVAGTRFRGDFEERMNNIIKDIEEDGQVILFIDELHTIMGSG SGIDSTLDAANILKPALARGTLRTVGATTQEEYQKHIEKDAALSRRFAKVTIEEPSVADSMTILQGLKATYEKHHRVQIT

DEAVETAVKMAHRYLTSRHLPDSAIDLLDEAAATVQNKAKHVKADDSDLSPADKALMDGKWKQAAQLIAKEEEVPV YKDLVTESDILTTLSRLSGIPVQKLTQTDAKKYLNLEAELHKRVIGQDQAVSSISRAIRRNQSGIRSHKRPIGSFMFLGPTG VGKTELAKALAEVLFDDESALIRFDMSEYMEKFAASRLNGAPPGYVGYEEGGELTEKVRNKPYSVLLFDEVEKAHPDIF NVLLQVLDDGVLTDSKGRKVDFSNTIIIMTSNLGATALRDDKTVGFGAKDIRFDQENMEKRMFEELKKAYRPEFINRIDE KVVFHSLSSDHMQEVVKIMVKPLVASLTEKGIDLKLQASALKLLANQGYDPEMGARPLRRTLQTEVEDKLAELLLKGD LVAGSTLKIGVKAGOLKFDIA

# ID40 1008bp

5

- 10 (SEQ ID NO: 75)
  ATGAAGAAACATGGAAAGTGTTTTTAACGCTTGTAACAGCTCTTGTAGCTGTTGTGCCTTGTGGCCTGTGGTCAAG
  GAACTGCTTCTAAAGACAACAAGAGGCAGAACTTAAGAAGGTTGACTTTATCCTAGACTGGACACCAAATACCA
  ACCACACAGGGCTTTATGTTGCCAAGGAAAAAGGTTATTTCAAAGAAGCTGGAGTGGATGTTGATTTGAAATTGCC
  ACCAGAAGAAAGTTCTTCTGACTTGGTTATCAACGGAAAGGCACCATTTGCAGTGTATTTCCAAGACTACATGGCT

- 25
  (SEQ ID NO: 76)
  MKKTWKVFLTLVTALVAVVLVACGQGTASKDNKEAELKKVDFILDWTPNTNHTGLYVAKEKGYFKEAGVDVDLKLP
  PEESSSDLVINGKAPFAVYFQDYMAKKLEKGAGITAVAAIVEHNTSGIISRKSDNVSSPKDLVGKKYGTWNDPTELAML
  KTLVESQGGDFEKVEKVPNDSNSITPIANGVFDTAWIYYGWDGILAKSQGVDANFMYLKDYVKEFDYYSPVIIANND
  YLKDNKEEARKVIQAIKKGYQYAMEHPEEAADILIKNAPELKEKRDFVIESQKYLSKEYASDKEKWGQFDAARWNAFY
  KWDKENGILKEDLTDKGFTNEFVK

## ID41 762bp

- 35 (SEQ ID NO: 77)
  TTGATGAGAAACTTGAGAAGTATACTGAGACGACACATTAGTCTATTGGGCTTTCTCGGAGTATTGTCAATCTGGC
  AGTTAGCAGGTTTTCTTAAACTTCTCCCCAAGTTTATCCTGCCGACACCTCTTGAAATTCTCCAGCCCTTTGTTCGTG
  ACAGAGAATTTCTCTGGCACCATAGCTGGGCGACCTTGAGAGTGGCTTTACTGGGGCTGATTTTGGGAGTTTTGATT
- TTGGTGTTTATATGATTCAGTCTAAAAAACTGTTTCAGTATGATACCATGTTTGCCATTATTATTCTGGTGTCGATTA

  45 TCAGTCTTTTGGGTATGAAGCTGGTCGATATCAGTGAAAAATATGTGATTAAATGGAAACGTTCGTAG
  - (SEQ ID NO: 78)
- MMRNLRSILRRHISLLGFLGVLSIWQLAGFLKLLPKFILPTPLEILQPFVRDREFLWHHSWATLRVALLGLILGVLIACLM AVLMDSLTWLNDLIYPMMVVIQTIPTIAIAPILVLWLGYGILPKIVLIILTTTFPIIVSILDGFRHCDKDMLTLFSLMRAKPW QILWHFKIPVSLPYFYAGLRVSVSYAFITTVVSEWLGGFEGLGVYMIQSKKLFQYDTMFAIIILVSIISLLGMKLVDISEKY VIKWKRS

# ID42 372bp

- 55 (SEQ ID NO: 79)
  - TIGATITITIAATCCTATTTGCTGTATGATAAGGGAAAAGAAAGGGGACAGAGATATGGCTTTTACCAATACCCACA
    TGCGATCTGCTAGTTTTGGTATTGTTACCAGCTTGCCTGATGACATCATTGACTCTTTTTGGTATATCATCGACCATT
    TCTTAAAAAATGTCTTTGAATTGGAAGAAGAACTCGAGTTTCAATTGCTTAATAACCAAGGAAAGATTACCTTCCA
    CTFTTCAAGTCAACACCTCCCTACAGCCATTGATTTTGACTTTAACCATCCTTTCGACCCTCGTTATCCCCCAAGAGT
- 60 ACTGGTTTTAGACATGGACGGTAGAGAAACTATCCTCCTCCCAGAAGAAAATGACCTATTTTAA
  - (SEQ ID NO: 80)
  - MIFNPICCMIREKKGDRDMAFTNTHMRSASFGIVTSLPDDIIDSFWYIIDHFLKNVFELEEELEFQLLNNQGKITFHFSSQH LPTAIDFDFNHPFDPRYPPRVLVLDMDGRETILLPEENDLF

### ID43 1569bp

ACAGCGGTGTCATTCTATCTATTTTAAGAAAAGTAATAATCAATTGTTAAAAAATAGTAAAAAATTGGAGGTTCTG ATGAAATATTTTGTTCCTAATGAGGTATTCAGTATTCGTAAATTAAAGGTGGGGACTTGCTCGGTACTATTGGCAAT 5 TTCAATTTTGGGAAGCCAAGGTATTTTATCGGATGAAGTTGTTACTAGTTCTTCACCGATGGCTACAAAAGAGTCTT CTAATGCAATTACTAATGATTTAGATAATTCACCAACTGTTAATCAGAATCGTTCTGCTGAAATGATTGCCTCTAAT TCAACCACTAATGGTTTAGATAATTCGTTAAGTGTTAATAGCATCAGCTCTAATGGTACTATTCGTTCCAATTCACA ATTAGACAACAGAACAGTTGAATCTACAGTAACATCTACTAATGAAAATAAGAGTTATAAGGAAGATGTTATAAG TGACAGAATTATCAAAAAAGAATTTGAAGATACTGCTTTAAGTGTAAAAGATTATGGTGCAGTAGGTGATGGGATT 10 CATGATGATCGACAAGCAATTCAAGATGCAATAGATGCTGCAGCTCAAGGGCTAGGTGGAGGAAATGTATATTTTC CTGAAGGAACTTATTTAGTAAAAGAAATTGTTTTTTTAAAAAGTCATACACACTTAGAATTGAATGAGAAAGCTAC AGGAACTAAAGCAAAAAATCTACCACTTATAAATTCTTCAGGTGCATTTGCTATTGGGAATTCAAATAACGTAACT 15 ATAAAAAATGTAACATTCAAGGATAGTTATCAAGGGCATGCTATTCAAATTGCAGGTTCGAAAAATGTATTAGTTG GATTGAACCATTAACTAGAAAAGGTTTTCCTTATGCCTTGAATGATGATGGGAAAAAATCTGAAAATGTGACTATT CAAAATTCCTATTTTGGCAAAAGTGATAAATCTGGGGAATTAGTAACAGCAATTGGCACACTATCAAACATTGT CGACACAGAACCCCTCTAATATTAAAATTCAAAATAATCATTTTGATAACATGATGTATGCAGGTGTACGTTTTACA 20 GGATTCACTGATGTATTAATCAAAGGAAATCGCTTTGATAAGAAAGTTAAAGGAGAGAGTGTACATTATCGAGAA TCGCCGAAAATATATTTAATATTGCCGATCCTAAAACAAAAGCGATACGAGTTGCAAAAGATAGTGCAGAATGTTT TGAATTATTACGAGTTAGTGATAATTTAGTAGTCTCAGAGAATAGT 25 QRCHSIYFKKSNNQLLKIVKKLEVLMKYFVPNEVFSIRKLKVGTCSVLLAISILGSQGILSDEVVTSSSPMATKESSNAITN DLDNSPTVNQNRSAEMIASNSTTNGLDNSLSVNSISSNGTIRSNSQLDNRTVESTVTSTNENKSYKEDVISDRIIKKEFEDT ALSVKDYGAVGDGIHDDRQAIQDAIDAAAQGLGGGNVYFPEGTYLVKEIVFLKSHTHLELNEKATILNGINIKNHPSIVF 30 MTGLFTDDGAQVEWGPTEDISYSGGTIDMNGALNEEGTKAKNLPLINSSGAFAIGNSNNVTIKNVTFKDSYGGHAIQIAG SKNVLVDNSRFLGOALPKTMKDGOIISKESIOIEPLTRKGFPYALNDDGKKSENVTIONSYFGKSDKSGELVTAIGTHYOT LSTQNPSNIKIQNNHFDNMMYAGVRFTGFTDVLIKGNRFDKKVKGESVHYRESGAALVNAYSYKNTKDLLDLNKQVVI AENIFNIADPKTKAIR VAKDSAECLGK VSDIT VTKN VINNNSKETE QPNIELLR VSDNL VVSENS 35 ID44 324bp (SEQ ID NO: 83) GTGATGAAAGAAACTCAGCTATTAAAAAGGTGTTCTTGAAGGTTGTGTCTTGGATATGATTGGTCAAAAAGAGCGGT ATGGTTATGAGTTGGTTCAGACTTTGCGAGAGGCTGGATTTGATACTATCGTTCCAGGAACTATTTATCCTTTGTTG 40 TCATTAATGAAAGAAGGAGAGAGGCGTGTCTCAGTCTTTTGGCAACAATGGGACGATTTGAGTCAAAAAGTAGAA GGGATTAAGAATGGGGGTTAA (SEQ ID NO: 84) 45 MMKETOLLKGVLEGCVLDMIGOKERYGYELVOTLREAGFDTIVPGTIYPLLOKLEKNOWIRGDMRPSPDGPDRKYFSL MKEGEERVSVFWQQWDDLSQKVEGIKNGG ID45 816bp 50 (SEO ID NO: 85) ATGAAGAAATGAAGTATTACGAAGAACAAGCGCTTTGCTACATGAGTTTTCTGAGGAGAATCAAAAGTATTTTG AGGAGTTGTGGGAAAGTTTTAATCTTGCTGGATTTCTCTATGATGAAGACTATCTCAGAGAGCAGATCTATTTGATG ATGAAAGAGATTCTCAAGGGAGCACCTCGCAGTTCTATCAAAGAGTCCCTTTTGACGCCAATTCTTGTCCTGGCGG 55 TATTACGTTATTATCAACTACTAAGTGATTTTTCTAAAGGTCCTCTCTTAACAGTCAATTTGCTCACATTTTTAGGGC AACTTCTTATTTTCTGATTGGATTTGGACTTGTGGCCACAATTTTACGAAGAAGTTTAGTCCAAGATTCTCCTAAA ATGAAAATTGGCACTTACATTGTTGTTGGGACTATAGTTCTTCTAGTTGTTTTAGGATATGTAGGAATGGCAAGCTT TTTGGAATTGGAAAGAAGCGGTCTTTCGTCCATTTGTCAGTATGATTATTGCCCATCTTGTGGTGGGTTCTCTGCTCC

MKKMKYYEETSALLHEFSEENQKYFEELWESFNLAGFLYDEDYLREQIYLMMLDFSEAERDGMSAEDYLGKNPKKIM KEILKGAPRSSIKESLLTPILVLAVLRYYQLLSDFSKGPLLTVNLLTFLGQLLIFLIGFGLVATILRRSLVQDSPKMKIGTYIV

TTGTCTTGTTCCGTGGGTTTAAGAAGATAAAATGGAGTGAAGTATAG

GTTATTATGAGTGGATGGGAATTTCAAATGTTTTCCTTACAAAAGTTATTCCTTTAGCTGTCCTCTTTATTGGAATCT

VGTIVLLVVLGYVGMASFIQEGAFYIPAPWDSLSVFTISLVIGIWNWKEAVFRPFVSMIIAHLVVGSLLRYYEWMGISNVF LTKVIPLAVLFIGIFVLFRGFKKIKWSEV

#### ID46 348bp

5

10

(SEO ID NO: 87)

CTGTTTTTTTATTTATACTCAATGAAAATCAAAGAGCAAACTAGGAAGCTAGCCGCAGGTTGCTCAAAACACTGTTT TGAGGTTGTAGACGAAACTGACGAAGTCAGCTCAAAACATGTTTTTTGAGGTTGTAGATGAAACTGACGAAGTCAGC TCAAAACACTGTTTTGAGGTTGTAGATGAAACTGACGAAGTCAGCTCAAAACACTGTTTTGAGGTTGTAGATGAAA 

GGCGACGCTGACGTGGTTTGAAGAGATTTTCGAAGAGTATTAA

(SEO ID NO: 88)

MFFYLYSMKIKEQTRKLAAGCSKHCFEVVDETDEVSSKHVFEVVDETDEVSSKHCFEVVDETDEVSSKHCFEVVDETDE 15 VSSKHVFEVVDETDEVSNHTYGRATLTWFEEIFEEY

#### ID47 1260bp

- 20 ATGCAGAATCTGAAATTTGCCTTTTCATCTATCATGGCTCACAAGATGCGTTCTTTGCTTACTATGATTGGGATTATT ATCGGTGTTTCATCAGTTGTTGTGATTATGGCTTTGGGTGATTCCCTATCTCGTCAAGTCAATAAAGATATGACTAA ATCTCAGAAAAATATTAGCGTCTTTTTCTCTCCTAAAAAAAGTAAAGACGGGTCTTTTACTCAGAAACAATCAGCTT TTACGGTTTCTGGAAAGGAAGAGGAAGTTCCTGTTGAACCGCCAAAACCGCAAGAATCCTGGGTCCAAGAGGCAG
- CTAAACTGAAGGGAGTGGATAGTTACTATGTAACCAATTCAACGAATGCCATCTTGACCTATCAAGATAAAAAGGT 25 TGAGAATGCTAATTTGACAGGTGGAAACAGAACTTACATGGACGCTGTTAAGAATGAAATTATTGCAGGTCGTAGT CTGAGAGAGCAAGATTTCAAAGAGTTTGCAAGTGTCATTTTGCTAGATGAGGAATTGTCCATTAGTTTATTTGAATC TCCTCAAGAGGCTATTAACAAGGTTGTAGAAGTCAATGGATTTAGTTACCGGGTCATTGGGGTTTATACTAGTCCG GAGGCTAAAAGATCAAAAATATATGGGTTTGGTGGCTTGCCTATTACTACCAATATCTCCCTTGCTGCGAATTTTAA
- TGTAGATGAAATAGCTAATATTGTCTTTCGAGTGAATGATACCAGTTTAACCCCAACTCTGGGTCCAGAACTGGCA 30 CGAAAAATGACAGAGCTTGCAGGCTTACAACAGGGAGAATACCAGGTGGCAGATGAGTCCGTTGTATTTGCAGAA ATTCAACAATCGTTTAGTTTTATGACGACGATTATTAGTTCCATCGCAGGGATTTCTCTCTTTTGTTGGAGGAACTGG TGTCATGAACATCATGCTGGTTTCGGTGACAGAGCGCACTCGTGAGATTGGTCTTCGTAAGGCTTTGGGTGCAACA CGTGCCAATATTITAATTCAGTTTTTGATTGAATCCATGATTTTGACCTTGTTAGGTGGCTTAATTGGCTTGACAATT GCAAGTGGTTTAACTGCCTTAGCAGGTTTGTTACTGCAAGGTTTAATAGAAGGTATAGAAGTTTGGAGTATCAATCC
- 35 AAACTTGATCCAATTGAAGCCCTTCGTTATGAATGA

MQNLKFAFSSIMAHKMRSLLTMIGIIIGVSSVVVIMALGDSLSRQVNKDMTKSQKNISVFFSPKKSKDGSFTQKQSAFTVS 40 GKEEEVPVEPPKPQESWVQEAAKLKGVDSYYVTNSTNAILTYQDKKVENANLTGGNRTYMDAVKNEIIAGRSLREQDF KEFASVILLDEELSISLFESPQEAINKVVEVNGFSYRVIGVYTSPEAKRSKIYGFGGLPITTNISLAANFNVDEIANIVFRVN DTSLTPTLGPELARKMTELAGLOOGEYOVADESVVFAEIQQSFSFMTTIISSIAGISLFVGGTGVMNIMLVSVTERTREIGL RKALGATRANILIQFLIESMILTLLGGLIGLTIASGLTALAGLLLQGLIEGIEVGVSIPVALFSLAVSASVGMIFGVLPANKA SKLDPIEALRYE 45

# ID48 705bp

- CTGATGAAGCAACTAATTAGTCTAAAAAATATCTTCAGAAGTTACCGTAATGGTGACCAAGAACTGCAGGTTCTCA 50 AAAATATCAATCTAGAAGTGAATGAGGGTGAATTTGTAGCCATCATGGGACCATCTGGGTCTGGTAAGTCCACTCT GATGAATACGATTGGCATGTTGGATACACCAACCAGTGGAGAATATTATCTTGAAGGTCAAGAAGTGGCTGGGCTT CAATGCTCTGCAAAATGTAGAATTGCCCTTGATTTACGCAGGAGTTTCGTCTTCAAAACGTCGCAAGTTGGCTGAG GAATATTTAGACAAGGTTGAATTGACAGAACGTAGTCACCATTTACCTTCAGAATTATCTGGTGGTCAAAAGCAAC
- 55 GTGTAGCCATTGCGCGTGCCTTGGTAAACAATCCTTCTATTATCCTAGCGGATGAACCGACAGGAGCCTTGGATAC CAAAACAGGTAACCAAATTATGCAATTATTGGTTGATTTGAATAAAGAAGGAAAAACCATTATCATGGTAACGCAT GAGCCTGAGATTGCCTATGCCAAACGTCAGATTGTCATTCGGGATGGGGTCATTTCGTCTGACAGTGCTCAGTT AGGAAAGGAGGAAAACTAA
- 60 (SEO ID NO: 92)

MMKOLISLKNIFRSYRNGDOELOVLKNINLEVNEGEFVAIMGPSGSGKSTLMNTIGMLDTPTSGEYYLEGOEVAGLGEK QLAKVRNQQIGFVFQQFFLLSKLNALQNVELPLIYAGVSSSKRRKLAEEYLDKVELTERSHHLPSELSGGQKQRVAIARA LVNNPSIILADEPTGALDTKTGNQIMQLLVDLNKEGKTIIMVTHEPEIAAYAKRQIVIRDGVISSDSAQLGKEEN

#### 65 ID49 1200bp

- CTACTTCAAGAAGTGGGGTTACATGGCTAAAAGCCAATGGCAAGGAAGTTATTTCTTGAATGGTCAAGGAGCTATG ATGCAAAATGAATGGCTCTATGATCCAGCCTATTCTGCTTATTTTTATCTAAAAATCCGATGGAACTTATGCTAACCA AGAGTGGCAAAAAGTGGGCGGCAAATGGTACTATTTCAAGAAGTGGGGCTATATGGCTCGGAATGAGTGGCAAGG 60 GCCTCTGGTGAGCTCAAAGAAAAAAAAAGATTTGAATGTCGGCTGGGTTCACAGAGATGGTAAGCGCTATTTCTTTA ATAATAGAGAAGAACAAGTGGGAACCGAACATGCTAAGAAAGTCATTGATATTAGTGAGCACAATGGTCGTATCA ATGATTGGAAAAAGGTTATTGATGAGAACGAAGTGGATGGTGTCATTGTTCGTCTAGGTTATAGCGGTAAAGAAGA CAAGGAATTGGCGCATAACATTAAGGAGTTAAACCGTCTGGGAATTCCTTATGGTGTCTATCTCTATACCTATGCTG AAAATGAGACCGTGCTGAGAGTGACGCTAAACAGACCATTGAACTTATAAAGAAATACAATATGAACCTGTCTTA 65 CCCTATCTATTATGATGTTGAGAATTGGGAATATGTAAATAAGAGCAAGAGAGCTCCAAGTGATACAGGCACTTGG GTTAAAATCATCAACAAGTACATGGACACGATGAAGCAGGCGGGTTATCAAAATGTGTATGTCTATAGCTATCGTA
- TTGAAAACAAAAATTGGATTAGCAAGTATCTGTTTACTAGGCTTGGCAACTAGTCATGTCGCTGCAAATGAAACTG AAGTAGCAAAAACTTCGCAGGATACAACGACAGCTTCAAGTAGTTCAGAGCAAAATCAGTCTTCTAATAAAACGC AAACGAGCGCAGAAGTACAGACTAATGCTGCTGCCCACTGGGATGGGGATTATTATGTAAAGGATGATGGTTCTA AAGCTCAAAGTGAATGGATTTTTGACAACTACTATAAGGCTTGGTTTTATATTAATTCAGATGGTCGTTACTCGCAG AATGAATGGCATGGAAATTACTACCTGAAATCAGGTGGATATATGGCCCAAAACGAGTGGATCTATGACAGTAATT 55
- (SEO ID NO: 97) 50

# ID51 1473bp

- MSRKPFIAGNWKMNKNPEEAKAFVEAVASKLPSSDLVEAGIAAPALDLTTVLAVAKGSNLKVAAONCYFENAGAFTGE TSPQVLKEIGTDYVVIGHSERRDYFHETDEDINKKAKAIFANGMLPIICCGESLETYEAGKAAEFVGAQVSAALAGLTAEQVAASVIAYEPIWAIGTGKSASQDDAQKMCKVVRDVVAADFGQEVADKVRVQYGGSVKPENVASYMACPDVDGALV 45 GGASLEAESFLALLDFVK
- GTGAAACTAGCCCACAAGTTTTGAAAGAAATCGGTACTGACTACGTTGTTATCGGTCACTCAGAACGCCGTGACTA CTTCCATGAAACTGATGAAGATATCAACAAAAAAGCAAAAGCAATCTTTGCGAACGGTATGCTTCCAATCATCTGT TGTGGTGAATCACTTGAAACTTACGAAGCTGGTAAAGCTGCTGAATTCGTAGGTGCTCAAGTATCTGCTGCATTGG CTGGATTGACTGCTGAACAAGTTGCTGCCTCAGTTATCGCTTATGAGCCAATCTGGGCTATCGGTACTGGTAAATCA GCTTCACAAGACGATGCACAAAAAATGTGTAAAGTTGTTCGTGACGTTGTAGCTGACTTTGGTCAAGAAGTCG CAGACAAAGTTCGTGTTCAATACGGTGGTTCTGTTAAACCTGAAAATGTTGCTTCATACATGGCTTGCCCAGACGTT GACGGTGCCCTTGTAGGTGGTGCGTCACTTGAAGCTGAAAGCTTCTTGGCTTTGCTTGACTTTGTAAAATAA 40
- (SEQ ID NO: 95) 30 ATGTCACGTAAACCATTTATCGCTGGTAACTGGAAAATGAACAAAAATCCAGAAGAAGCTAAAGCATTCGTTGAA GCAGTTGCATCAAAACTTCCTTCATCAGATCTTGTTGAAGCAGGTATCGCTGCTCCAGCTCTTGATTTGACAACTGT TCTTGCTGTTGCAAAAGGCTCAAACCTTAAAGTTGCTGCTCAAAACTGCTACTTTGAAAATGCAGGTGCTTTCACTG 35

(SEQ ID NO: 93)

# ID50 759bp

- 20 MKKKNGKAKKWQLYAAIGAASVVVLGAGGILLFRQPSQTALKDEPTHLVVAKEGSVASSVLLSGTVTAKNEQYVYFD ASKGDLDEILVSVGDKVSEGQALVKYSSSEAQAAYDSASRAVARADRHINELNQARNEAASAPAPQLPAPVGGEDATV QSPTPVAGNSVASIDAQLGDARDARADAAAQLSKAQSQLDATTVLSTLEGTVVEVNSNVSKSPTGASQVMVHIVSNEN LQVKGELSEYNLANLSVGQEVSFTSKVYPDKKWTGKLSYISDYPKNNGEAASPAAGNNTGSKYPYTIDVTGEVGDLKQ GFSVNIEVKSKTKAILVPVSSLVMDDSKNYVWIVDEQQKAKKVEVSLGNADAENQEITSGLTNGAKVISNPTSSLEEGKE 25 VKADEATN
- AACAATGGTGAAGCAGCTAGTCCAGCAGCCGGGAATAATACAGGTTCTAAATACCCTTATACTATTGATGTGACAG GCGAGGTTGGTGATTTGAAACAAGGTTTTTCTGTCAACATTGAGGTTAAAAGCAAAACTAAGGCTATTCTTGTTCCT 15 GTTAGCAGTCTAGTAATGGATGATAGTAAAAATTATGTCTGGATTGTGGATGAACAACAAAAGGCTAAAAAAGTT GTAATCCAACATCTTCCTTGGAAGAAGGAAAAGAGGTGAAGGCTGATGAAGCAACTAATTAG
- 5 GATGCTAGTAAGGGTGATTTAGATGAAATCCTTGTTTCTGTGGGCGATAAGGTCAGCGAAGGGCAGGCTTTAGTCA AGTACAGTAGTTCAGAAGCGCAGGCGGCCTATGATTCAGCTAGTCGAGCAGTAGCTAGGGCAGATCGTCATATCA ATGAACTCAATCAAGCACGAAATGAAGCCGCTTCAGCTCCGGCTCCACAGTTACCAGCGCCAGTAGGAGGAGAAG ATGCAACGGTGCAAAGCCCAACTCCAGTGGCTGGAAATTCTGTTGCTTCTATTGACGCTCAATTGGGTGATGCCCG TGATGCGCGTGCAGATGCTGCGGCGCAATTAAGCAAGGCTCAAAGTCAATTGGATGCAACAACTGTTCTCAGTACC 10 CTAGAGGGAACTGTGGTCGAAGTCAATAGCAATGTTTCTAAATCTCCAACAGGGGCGAGTCAAGTTATGGTTCATA TTGTCAGCAATGAAAATTTACAAGTCAAGGGAGAATTGTCTGAGTACAATCTAGCCAACCTTTCTGTAGGTCAAGA AGTAAGCTTTACTTCTAAAGTGTATCCTGATAAAAAAATGGACTGGGAAATTAAGCTATATTTCTGACTATCCTAAA

ATGAAGAAAAGAATGGTAAAGCTAAAAAGTGGCAACTGTATGCAGCAATCGGTGCTGCGAGTGTAGTTGTATTG GGTGCTGGGGGGATTTTACTCTTTAGACAACCTTCTCAGACTGCTCTAAAAGATGAGCCTACTCATCTTGTTGTTGC CAAGGAAGGAAGCGTGGCCTCCTCTGTTTTATTGTCAGGGACAGTAACAGCAAAAAATGAACAATATGTTTATTTT GTTTATTACAGACGCGTTTAAAACACCCAGATATTTTAAAACATGTAAACTGGGTAGCGGCCTATACGAATGCTTT AGAATGGGAAAAACCCTCATTATTCAGGAAAAAAAGGTTGGCAATATACCTCTTCTGAATACATGAAAGGAATCCA AGGGCGCGTAGATGTCAGCGTTTGGTATTAA

5 (SEQ ID NO: 98)

MKTKIGLASICLLGLATSHVAANETEVAKTSQDTTTASSSSEQNQSSNKTQTSAEVQTNAAAHWDGDYYVKDDGSKAQ
SEWIFDNYYKAWFYINSDGRYSQNEWHGNYYLKSGGYMAQNEWIYDSNYKSWFYLKSDGAYAHQEWQLIGNKWYY
FKKWGYMAKSQWQGSYFLNGQGAMMQNEWLYDPAYSAYFYLKSDGTYANQEWQKVGGKWYYFKKWGYMARNE
WQGNYYLTGSGAMATDEVIMDGTRYIFAASGELKEKKDLNVGWVHRDGKRYFFNNREEQVGTEHAKKVIDISEHNGR
INDWKKVIDENEVDGVIVRLGYSGKEDKELAHNIKELNRLGIPYGVYLYTYAENETDAESDAKQTIELIKKYNMNLSYPI
YYDVENWEYVNKSKRAPSDTGTWVKIINKYMDTMKQAGYQNVYVYSYRSLLQTRLKHPDILKHVNWVAAYTNALE
WENPHYSGKGWQYTSSEYMKGIOGRVDVSVWY

# ID52 774bp

15

20

35

(SEQ ID NO: 100)

MKKFANLYLGLVFLVLYLPIFYLIGYAFNAGDDMNSFTGFSWTHFETMFGDGRLMLILAQTFFLAFLSALIATIIGTFGAI YIYQSRKKYQEAFLSLNNILMVAPDVMIGASFLILFTQLKFSLGFLTVLSSHVAFSIPIVVLMVLPRLKEMNGDMIHAAYD LGASQFQMFKEIMLPYLTPSIITGYFMAFTYSLDDFAVTFFVTGNGFSTLSVEIYSRARKGISLEINALSALVFLFSIILVVG YYFISREKEEQA

### ID59 1071bp

(SEO ID NO: 101)

ATGAAAAAAATCTATTCATTTTTAGCAGGAATTGCAGCGATTATCCTTGTCTTGTGGGGAATTGCGACTCATTTAGA TAGTAAAATCAATAGTCGAGATAGTCAAAAATTGGTTATCTATAACTGGGGAGACTATATCGATCCTGAACTCTTG ACTCAGTTTACAGAAGAAACAGGAATTCAAGTTCAGTACGAGACTTTTGACTCCAACGAAGCCATGTACACTAAGA 40 TAAAGCAGGGTGGAACGACCTACGATATTGCCATTCCAAGTGAATACATGATTAACAAGATGAAGGACGAAGACC TCTTGGTTCCGCTTGATTATTCAAAAATTGAAGGAATCGAAAATATCGGACCAGAGTTTCTCAACCAGTCCTTTGAC CCAGGTAATAAATTCTCCATCCTTACTTCTGGGGAACCTTAGGAATTGTCTACAACGAAACCATGGTAGATGAAG CGCCTGAGCATTGGGATGACCTTTGGAAGCCGGAGTATAAGAATTCTATCATGCTCTTTGATGGGGCGCGTGAGGT GCTGGGACTAGGACTCAATTCCCTCGGCTACAGCCTCAACTCCAAGGATCTGCAGCAGTTGGAAGAGACAGTGGAT 45 AAGCTCTACAAACTGACTCCAAATATCAAGGCTATCGTTGCGGACGAGATGAAGGGCTATATGATTCAGAATAATG GACAGAGGCCAGCAATCTTTGGTTTGACAATATGGTCATTCCCAAAACAGTTAAAAACCAAAACTCAGCCTATGCC TTTATCAACTTTATGTTGAAACCTGAAAATGCTCTCCAAAATGCGGAGTATGTCGGCTATTCAACACCAAACCTACC AGCGAAGGAATTGCTCCCAGAGGAAACAAAGGAAGATAAGGCCTTCTATCCCGATGTTGAAACCATGAAACACCT 50 AGAAGTTTATGAGAAATTTGACCATAAATGGACAGGGAAATATAGCGACCTCTTCCTACAGTTTAAAATGTATCGG

(SEQ ID NO: 102)

AAGTAG

MKKIYSFLAGIAAIILVLWGIATHLDSKINSRDSQKLVIYNWGDYIDPELLTQFTEETGIQVQYETFDSNEAMYTKIKQGG
TTYDIAIPSEYMINKMKDEDLLVPLDYSKIEGIENIGPEFLNQSFDPGNKFSIPYFWGTLGIVYNETMVDEAPEHWDDLW
KPEYKNSIMLFDGAREVLGLGLNSLGYSLNSKDLQQLEETVDKLYKLTPNIKAIVADEMKGYMIQNNVAIGVTFSGEAS
QMLEKNENLRYVVPTEASNLWFDNMVIPKTVKNQNSAYAFINFMLKPENALQNAEYVGYSTPNLPAKELLPEETKEDK
AFYPDVETMKHLEVYEKFDHKWTGKYSDLFLQFKMYRK

# 60 ID61 1851bp

65

(SEQ ID NO: 103)

AGTATCTGTTATGCCTTCTTGCCACTCTTCTCCATCCGTTTCATCATTCTCTTTATCTTGTTGAGTACCTTCTTGATTT TATTGCCACGGATTACTTGGCAGTTAATCTACTCCAGACGCAAAAAAGGTAGTGGTGATGGAGAACACCGTCGGAC CTTCTTGATTGGTGCCGGTGATGGTGGGGCTCTTTTTATGGATAGTTACCAACATCCAACCAGTGAATTAGAACTGG TCGGTATTTTGGATAAGGATTCTAAGAAAAAGGGTCAAAAACTTGGTGGTATTCCTGTTTTTGGGCTCTTATGACAAT 5 CTGCCTGAATTAGCCAAACGCCATCAAATCGAGCGTGTCATCGTTGCGATTCCGTCGCTGGATCCGTCAGAATATG AGCGTATCTTGCAGATGTGTAATAAGCTGGGTGTCAAATGTTACAAGATGCCTAAGGTTGAAACTGTTGTTCAGGG CCTTCACCAAGCAGGTACTGGCTTCCAAAAAATTGATATTACGGACCTTTTGGGTCGTCAGGAAATCCGTCTTGAC GAATCGCGTCTGGGTGCAGAACTGACAGGTAAGACCATCTTAGTCACAGGAGCTGGAGGTTCAATCGGTTCTGAAA TCTGTCGTCAAGTTAGTCGCTTCAATCCTGAACGCATTGTCTTGCTCGGTCATGGGGAAAACTCAATCTACCTTGTT 10 TATCATGAATTGATTCGTAAGTTCCAAGGGATTGATTATGTACCTGTGATTGCGGACATTCAAGACTATGATCGTTT GTTGCAAGTCTTTGAGCAGTACAAACCTGCTATTGTTTATCATGCGGCAGCCCACAAGCATGTTCCTATGATGGAGC GCAATCCAAAAGAAGCCTTCAAAAACAATATCCGTGGAACTTACAATGTTGCTAAGGCTGTTGATGAAGCTAAAGT GTCTAAGATGGTTATGATTTCGACAGATAAGGCAGTCAATCCACCAAATGTTATGGGAGCAACCAAGCGCGTGGCG GAGTTGATTGTCACTGGCTTTAACCAACGTAGCCAATCAACCTACTGTGCAGTTTCGTTTTGGGAATGTTCTTGGTAG 15 CCGTGGTAGTGTCATTCCAGTCTTTGAACGTCAGATTGCTGAAGGTGGGCCTGTAACGGTGACAGACTTCCGTATG ACCCGTTACTTTATGACCATTCCAGAAGCTAGCCGTCTGGTTATCCATGCTGGTGCTTATGCCAAAGATGGGGAAGT CTTTATCCTTGATATGGGCAAACCAGTCAAGATTTATGACTTGGCCAAGAAGATGGTGCTTCTAAGTGGCCACACT GAAAGTGAAATTCCAATCGTTGAAGTTGGAATCCGCCCAGGTGAAAAACTCTACGAAGAACTCTTGGTATCAACCG 20 **ACATTGAATAA** 

(SEQ ID NO: 104)

25 MNKKLTDYVIDLVEILNKQQKQVFWGIFDIFSMVVSIIVSYILFYGLINPAPVDYIIYTSLAFLFYQLMIGFWGLNASISRYS
KITDFMKIFFGVTASSVLSYSICYAFLPLFSIRFIILFILLSTFLILLPRITWQLIYSRRKKGSGDGEHRRTFLIGAGDGGALFM
DSYQHPTSELELVGILDKDSKKKGQKLGGIPVLGSYDNLPELAKRHQIERVIVAIPSLDPSEYERILQMCNKLGVKCYKM
PKVETVVQGLHQAGTGFQKIDITDLLGRQEIRLDESRLGAELTGKTILVTGAGGSIGSEICRQVSRFNPERIVLLGHGENSI
YLVYHELIRKFQGIDYVPVIADIQDYDRLLQVFEQYKPAIVYHAAAHKHVPMMERNPKEAFKNNIRGTYNVAKAVDEA
KVSKMVMISTDKAVNPPNVMGATKRVAELIVTGFNQRSQSTYCAVRFGNVLGSRGSVIPVFERQIAEGGPVTVTDFRMT
RYFMTIPEASRLVIHAGAYAKDGEVFILDMGKPVKIYDLAKKMVLLSGHTESEIPIVEVGIRPGEKLYEELLVSTELVDNQ
VMDKIFVGKVNVMPLESINOKIGEFRTLSGDELKOAIIAFANOTTHIE

#### ID101 1338bp

- 35 (SEO ID NO: 105) ATGATTGAACTTTATGATAGTTACAGTCAAGAAAGTCGAGATTTACATGAAAGTCTAGTCGCTACTGGTCTTTCTCA ACTTGGAGTGGTCATCGATGCAGATGGTTTTCTGCCTGATGGTCTGCTTTTCTCCTTTTACCTATTATCTAGGTTACGA GGATGGAAAACCTCTCTATTTTAATCAAGTTCCCGTTTCAGATTTTTGGGAAATTTTTAGGAGATAATCAGTCTGCTT GTATTGAAGATGTGACGCAGGAGAGGGCTGTCATTCATTATGCTGATGGAATGCAGGCTCGCTTGGTTAAACAGGT 40 AGACTGGAAAGACCTAGAAGGTCGAGTACGTCAGGTTGACCACTACAATCGCTTCGGAGCTTGTTTTGCTACAACG ACTTATAGCGCAGATAGCGAGCCGATTATGACAGTTTACCAAGATGTCAATGGTCAACAAGTTTTACTGGAAAAACC ATGTGACGGGTGATATCTTATTGACTTTGCCAGGTCAGTCCATGCGTTACTTTGCAAATAAAGTTGAATTTATCACC TTCTTTTTGCAAGATTTGGAAATAGATACCAGTCAGCTTATCTTTAATACTCTAGCGACTCCTTTCTTGGTTTCCTTC CATCATCCAGATAAATCTGGCTCGGATGTCTTGGTATGGCAGGAACCTCTCTATGATGCCATTCCAGGTAATATGCA 45 GTTGATTTTGGAAAGTGATAATGTGCGTACTAAGAAGATCATCATTCCAAATAAGGCGACTTATGAGCGCGCTTTA GAGTTAACTGACGAGAAATACCATGATCAGTTTGTGCACTTGGGTTATCATTACCAGTTCAAACGTGATAATTTCCT GTCACTTTCCGTATTGCAGCGGTGACAGAGATGTCTTCTAAGCTCTTAGACATGCTTTGCTATCCTAATGTGGCCCT TTACCAGAACGCTAGTCCACAGAAGATTCAGGAGCTGTATCAACTGTCGGATATTTACTTGGATATAAACCACAGT 50 AATGAGTTGCTACAGGCAGTGCGTCAGGCCTTTGAGCACAATCTCTTGATTCTTGGCTTTAATCAGACGGTGCACA ATAGACTITATATCGCTCCAGACCATCTATTTGAAAGTAGTGAAGTTGCTGCTTTTGGTTGAGACCATTAAATTGGCC
- (SEQ ID NO: 106)
   MIELYDSYSQESRDLHESLVATGLSQLGVVIDADGFLPDGLLSPFTYYLGYEDGKPLYFNQVPVSDFWEILGDNQSACIE
   DVTQERAVIHYADGMQARLVKQVDWKDLEGRVRQVDHYNRFGACFATTTYSADSEPIMTVYQDVNGQQVLLENHVT
   GDILLTLPGQSMRYFANKVEFITFFLQDLEIDTSQLIFNTLATPFLVSFHHPDKSGSDVLVWQEPLYDAIPGNMQLILESDN
   VRTKKIIIPNKATYERALELTDEKYHDQFVHLGYHYQFKRDNFLRDALILTNSDQIEQVEAIAGALPDVTFRIAAVTEMS
   SKLLDMLCYPNVALYQNASPQKIQELYQLSDIYLDINHSNELLQAVRQAFEHNLLILGFNQTVHNRLYIAPDHLFESSEV
   AALVETIKLALSDVDQMRQALGKQGQHANYVDLVRYQETMQTVLGG

CTTTCAGATGTTGATCAAATGCGTCAGGCACTTGGCAAACAAGGCCAACATGCAAATTATGTTGACTTGGTGAGAT

### ID102 1512bp

ATCAGGAAACCATGCAAACTGTTTTAGGAGGCTAA

65 (SEO ID NO: 107)

ATGACAATTTACAATATAAATTTAGGAATTGGTTGGGCTAGTAGCGGTGTTGAATACGCTCAAGCCTATCGTGCTG GTGTTTTTCGGAAATTAAATCTGTCCTCTAAGTTTATCTTTACAGATATGATTTTTAGCCGATAATATTCAGCACTTAA CAGCCAATATTGGTTTTGATGATAATCAGGTTATCTGGCTTTATAATCATTTCACAGATATCAAAATTGCACCTACT 5 GTGTATTCTTTTTTGACCAAGATAAGTTTGTAACCTGTTATTTGGTTGATGAGAACAAGGACTTGGTTCAACATGCC GAGTATGTTTTTAAGGGAAACCTGATTCGGAAGGATTACTTTTCTTATACGCGTTATTGTAGCGAGTATTTTGCTCC CAAGGACAATGTTGCAGTCTTATACCAACGAACTTTTTATAATGAAGACGGGACTCCAGTCTATGATATCTTGATG TGAAATCTTTGAATTTGAATAAGTCTGATTTGGTCATTCTCGATAGGGAGACAGGTATTGGACAGGTTGTGTTTTGAG 10 GAAGCACAGACACATCTAGCGGTAGTTGTTCATGCGGAGCATTATAGTGAAAATGCTACAAATGAGGACTAT ATCCTTTGGAATAACTATTATGACTATCAGTTTACCAATGCAGATAAGGTTGACTTCTTTATCGTGTCTACTGATAG ACAAAATGAAGTTCTACAAGAGCAATTTGCCAAATATACTCAGCATCAGCCAAAGATTGTTACCATTCCTGTAGGC AGTATTGATTCCTTGACAGATTCAAGTCAAGGGCGCAAACCATTTTCATTGATTACGGCTTCACGTCTTGCCAAAGA AAAGCACATTGATTGGCTTGTGAAAGCTGTGATTGAAGCTCATAAGGAGTTACCGGAACTAACCTTTGATATCTAT 15 GGTAGTGGTGGAGAAGATTCTCTGCTTAGAGAAATTATTGCAAATCATCAGGCAGAGGACTATATCCAACTCAAGG GGCATGCGGAACTTTCGCAGATTTATAGCCAGTATGAGGTCTACTTAACGGCTTCTACCAGCGAAGGATTTGGTCT GACCTTGATGGAAGCTATTGGTTCAGGTCTACCTCTAATTGGTTTTGATGTGCCTTATGGTAATCAGACCTTTATAG TAAGATTTGTCAATTGTATCAAGAAAATCGTTTTGGAAGCTATGCGTGCCTATTCTTACCAAATTGCAGAAGGCTTCT 20

(SEQ ID NO: 108) MTIYNINLGIGWASSGVEYAQAYRAGVFRKLNLSSKFIFTDMILADNIQHLTANIGFDDNQVIWLYNHFTDIKIAPTSVTV DDVLAYFGGEESHREKNGKVLRVFFFDQDKFVTCYLVDENKDLVQHAEYVFKGNLIRKDYFSYTRYCSEYFAPKDNVA VLYQRTFYNEDGTPVYDILMNQGKEEVYHFKDKIFYGKQAFVRAFMKSLNLNKSDLVILDRETGIGQVVFEEAQTAHL AVVVHAEHYSENATNEDYILWNNYYDYOFTNADKVDFFIVSTDRONEVLOEOFAKYTOHOPKIVTIPVGSIDSLTDSSO GRKPFSLITASRLAKEKHIDWLVKAVIEAHKELPELTFDIYGSGGEDSLLREIIANHQAEDYIQLKGHAELSQIYSQYEVYL TASTSEGFGLTLMEAIGSGLPLIGFDVPYGNQTFIEDGQNGYLIPSSSDHVEDQIKQAYAAKIQLYQENRLEAMRAYSY OIAEGFLTKEILEKWKKTVEEVLHD

TGACCAAAGAAATTTTAGAAAAGTGGAAGAAAACAGTAGAGGAGGTGCTCCATGATTGA

# ID103 2292bp

25

30

(SEQ ID NO: 109) 35 ATGTCCTCTCTTTCGGATCAAGAATTAGTAGCTAAAACAGTAGAGTTTCGTCAGCGTCTTTCCGAGGGAGAAAGTC TAGACGATATTTTGGTTGAAGCTTTTGCTGTGGTGCGTGAAGCAGATAAGCGGATTTTAGGGATGTTTCCTTATGAT GTTCAAGTCATGGGAGCTATTGTCATGCACTATGGAAATGTTGCTGAGATGAATACGGGGGGAAGGTAAGACCTTGA CAGCTACCATGCCTGTCTATTTGAACGCTTTTTCAGGAGAAGGAGTGATGGTTGTGACTCCTAATGAGTATTTATCA AAGCGTGATGCCGAGGAAATGGGTCAAGTTTATCGTTTTCTAGGATTGACCATTGGTGTACCATTTACGGAAGATC 40 CAAAGAAGGAGATGAAAGCTGAAGAAAAGAAGCTTATCTATGCTTCGGATATCATCTACACAACCAATAGTAATT TAGGTTTTGATTATCTAAATGATAACCTAGCCTCGAATGAAGAAGGTAAGTTTTTACGACCGTTTAACTATGTGATT ATTGATGAAATTGATGATATCTTGCTTGATAGTGCACAAACTCCTCTGATTATTGCGGGGTTCTCCTCGTGTTCAGTCT AATTACTATGCGATCATTGATACACTTGTAACAACCTTGGTCGAAGGAGAGGATTATATCTTTAAAGAGGAGAAAG AGGAGGTTTGGCTCACTACTAAGGGGGCCAAGTCTGCTGAGAATTTCCTAGGGATTGATAATTTATACAAGGAAGA 45 GCATGCGTCTTTTGCTCGTCATTTTGGTTTATGCGATTCGAGCTCATAAGCTCTTTACTAAAGATAAGGACTATATCA TTCGTGGAAATGAGATGGTACTGGTTGATAAGGGAACAGGGCGTCTAATGGAAATGACTAAACTTCAAGGAGGTC TCCATCAGGCTATTGAAGCCAAGGAACATGTCAAATTATCTCCTGAGACGCGGGCTATGGCCTCGATCACCTATCA GAGTCTTTTTAAGATGTTTAATAAGATATCTGGTATGACAGGGACAGGTAAGGTCGCGGAAAAAGAGTTTATTGAA ACTTACAATATGTCTGTAGTACGCATTCCAACCAATCGTCCGAGACAACGGATTGACTATCCAGATAATCTATATAT 50 CACTTTACCTGAAAAAGTGTATGCATCCTTGGAGTACATCAAGCAATACCATGCTAAGGGAAATCCTTTACTCGTTT TTGTAGGCTCAGTTGAAATGTCTCAACTCTATTCGTCTCTCTTGTTTCGTGAAGGGATTGCCCATAATGTCCTAAAT GCTAATAATGCGGCGCGTGAGGCTCAGATTATCTCCGAGTCAGGTCAGATGGGGGCTGTGACAGTGGCTACCTCTA TGGCAGGACGTGGTACGGATATCAAGCTTGGTAAAGGAGTCGCAGAGCTTGGGGGGCTTGATTGTTATTGGGACTGA GCGGATGGAAAGTCAGCGGATCGACCTACAAATTCGTGGCCGTTCTGGTCGTCAGGGAGATCCTGGTATGAGTAAA 55 TTTTTTGTATCCTTAGAGGATGATGTTATCAAGAAATTTGGTCCATCTTGGGTGCATAAAAAGTACAAAGACTATCA GGTTCAAGATATGACTCAACCGGAAGTATTGAAAGGTCGTAAATACCGGAAACTAGTCGAAAAGGCTCAGCATGC CAGTGATAGTGCTGGACGTTCAGCACGTCGTCAGACTCTGGAGTATGCTGAAAGTATGAATATACAACGGGATATA GTCTATAAAGAGAGAAATCGTCTAATAGATGGTTCTCGTGACTTAGAGGGATGTTGTTGTGGATATCATTGAGAGAT ATACAGAAGAGGTAGCGGCTGATCACTATGCTAGTCGTGAATTATTGTTTCACTTTATTGTGACCAATATTAGTTTT 60 CATGTTAAAGAGGTTCCAGATTATATAGATGTAACTGACAAAACTGCAGTTCGTAGCTTTATGAAGCAGGTGATTG ATAAAGAACTTTCTGAAAAGAAGAATTACTTAATCAACATGACTTATATGAACAGTTTTTACGACTTTCACTGCTT AAAGCCATTGATGACAACTGGGTAGAGCAGGTAGACTATCTACAACAGCTATCCATGGCTATCGGTGGTCAATCTG CTAGTCAGAAAAATCCAATCGTAGAGTACTATCAAGAAGCCTACGCGGGCTTTGAAGCTATGAAAGAACAGATTC ATGCGGATATGGTGCGTAATCTCCTGATGGGGCTGGTTGAGGTCACTCCAAAAGGTGAAATCGTGACTCATTTTCC 65 ATAA

(SEQ ID NO: 110)

MSSLSDQELVAKTVEFRQRLSEGESLDDILVEAFAVVREADKRILGMFPYDVQVMGAIVMHYGNVAEMNTGEGKTLTA TMPVYLNAFSGEGVMVVTPNEYLSKRDAEEMGQVYRFLGLTIGVPFTEDPKKEMKAEEKKLIYASDIIYTTNSNLGFDY LNDNLASNEEGKFLRPFNYVIIDEIDDILLDSAQTPLIIAGSPRVQSNYYAIIDTLVTTLVEGEDYIFKEEKEEVWLTTKGA KSAENFLGIDNLYKEEHASFARHLVYAIRAHKLFTKDKDYIIRGNEMVLVDKGTGRLMEMTKLQGGLHQAIEAKEHVK LSPETRAMASITYQSLFKMFNKISGMTGTGKVAEKEFIETYNMSVVRIPTNRPRQRIDYPDNLYITLPEKVYASLEYIKQY HAKGNPLLVFVGSVEMSQLYSSLLFREGIAHNVLNANNAAREAQIISESGQMGAVTVATSMAGRGTDIKLGKGVAELG GLIVIGTERMESQRIDLQIRGRSGRQGDPGMSKFFVSLEDDVIKKFGPSWVHKKYKDYQVQDMTQPEVLKGRKYRKLV EKAQHASDSAGRSARRQTLEYAESMNIQRDIVYKERNRLIDGSRDLEDVVVDIIERYTEEVAADHYASRELLFHFIVTNIS FHVKEVPDYIDVTDKTAVRSFMKQVIDKELSEKKELLNQHDLYEGFLRLSLLKAIDDNWVEQVDYLQQLSMAIGGQSA SQKNPIVEYYQEAYAGFEAMKEQIHADMVRNLLMGLVEVTPKGEIVTHFP

#### ID104 879bp

15 (SEQ ID NO: 111)

5

10

- 25 GACAACACTACTTCCTTTCCTCTTGGGTAGCTGCTTCTTTGTGTGAGCAGCATTTATCCACCAGGAAAAGGACTGGA CGCTAGACAAGGTTCTCCAACAATATAGTCAACTCTTGGCAATTCCACCACTCCTCACTGCTATTGCTAGTTTCTTTG CTTTCTTTGATAGCCTACGATTTACAGCCCTCTTGTGTGA

(SEO ID NO: 112)

- 30 MKQEWFESNDFVKTTSKNKPEEQAQEVADKAEERIPDLDTPIEKNTQLEEEVSQAEVELESQQEEKIEAPEDSEARTEIEE KKASNSTEEEPDLSKETEKVTIAEESQEALPQQKATTKEPLLISKSLESPYIPDQAPKSRDKWKEQVLDFWSWLVEAIKSP TSKLETSITHSYTAFLLLILFSASSFFFSIYHIKHAYYGHIASINSRFPEQLAPLTLFSIISILVATTLFFFSFLLGSFVVRRFIHQ EKDWTLDKVLQQYSQLLAIPISSLLLLVSLLSLIAYDLQPSCV
- 35 <u>ID106 327bp</u>

(SEQ ID NO: 113)

ATGTACTTTCCAACATCCTCTGCTTGATTGAATTTCTCATCTTGGCTGACCAGGGTGATTCTTATGGTTAT
GAGATTAGCCAAACCATTAAGCTGATCGCTAATATCAAAGAATCCACACTCTATCCCATTCTCAAAAAAATTGGAAG
GCAATAGCTTTCTGACAACCTATTCTAGAGAGTTCCAAGGTCGCATGCGCAAATACTACTCCTTGACAAACGGTGG
TATAGAGCAGCTCTTGACCCTAAAAGATGAATGGGCACTCTATACAGACACCATCAATGGCATCATAGAAGGGAG
TATCCGCCATGACAAGAACTGA

(SEQ ID NO: 114)

45 MYFPTSSALIEFLILAVLEQGDSYGYEISQTIKLIANIKESTLYPILKKLEGNSFLTTYSREFQGRMRKYYSLTNGGIEQLLT LKDEWALYTDTINGIIEGSIRHDKN

# ID108 954bp

50 (SEQ ID NO: 115)

- 60 TCTAGCTCCGAGTGATTTGTTGACCAAAGTGATTTGTTAAAAGAATGGCTGAAGGAGAAGAGGCGAGTCTG
  GTTGCTATGATTAGTCTGCCTGAAAATCTCTTTGCTAAATGCCAAACAATCTAAGACTATTTTTATCTTACAGAAGAA
  AAATGAAATAGCAGTAGAGCCTTTTGTTTATCCACTTGCTAGCTTGCAAGATGCAAGTGTTTTAATGAAATTTAAAG
  AAAATTTTCAAAAATGGACTCAAGGTACTGAAATATAA
- 65 (SEQ ID NO: 116)

MDFEKIEQAYIYLLENVQVIQSDLATNFYDALVEQNSIYLDGETELNQVKDNNQALKRLALRKEEWLKTYQFLLMKAG QTEPLQANHQFTPDAIALLLVFIVEELFKEEEITILEMGSGMGILGAIFLTSLTKKVDYLGMEVDDLLIDLAASMADVIGL QAGFVQGDAVRPQMLKESDVVISDLPVGYYPDDAVASRHQVASSQEHTYAHHLLMEQGLKYLKSDGYAIFLAPSDLLT SPQSDLLKEWLKEEASLVAMISLPENLFANAKQSKTIFILQKKNEIAVEPFVYPLASLQDASVLMKFKENFQKWTQGTEI

#### ID110 1902bp

5

10

15

20

25

30

(SEQ ID NO: 117)

- ATGATTATTTTACAAGCTAATAAAATTGAACGTTCTTTTGCAGGAGAGGTTCTTTTCGATAATATCAACCTGCAGGT TGATGAACGAGATCGGATTGCTCTTGTTGGGAAAAATGGTGCAGGTAAGTCTACTCTTTTGAAGATTTTAGTTGGA GAAGAGGAGCCAACTAGCGGAGAAATCAATAAGAAAAAAGATATTTCTCTGTCTTACCTAGCCCAAGATAGCCGT GTCAGATGGAGCTGGAGATGGGTGAAAAGTCTGGTGAGGATTTTGGATAAACTGATGTCAGATTATGACCGCTTATC TGAGAATTTTCGCCAAGCAGGTGGCTTTACCTATGAAGCTGATATTCGAGCGATTTTGAATGGATTCAAGTTTGACG AGTCTATGTGGCAGATGAAAATTGCTGAGCTTTCTGGTGGTCAAAATACTCGTTTGGCACTTGCCAAAATGCTCCTT GAAAAGCCCAATCTCTTGGTCTTGGACGAGCCAACTAACCACTTGGATATTGAAACCATCGCCTGGCTAGAGAATT ACTTGGTAAACTATAGCGGTGCCCTCATTATCGTCAGCCACGACCGTTATTTCTTGGACAAGGTTGCGACAATTACG CTAGATTTGACCAAGCATTCCTTGGATCGCTATGTGGGGAATTACTCTCGTTTTGTCGAATTGAAGGAGCAAAAGCT AGTTACTGAGGCAAAAAACTATGAAAAGCAACAGAAGGAAATCGCTGCTCTGGAAGACTTTGTCAATCGCAATCT AGTTCGTGCTTCAACGACTAAACGTGCTCAATCTCGCCGTAAACAACTAGAAAAAATGGAGCGTTTGGACAAGCCT GAAGCTGGCAAGAAGCAGCCAACATGACCTTCCAGTCTGAAAAAACGTCGGGCAATGTTGTTTTGACTGTTGAAA ATGCAGCTGTTGGCTATGACGGGGAAGTCTTGTCACAACCTATCAACCTAGATCTTCGTAAGATGAATGCTGTCGC TATCGTTGGTCCAAATGGTATCGGCAAGTCAACCTTTATCAAGTCTATTGTGGACCAGATTCCTTTTATCAAGGGAG CAGGAGATGATGTTAAAAAATCAGTCGGCATGCTATCTGGTGGCGAAAAAGCTCGTTTGCTTTTAGCTAAATTGTC GTTTTGGAATTGTCTGAGAATGGTTCAACTCTCTACCTTGGAGATTACGACTACTATGTTGAGAAGAAAGCAACAG CAGAAATGAGTCAGACTGAGGAAGCTTCAACTAGCAATCAAGCAAAGGAAGCAAGTCCAGTCAATGACTATCAGG CCCAGAAAGAAAGTCAAAAAGAAGTTCGCAAACTCATGCGACAAATCGAAAGTCTAGAAGCTGAAATTGAAGAGC
- 35 (SEQ ID NO: 118)

  MIILQANKIERSFAGEVLFDNINLQVDERDRIALVGKNGAGKSTLLKILVGEEEPTSGEINKKKDISLSYLAQDSRFESENT
  IYDEMLHVFNDLRRTERQLRQMELEMGEKSGEDLDKLMSDYDRLSENFRQAGGFTYEADIRAILNGFKFDESMWQMKI
  AELSGGQNTRLALAKMLLEKPNLLVLDEPTNHLDIETIAWLENYLVNYSGALIIVSHDRYFLDKVATITLDLTKHSLDRY
  VGNYSRFVELKEQKLVTEAKNYEKQQKEIAALEDFVNRNLVRASTTKRAQSRRKQLEKMERLDKPEAGKKAANMTFQ
  SEKTSGNVLTVENAAVGYDGEVLSQPINLDLRKMNAVAIVGPNGIGKSTFIKSIVDQIPFIKGEKRFGANVEVGYYDQT
  QSKLTPSNTVLDELWNDFKLTPEVEIRNRLGAFLFSGDDVKKSVGMLSGGEKARLLLAKLSMENNNFLILDEPTNHLDID
  SKEVLENALIDFDGTLLFVSHDRYFINRVATHVLELSENGSTLYLGDYDYYVEKKATAEMSQTEEASTSNQAKEASPVN
  DYQAQKESQKEVRKLMRQIESLEAEIEELESQSAISEQMLETNDADKLMELQAELDKISHRQEEAMLEWEELSEQV

CTGAGCTGGACAAAATCAGCCATCGTCAGGAAGAAGCTATGCTTGAGTGGGAAGAATTATCAGAGCAGGTGTAA

# 45 <u>ID111 1179ьр</u>

(SEQ ID NO: 119)

- ATGAATCGCTATGCAGTGCAGTTGATTAGCCGTGGGGCTATCAATAAAATGGGAAATATGCTCTATGATTATGGAA 50 TCTATTCTCGTCAATCCCTTTGGCGGAGTTATTTCAGACCGTTTTTCTCGTCGTAAGATTTTAATGACGGCAGATCTT GTTTGTGGGATTCTTTGTCTGGCTATTTCTTTCATAAGGAATGATAGCTGGATGATTGGCGCTTTGATTGTTGCTAAC ATTGTGCAGGCTATTGCTTTTCCCGCACAGCCAATAAAGCTATCATAACTGAAGTGGTGGAGAAAGATG AGATTGTGATCTATAATTCTCGCTTAGAGCTGGTTTTGCAGGTTGTAGGTGTTAGCTCTCCTGTTCTTTCCTTG TTTTACAGTTTGCAAGTCTCCATATGACGCTACTGCTAGACTCGCTGACTTTTTTCATTGCTTTTGTTCTAGTGGCTT 55 TCCTTCCAAAAGAGGAAGCAAAAGTTCAAGAGAAAAAGGCTTTTACTGGGAGAGATATTTTTGTAGATATCAAGG ATGGGTTACACTATATCTGGCATCAGCAAGAAATTTTCTTCCTTTTGCTGGTAGCTTCCAGCGTTAATTTCTTTTTTG CAGCTTTTGAATTTCTACTTCCCTTTTCGAATCAGCTTTACGGGTCAGAAGGAGCCTATGCAAGTATTTTAACTATG GGGGCTATTGGTTCCATCATTGGGGCTCTTCTAGCTAGTAAAATTAAAGCTAATATTTATAATCTTTTGATTTTACTG 60 GAATTGTTTATGACGATTTTTAATATTCACTTTTTTACTCAAGTACAAACCAAGGTTGAGAGCGAATTTCTTGGAAG AGTACTGAGTACAATTTTTACCTTAGCTATTCTATTTATGCCTATTGCAAAAGGATTTATGACAGTCTTGCCAAGTG TCCATCTTTATTCTTTGATTATTGGACTTGGAGTTGTAGCCTTATATTTCTTAGCTCTCGGATATGTTCGAACTC **ATTTTGAAAAATTGATATAA**
- 65 (SEQ ID NO: 120)

MNRYAVQLISRGAINKMGNMLYDYGNSVWLASMGTIGQTVLGMYQISELVTSILVNPFGGVISDRFSRRKILMTADLVC GILCLAISFIRNDSWMIGALIVANIVQAIAFAFSRTANKAIITEVVEKDEIVIYNSRLELVLQVVGVSSPVLSFLVLQFASLH MTLLLDSLTFFIAFVLVAFLPKEEAKVQEKKAFTGRDIFVDIKDGLHYIWHQQEIFFLLLVASSVNFFFAAFEFLLPFSNQL YGSEGAYASILTMGAIGSIIGALLASKIKANIYNLLILLALTGVGVFMMGLPLPTFLSFSGNLVCELFMTIFNIHFFTQVQT KVESEFLGRVLSTIFTLAILFMPIAKGFMTVLPSVHLYSFLIIGLGVVALYFLALGYVRTHFEKLI

#### ID113 2466bp

5

(SEO ID NO: 121) 10 GCTAGACCTGGCAAGAAAGGTTCAAGTACCAAAAAATCTAAAACCTTAGATAAGTCAGCCATTTTCCCAGCTATTT TACTGAGTATAAAAGCCTTATTTAACTTACTCTTTGTACTCGGTTTTCTAGGAGGAATGTTGGGAGCTGGGATTGCT 15 TATCTCATCTGAGCAAATTTCGGAAAATCTGAAGAAGGCTATCATTGCGACAGAAGATGAACACTTTAAAGAACAT AAGGGTGTAGTACCCAAGGCGGTGATTCGTGCGACCTTGGGGAAATTTGTAGGTTTGGGTTCCTCTAGTGGGGGTT CAACCTTGACCCAGCAACTAATTAAACAGCAGGTGGTTGGGGATGCGCCGACCTTGGCTCGTAAGGCGGCAGAGA TTGTGGATGCTCTTGCCTTGGAACGCGCCATGAATAAAGATGAGATTTTAACGACCTATCTCAATGTGGCTCCCTTT GGCCGAAATAATAAGGGACAGAATATTGCAGGGGCTCGGCAAGCAGCTGAGGGAATTTTCGGTGTAGATGCCAGT 20 ACAGGTGCATTAAGCAAAGACGAGTATTCTCAGTACAAGGATTATGACCTTAAACAGGACTTTTTACCATCGGGCA GCTCAGAGAGACAATGTCTCCGCTAAGGAGTTGAAAAATGAGGCAACTCAGAAGTTTTATCGAGATTTGGCAGCC 25 TTGCTGATTATGGCTATCTTTTAGACGATGGAACAGGTCGTGTAGAAGTAGGGAATGTCTTGATGGATAACCAAAC AGGTGCTATTCTAGGCTTTGTAGGTGGTCGTAATTATCAAGAAAATCAAAATAATCATGCCTTTGATACCAAACGTT CGCCAGCTTCTACTACCAAGCCCTTGCTGGCCTACGGTATTGCTATTGACCAGGGCTTGATGGGAAGTGAAACGAT 30 ACCTTGGGAGAGCTCTGAACTATTCATGGAATATCCCTGCTTACTGGACCTATCGTATGCTCCGTGAAAAGGGTG TTGATGTCAAGGGTTATATGGAAAAGATGGGTTACGAGATTCCTGAGTACGGTATTGAGAGCTTGCCAATGGGTGG TGGTATTGAAGTCACAGTTGCCCAGCATACCAATGGCTATCAGACCTTAGCTAATAATGGAGTTTATCATCAGAAG CAAAAGCTACTGCGACGATTATGCAGGGATTGCTACGAGAAGTTCTATCCTCTCGTGTGACAACAACCTTCAAGTC 35 ACGTAGAGCAGGTTATTCTAATAACTCTAATTACATGGCTCATCTGGTAAATGCGATTCAGCAAGCTTCCCCAAGC ATTTGGGGGAACGAGCGCTTTGCTTTAGATCCTAGTGTAGTGAAATCGGAAGTCTTGAAATCAACAGGTCAAAAAC CAGAGAAGGTTTCTGTTGAAGGAAAAGAAGTAGAGGTCACAGGTTCGACTGTTACCAGCTATTGGGCTAATAAGTC 40 AGGAGCGCCAGCGACAAGTTATCGCTTTGCTATTGGCGGAAGTGATGCGGATTATCAGAATGCTTGGTCTAGTATT

45 (SEQ ID NO: 122)

MQNQLNELKRKMLEFFQQKQKNKKSARPGKKGSSTKKSKTLDKSAIFPAILLSIKALFNLLFVLGFLGGMLGAGIALGY
GVALFDKVRVPQTEELVNQVKDISSISEITYSDGTVIASIESDLLRTSISSEQISENLKKAIIATEDEHFKEHKGVVPKAVIRA
TLGKFVGLGSSSGGSTLTQQLIKQQVVGDAPTLARKAAEIVDALALERAMNKDEILTTYLNVAPFGRNNKGQNIAGARQ
AAEGIFQVDASQLTVPQAAFLAGLPQSPITYSPYENTGELKSDEDLEIGLRRAKAVLYSMYRTGALSKDEYSQYKDYDL
KQDFLPSGTVTGISRDYLYFTTLAEAQERMYDYLAQRDNVSAKELKNEATQKFYRDLAAKEIENGGYKITTTIDQKIHS
AMQSAVADYGYLLDDGTGRVEVGNVLMDNQTGAILGFVGGRNYQENQNNHAFDTKRSPASTTKPLLAYGIAIDQGLM
GSETILSNYPTNFANGNPIMYANSKGTGMMTLGEALNYSWNIPAYWTYRMLREKGVDVKGYMEKMGYEIPEYGIESLP
MGGGIEVTVAQHTNGYQTLANNGVYHQKHVISKIEAADGRVVYEYQDKPVQVYSKATATIMQGLLREVLSSRVTTTFK
SNLTSLNPTLANADWIGKTGTTNQDENMWLMLSTPRLTLGGWIGHDDNHSLSRRAGYSNNSNYMAHLVNAIQQASPSI
WGNERFALDPSVVKSEVLKSTGQKPEKVSVEGKEVEVTGSTVTSYWANKSGAPATSYRFAIGGSDADYQNAWSSIVGS
LPTPSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSRARR

GTGGGGAGTCTACCAACTCCATCCAGCTCCAGCAGTTCAAGTAGTAGTTCTAGCGATAGCAGTAACTCAAGTACTA

### ID114 1974bp

CACGACCTTCTTCTTCAAGGGCGAGACGATAA

TGGATAATTATGATGATTTTGGAGGATGAAACTTCTGAGTCAGATATTAGTCAAATCAATAGTTTTTGTAGCTAATTTT ATATCAGAGTTTTCAGAAAAACACATGATGTTTTCTCGTCGGGTAAGTATGGATCGATTTTATCTATTTACTGACTA CACGGTGCTTGAGGGCTTGATGAATGATAAATTTTCTGTTATTGATGCTTTCAGAGAAGAGTCGAAACAGAGACAG TTGCCCTTGACCTTAAGTATGGGATTTTCTTATGGCGATGGAAATCATGATGAGATAGGGAAAGTTGCTTTGCTCAA 5 TTTGAACTTGGCTGAAGTACGTGGTGGCGACCAGGTGGTTGTTAAGGAAAACGACGAAAACGAAAAATCCAGTTTAT TTTGGTGGTGGGTCTGCTTCAATCAAGCGTACACGGACTCGTACGCGCGCTATGATGACAGCTATTTCAGATA AGATTCGGAGTGTAGATCAGGTTTTTGTAGTCGGTCACAAAAATTTAGACATGGATGCTTTTGGGCTCTGTAGGT ATGCAGTTGTTCGCCAGCAATGTGATTGAAAATAGCTATGCTCTTTATGATGAAGAACAAATGTCTCCAGATATTG AACGAGCTGTTTCATTCATAGAAAAAGAAGGAGTTACGAAGTTGTTGTCTGTTAAGGATGCAATGGGGATGGTGAC 10 CCAAACCATTGTTATTGACCACCATAGAAGGGATCAGGATTTTCCAGATAATGCGGTTATTACTTATATCGAAAGT GGTGCAAGTAGTGCCAGTGAGTTGGTAACGGAATTGATTCAGTTCCAGAATTCTAAGAAAAATCGTTTGAGTCGTA TGCAAGCAAGTGTCTTGATGGCTGGTATGATGTTGGATACTAAAAATTTCACCTCGCGAGTAACTAGTCGGACATT TGATGTTGCTAGCTATCTCAGAACGCGCGGAAGTGATAGTATTGCTATCCAGGAAATCGCTGCGACAGATTTTGAA 15 GAATATCGTGAGGTCAATGAACTTATTTTACAGGGGCGTAAATTAGGTTCAGATGTACTAATAGCAGAGGCTAAGG ACATGAAATGCTATGATACAGTTGTTATTAGTAAGGCAGCAGATGCCATGTTAGCCATGTCAGGTATTGAAGCGAG TTTTGTTCTTGCGAAGAATACACAAGGATTTATCTCTATCTCAGCTCGAAGTCGTAGTAAACTGAATGTACAACGGA TTATGGAAGAGTTAGGCGGTGGAGGCCACTTTAATTTGGCAGCAGCTCAAATTAAAGATGTAACCTTGTCAGAAGC 

(SEQ ID NO: 124)

25

30

MKKFYVSPIFPILVGLIAFGVLSTFIIFVNNNLLTVLILFLFVGGYVFLFKKLRVHYTRSDVEQIQYVNHQAEESLTALLEQ MPVGVMKLNLSSGEVEWFNPYAELILTKEDGDFDLEAVQTIIKASVGNPSTYAKLGEKRYAVHMDASSGVLYFVDVSR EQAITDELVTSRPVIGIVSVDNYDDLEDETSESDISQINSFVANFISEFSEKHMMFSRRVSMDRFYLFTDYTVLEGLMNDK FSVIDAFREESKQRQLPLTLSMGFSYGDGNHDEIGKVALLNLNLAEVRGGDQVVVKENDETKNPVYFGGGSAASIKRTR TRTRAMMTAISDKIRSVDQVFVVGHKNLDMDALGSAVGMQLFASNVIENSYALYDEEQMSPDIERAVSFIEKEGVTKLL SVKDAMGMVTNRSLLILVDHSKTALTLSKEFYDLFTQTIVIDHHRRDQDFPDNAVITYIESGASSASELVTELIQFQNSKK NRLSRMQASVLMAGMMLDTKNFTSRVTSRTFDVASYLRTRGSDSIAIQEIAATDFEEYREVNELILQGRKLGSDVLIAEA KDMKCYDTVVISKAADAMLAMSGIEASFVLAKNTQGFISISARSRSKLNVQRIMEELGGGGHFNLAAAQIKDVTLSEAG EKLTEIVLNEMKEKEKEE

### ID115 663bp

(SEQ ID NO: 125)

- 45 (SEQ ID NO: 126)
  MKCLLCGQTMKTVLTFSSLLLLRNDDSCLCSDCDSTFERIGEENCPNCMKTELSTKCQDCQLWCKEGVEVSHRAIFTYN
  QAMKDFFSRYKFDGDFLLRKVFASFLSEELKKYKEYQFVVIPLSPDRYANRGFNQVEGLVEAAGFEYLDLLEKREERAS
  SSKNRSERLGTELPFFIKSGVTIPKKILLIDDIYTTGATINRVKKLLEEAGAKDVKTFSLVR

GTTGGAAGAAGCTGGTGCTAAGGATGTAAAAACATTTTCCCTTGTAAGATGA

# 50 ід116 1299ьр

(SEQ ID NO: 127)

- TTAGACAAGAATCGTTTGTCACCAAAGTTAAAGTCCTATATTGAGAAGCAGAAAAAGACAGCTTATCCGTTACTCA
  TTTTTGCTTCAGAAAATTAAGAAAGGGGAGCAGTTAGCAGAAAATCTTACAGGAGCAATTTCCAAATGAGAAAATTGG
  CTTTGTATCTTCTGTAACAGAGGATCGATTAGAGCAAGTACAAGCTTTTCGAGATGGAGAACTGACAATACTTATC

AGTACGACAATCTTGGAGCGCGGAGTTACCTTCCCTTGTGTGGATGTTTTCGTAGTAGAGGCCAATCATCGTTTGTT TACCAAGTCTAGTTTGATTCAGATTGGTGGACGAGGTTGGACGAAGCATGGATAGACCGACAGGAGATTTGCTTTTC TTCCATGATGGGTTAAATGCTTCAATCAAGAAGGCGATTAAGGAAATTCAGATGATGAATAAGGAGGCTGGTCTAT

5 (SEO ID NO: 128)

MKVNLDYLGRLFTENELTEEERQLAEKLPAMRKEKGKLFCQRCNSTILEEWYLPIGAYYCRECLLMKRVRSDQTLYYFP OEDFPKODVLKWRGOLTPFOEKVSEGLLOVVDKOKPTLVHAVTGAGKTEMIYOVVAKVINAGGAVCLASPRIDVCLEL YKRLOODFSCGIALLHGESEPYFRTPLVVATTHOLLKFYOAFDLLIVDEVDAFPYVDNPMLYHAVKNSVKENGLRIFLT

10 ATSTNELDKKVRLGELKRLNLPRRFHGNPLIIPKPIWLSDFNRYLDKNRLSPKLKSYIEKQRKTAYPLLIFASEIKKGEQLA EILQEQFPNEKIGFVSSVTEDRLEQVQAFRDGELTILISTTILERGVTFPCVDVFVVEANHRLFTKSSLIQIGGRVGRSMDRP TGDLLFFHDGLNASIKKAIKEIOMMNKEAGL

## ID117 870bp

15 (SEQ ID NO: 129)

ATGCAAATTCAAAAAAGTTTTAAGGGGCAGTCTCCCTATGGCAAGCTGTATCTAGTGGCAACGCCGATTGGCAATC TAGATGATATGACTTTTCGTGCTATCCAGACCTTGAAAGAAGTGGACTGGATTGCTGCTGAGGATACGCGCAATAC AGGGCTTTTGCTCAAGCATTTTGACATTTCCACCAAGCAGATCAGTTTTCATGAGCACAATGCCAAGGAAAAAATT

- 20 CCCTGGTCATGATTTAGTTAAGGCAGCTATTGAGGAAGAAATTGCAGTTGTGACAGTTCCAGGTGCCTCTGCAGGA ATTTCTGCCTTGATTGCCAGTGGTTTAGCGCCACAGCCACATATCTTTTACGGTTTTTTACCGAGAAAATCAGGTCA GCAGAAGCAATTTTTTGGCTTGAAAAAAGATTATCCTGAAACACAGATTTTTTTATGAATCACCTCATCGTGTAGCA GACACGTTGGAAAATATGTTAGAAGTCTACGGTGACCGCTCCGTTGTCTTGGTCAGGGAATTGACCAAAATCTATG
- 25 AAGAATACCAACGAGGTACTATCTCTGAGTTATTAGAAAGCATTGCTGAAACGCCACTCAAGGGCGAATGTCTTCT CATTGTTGAGGGTGCCAGTCAGGGTGTGGAGGAAAAGGACGAGGAAGACTTGTTCGTAGAAATTCAAACCCGCAT
- 30 (SEO ID NO: 130) MQIQKSFKGQSPYGKLYLVATPIGNLDDMTFRAIQTLKEVDWIAAEDTRNTGLLLKHFDISTKQISFHEHNAKEKIPDLIG FLKAGQSIAQVSDAGLPSISDPGHDLVKAAIEEEIAVVTVPGASAGISALIASGLAPQPHIFYGFLPRKSGQQKQFFGLKKD YPETQIFYESPHRVADTLENMLEVYGDRSVVLVRELTKIYEEYQRGTISELLESIAETPLKGECLLIVEGASQGVEEKDEE DLFVEIQTRIQQGVKKNQAIKEVAKIYQWNKSQLYAAYHDWEEKQ

# ID118 345bp

35

(SEO ID NO: 131)

- ATGATAAAGAAAGGAAAGGGCTGTTTTATGGACAAAAAAGAATTATTTGACGCGCTGGATGATTTTTCCCAACAAT 40 TATTGGTAACCTTAGCCGATGTGGAAGCCATCAAGAAAATCTCAAGAGCCTGGTAGAGGAAAATACAGCTCTTCG CTTGGAAAATAGTAAGTTGCGAGAACGCTTGGGTGAGGTGGAAGCAGATGCTCCTGTCAAGGCCAAGCATGTTCG CGAAAGTGTCCGTCGTATTTACCGTGATGGATTTCACGTATGTAATGATTTTTATGGACAACGTCGAGAGCAGGAC GAAGAATGTATGTTTTGTGACGAGTTGTTATACAGGGAGTAA
- 45 (SEO ID NO: 132) MIKKGKGCFMDKKELFDALDDFSQQLLVTLADVEAIKKNLKSLVEENTALRLENSKLRERLGEVEADAPVKAKHVRES VRRIYRDGFHVCNDFYGQRREQDEECMFCDELLYRE

#### ID119 639bp 50

(SEQ ID NO: 133)

ATGTCAAAAGGATTTTTAGTCTCTCTTGAGGGACCAGAGGGAGCAGGCAAGACCAGTGTTTTAGAGGCTCTGCTAC CAATTTTAGAGGAAAAAGGAGTAGAGGTGTTGACGACCCGTGAACCTGGCGGAGTCTTGATTGGGGAGAAGATTC GGGAAGTGATTTTGGATCCAAGTCATACTCAGATGGATGCTAAAACAGAGCTACTTCTCTATATTGCCAGTCGCAG

- 55 ACAGCATTTGGTGGAAAAAGTTCTTCCAGCCCTTGAAGCTGGCAAGTTGGTCATCATGGATCGTTTTATCGATAGTT CTGTTGCCTATCAGGGATTTGGTCGTGGCTTAGATATTGAAGCCATTGACTGGCTCAATCAGTTTTGCGACAGATGGC GCGAGGTTAATCGTTTGGATTTGGAAGGGTTGGACTTGCATAAAAAAGTTCGTCAAGGCTACCTTTCTCTGGAT AAAGAGGGAAATCGCATTGTCAAGATTGATGCTAGTCTCCCTTTGGAGCAAGTTGTGGAAACTACCAAGGCTGTCT 60 TGTTTGACGGAATGGGCTTGGCCAAATGA

(SEQ ID NO: 134)

MSKGFLVSLEGPEGAGKTSVLEALLPILEEKGVEVLTTREPGGVLIGEKIREVILDPSHTOMDAKTELLLYIASRROHLVE KVLPALEAGKLVIMDRFIDSSVAYQGFGRGLDIEAIDWLNQFATDGLKPDLTLYFDIEVEEGLARIAANSDREVNRLDLE GLDLHKKVRQGYLSLLDKEGNRIVKIDASLPLEQVVETTKAVLFDGMGLAK

#### ID120 408bp

(SEO ID NO: 135)

- ATGGTAGAACAAAGAAAATCAATTACCATGAAAGATGTTGCTTTAGAAGCAGGAGTTAGTGTTGGAACTGTTTCAC 5 GTGTAATTAATAAAGAAAAAGGCATTAAAGAAGTAACTTTGAAAAAAGTGGAACAAGCGATTAAAACTTTGAATT ACATTCCAGATTACTACGCTAGAGGAATGAAAAAAAATCGAACAGAAACGATTGCAATCATTGTACCAAGTATCT GGCATCCCTTCTTTCAGAATTTGCTATGCATGTGGAAAATGAAGTCTATAAGAGAAATAACAAATTACTCTTATGT TCTATCAATGGTACAAATAGAGAGCAAGACTATCTGGAGATGTTGCGTCATAATAAAGTTGATGGAGTGGTTGCCA TTACCTATAGGCCAATTGAACATTACTTGACGTCAGGAATTCCCTTTGTTAGTATTGACCGCACATACTCAGAGATT 10 GCCATTCCTTGTGTTTCA
  - (SEO ID NO: 136) MVEQRKSITMKDVALEAGVSVGTVSRVINKEKGIKEVTLKKVEQAIKTLNYIPDYYARGMKKNRTETIAIIVPSIWHPFFS EFAMHVENEVYKRNNKLLLCSINGTNREQDYLEMLRHNKVDGVVAITYRPIEHYLTSGIPFVSIDRTYSEIAIPCVS

# ID121 285bp

15

(SEQ ID NO: 137)

- ATGAATATATTTAGAACAAAGAATGTTAGTTTAGATAAAACAGAGATGCATAGGCATTTGAAGTTATGGGATTTGA 20 TTTTGCTGGGTATCGGAGCCATGGTAGGGACAGGCGTCTTTACAATCACAGGTACTGCAGCTGCAACACTTGCTGG GGTTAACCATGATGGAGTTCATGACAGCCATATCAGGCGTAGCTTCGGGTTGGGCAGCTTATTTTAA
- 25 (SEQ ID NO: 138) MNIFRTKNVSLDKTEMHRHLKLWDLILLGIGAMVGTGVFTITGTAAATLAGPALVISIVISALCVGLSALFFAEFASRVPA TGGAYSYLYAILGEFPAWLAGWLTMMEFMTAISGVASGWAAYF

#### ID124 1311bp 30

(SEO ID NO: 139) ATGAAATCAAGAGTAAAGGAAACGAGTATGGATAAAATTGTGGTTCAAGGTGGCGATAATCGTCTGGTAGGAAGC GTGACGATCGAGGGAGCAAAAAATGCAGTCTTACCCTTGTTGGCAGCGACTATTCTAGCAAGTGAAGGAAAGACC 35

- GTCTTGCAGAATGTTCCGATTTTGTCGGATGTCTTTATTATGAATCAGGTAGTTGGTGGTTTGAATGCCAAGGTTGA  $\tt CTTTGATGAGGAAGCTCATCTTGTCAAGGTGGATGCTACTGGCGACATCACTGAGGAAGCCCCTTACAAGTATGTC$ AGCAAGATGCGCGCCTCCATCGTTGTATTAGGGCCAATCCTTGCCCGTGTGGGTCATGCCAAGGTATCCATGCCAG GTGGTTGTACGATTGGTAGCCGTCCTATTGATCTTCATTTGAAAGGTCTGGAAGCTATGGGGGGTTAAGATTAGTCAG ACAGCTGGTTACATCGAAGCCAAGGCAGAACGCTTGCATGGTGCTCATATCTATATGGACTTTCCAAGTGTTGGTG CAACGCAGAACTTGATGATGGCAGCGACTCTGGCTGATGGGGTGACAGTGATTGAGAATGCTGCGCGTGAGCCTG
- 40 AGATTGTTGACTTAGCCATTCTCCTTAATGAAATGGGAGCCAAGGTCAAAGGTGCTGGTACAGAGACTATAACCAT TACTGGTGTTGAGAAACTTCATGGTACGACTCACAATGTAGTCCAAGACCGTATCGAAGCAGGAACCTTTATGGTA CCTGCTGCCATGACTGGTGGTGATGTCTTGATTCGAGACGCTGTCTGGGAGCACAACCGTCCCTTGATTGCCAAGTT
- GTTCATGTGAAAACCTTGCCCCACCCAGGATTTCCAACAGATATGCAGGCTCAATTTACAGCCTTGATGACAGTTG 45 CAAAAGGCGAATCAACCATGGTGGAGACAGTTTTCGAAAATCGTTTCCAAACCTAGAAGAGATGCGCCGCATGGG CTTGCATTCTGAGATTATCCGTGATACAGCTCGTATTGTTGGTGGACAGCCTTTGCAGGGAGCAGAAGTTCTTTCAA CTGACCTTCGTGCCAGTGCGGCCTTGATTTTGACAGGTTTGGTAGCACAGGGAGAAACTGTGGTCGGTAAATTGGT TCACTTGGATAGAGGTTACTACGGTTTCCATGAGAAGTTGGCGCAGCTAGGTGCTAAGATTCAGCGGATTGAGGCA
- AGTGATGAAGATGAATAA 50

(SEQ ID NO: 140)

MKSRVKETSMDKIVVOGGDNRLVGSVTIEGAKNAVLPLLAATILASEGKTVLONVPILSDVFIMNOVVGGLNAKVDFD EEAHLVKVDATGDITEEAPYKYVSKMRASIVVLGPILARVGHAKVSMPGGCTIGSRPIDLHLKGLEAMGVKISOTAGYIE AKAERLHGAHIYMDFPSVGATQNLMMAATLADGVTVIENAAREPEIVDLAILLNEMGAKVKGAGTETITITGVEKLHGT 55 THNVVQDRIEAGTFMVAAAMTGGDVLIRDAVWEHNRPLIAKLLEMGVEVIEEDEGIRVRSQLENLKAVHVKTLPHPGF PTDMOAOFTALMTVAKGESTMVETVFENRFOHLEEMRRMGLHSEIIRDTARIVGGOPLOGAEVLSTDLRASAALILTGL VAQGETVVGKLVHLDRGYYGFHEKLAQLGAKIQRIEASDEDE

# ID125 1101bp

60 (SEO ID NO: 141)

ATGTTATTAGCGTCAACAGTAGCCTTGTCATTTGCCCCAGTATTGGCAACTCAAGCAGAAGAAGTTCTTTGGACTGC TACTTTGAGCACCATTGCAGAAGCCTTGGGTGTAGATGTCACAGTGCTTGCGAATCTGAACAAAATCACTAATATG 65 GACTTGATTTTCCCAGAAACTGTTTTGACAACGACTGTCAATGAAGCAGAAGAAGTAACAGAAGTTGAAATCCAAA CACCTCAAGCAGACTCTAGTGAAGAAGTGACAACTGCGACAGCAGATTTGACCACTAATCAAGTGACCGTTGATG

(SEQ ID NO: 142)
MLLASTVALSFAPVLATQAEEVLWTARSVEQIQNDLTKTDNKTSYTVQYGDTLSTIAEALGVDVTVLANLNKITNMDLI
FPETVLTTTVNEAEEVTEVEIQTPQADSSEEVTTATADLTTNQVTVDDQTVQVADLSQPIAEVTKTVIASEEVAPSTGTSV
PEEQTTETTRPVAEEAPQETTPAEKQETQTSPQAASAVEATTTSSEAKEVASSNGATAAVSTYQPEETKVISTTYEAPAAP
DYAGLAVAKSENAGLQPQTAAFKKKLLTCLALHPLVVIVQETVEITEKVWLSTLWYQNVQNZGIRLRNMLFKIWPAVA
LVTSSGNNVSMLHSIANMGQLTLGTQCQTVVVZQKITMITFTFQZMD

# ID126 1281bp

5

10

20

(SEQ ID NO: 143) TTGTTTAAGAAAAATAAAGACATTCTTAATATTGCATTGCCAGCTATGGGTGAAAACTTTTTTGCAGATGCTAATGG GAATGGTGGACAGTTATTTGGTTGCTCATTTAGGATTGATAGCTATTTCAGGGGGTTTCAGTAGCTGGTAATATTATC ACCATTTATCAGGCGATTTTCATCGCTCTGGGAGCTGCTATTTCCAGTGTTATTTCAAAAAGCATAGGGCAGAAAG 25 ACCAGTCGAAGTTGGCCTATCATGTGACTGAGGCGTTGAAGATTACCTTACTATTAAGTTTCCTTTTAGGATTTTTG TCCATCTTCGCTGGGAAAGAGATGATAGGACTTTTGGGGACGGAGAGGGATGTAGCTGAGAGTGGTGGACTGTAT CTATCTTTGGTAGGCGGATCGATTGTTCTCTTAGGTTTAATGACTAGTCTAGGAGCCTTGATTCGTGCAACGCATAA TCCACGTCTGCCTCTATGTTAGTTTTTTATCCAATGCCTTGAATATTCTTTTTTCAAGTCTAGCTATTTTTGTTCTG GATATGGGGATAGCTGGTGTTGCTTGGGGGACAATTGTGTCTCGTTTGGTTTGTGTCTTGTGATTTTTGTGGTCACAATT 30 AAAACTGCCTTATGGGAAGCCAACTTTTGGTTTAGATAAGGAACTGTTGACCTTGGCTTTACCAGCAGCTGGAGAG CGACTTATGATGAGGGCTGGAGATGTAGTGATCATTGCCTTGGTCGTTTCTTTTGGGACGGAGGCAGTTGCTGGGA TCATGTTGCCCCTGTCCTTTAGTATATGTCTTGGGTGTACCATTAACTCATCTCTATACGACTGATTCTCTAGCGG 35 TGGAGGCTAGTGTTCTAGTGACACTGTTTTCACTACTTGGGACCCCTATGACGACAGGAACAGTCATCTATACGGC AGTCTGGCAGGGATTAGGAAATGCACGCCTCCTTTTTATGCGACAAGTATAGGAATGTGGTGTATCCGCATTGGG ACAGGATATCTGATGGGGATTGTGCTTGGTTGGGGCTTGCCTGGTATTTGGGCAGGGTCTCTCTTGGATAATGGTTT TCGCTGGTTATTTCTACGCTATCGTTACCAGCGCTATATGAGCTTGAAAGGATAG

40 (SEQ ID NO: 144)
LFKKNKDILNIALPAMGENFLQMLMGMVDSYLVAHLGLIAISGVSVAGNIITIYQAIFIALGAAISSVISKSIGQKDQSKLA
YHVTEALKITLLLSFLLGFLSIFAGKEMIGLLGTERDVAESGGLYLSLVGGSIVLLGLMTSLGALIRATHNPRLPLYVSFLS
NALNILFSSLAIFVLDMGIAGVAWGTIVSRLVGLVILWSQLKLPYGKPTFGLDKELLTLALPAAGERLMMRAGDVVIIAL
VVSFGTEAVAGNAIGEVLTQFNYMPAFGVATATVMLLARAVGEDDWKRVASLSKQTFWLSLFLMLPLSFSIYVLGVPL
THLYTTDSLAVEASVLVTLFSLLGTPMTTGTVIYTAVWQGLGNARLPFYATSIGMWCIRIGTGYLMGIVLGWGLPGIWA
GSLLDNGFRWLFLRYRYQRYMSLKG

### ID127 894bp

- 50 (SEQ ID NO: 145) GTGGGAAGAATTATCAGAGCAGGTGTAAAGATGGAACATCTTGGAAAAGTATTTCGTGAATTTCGAACAAGTGGA AATTATTCTTTAAAGGAAGCAGCAGCGAATCCTGCTCTACCTCTCAGTTATCTCGCTTTGAGCTTGGGGAGTCTGA CCTGGCAGTCTCCCGTTTCTTTGAGATTTTGGATAACATTCATGTAACAATCGAAAATTTCATGGATAAGGCAAGGA ATTTTCATAATCATGAACATGTGTCTATGATGGCACAGATTATCCCACTTTACTATTCAAACGATATTGCAGGTTTT 55 CAAAAGCTTCAAAGAGAACAACTTGAAAAGTCTAAGAGTTCGACGACTCCCCTTTATTTTGAGCTGAACTGGATTT TGCTACAAGGTCTGATTTGTCAAAGAGATGCGAGTTATGATATGAAGCAGGATGATTTGGGTAAGGTAGCAGATTA TCTCTTCAAAACAGAAGAATGGACCATGTATGAGTTGATTCTTTTCGGTAACCTCTATAGTTTCTACGATGTAGACT ATGTCACTCGGATTGGTAGAGAAGTTATGGAGAGGGAAGGATTTTACCAAGAGATTAGTCGCCATAAGAGATTAG TGTTGATTTTGGCCCTCAATTGTTACCAGCATTGTTTAGAGCATTCTTCTTTTTATAATGCCAACTATTTTGAGGCTT 60 ATACAGAGAAGATTATTGACAAAGGTATTAAGCTITATGAGCGTAATGTTTTCCATTATTTAAAAGGTTTTTGCCTTA TATCAAAAAGGACAGTGTAAAGAAGGCTGTAAGCAGATGCAAGAGGCCATGCATATTTTTGATGTGTTAGGTCTTC CAGAGCAAGTAGCCTATTATCAGGAACACTACGAAAAATTTGTCAAAAGTTAA
- (SEQ ID NO: 146)
  VGRIIRAGVKMEHLGKVFREFRTSGNYSLKEAAGESCSTSQLSRFELGESDLAVSRFFEILDNIHVTIENFMDKARNFHNH
  EHVSMMAQIIPLYYSNDIAGFQKLQREQLEKSKSSTTPLYFELNWILLQGLICQRDASYDMKQDDLGKVADYLFKTEEW

TMYELILFGNLYSFYDVDYVTRIGREVMEREEFYQEISRHKRLVLILALNCYQHCLEHSSFYNANYFEAYTEKIIDKGIKLYERNVFHYLKGFALYQKGQCKEGCKQMQEAMHIFDVLGLPEQVAYYQEHYEKFVKS

#### TABLE 3

# ID1 1068bp

5 (SEO ID NO: 147) ATGTCTAACATTCAAAACATGTCCCTGGAGGACATCATGGGAGAGCGCTTTGGTCGCTACTCCAAGTACATTATTC AAGACCGGGCTTTGCCAGATATTCGTGATGGGTTGAAGCCGGTTCAGCGCCGTATTCTTTATTCTATGAATAAGGAT GGGATTCTTCTATCTATGATGCCATGGTTCGTATGTCACAGAACTGGAAAAATCGTGAGATTCTAGTTGAAATGCA 10 CGGTAATAACGGTTCTATGGACGGAGATCCTCCTGCGGCTATGCGTTATACTGAGGCACGTTTGTCTGAAATTGCA CGGTCTTGCCAGCAGCCTTTCCAAACCTCTTGGTCAATGGTTCGACTGGGATTTCGGCTGGTTATGCCACAGACATT  ${\tt CCTCCCCATAATTTAGCTGAGGTCATAGATGCTGCAGTTTACATGATTGACCACCCAACTGCAAAGATTGATAAAC}$ TCATGGAATTCTTGCCTGGACCAGACTTCCCTACAGGGGCTATTATTCAGGGTCGTGATGAAATCAAGAAAGCTTA 15 TGAGACTGGGAAAGGGCGCGTGGTTGTTCCTTCCAAGACTGAAATTGAAAAGCTAAAAGGTGGTAAGGAACAAAT CGTTATTATTGAGATTCCTTATGAAATCAATAAGGCCAATCTAGTCAAGAAAATCGATGATGTTCGTGTTAATAAC AAGGTAGCTGGGATTGCTGAGGTTCGTGATGAGCCGTGATGGTCTTCGTATCGCTATCGAACTTAAGAAAG ACGCTAATACTGAGCTTGTTCTCAACTACTTATTTAAGTACACCGACCTACAAATCAACTACAACTTTAATATGGTG GCGATTGACAATTTCACACCTCGTCAGGTTGGATTGTTCCAATCCTGTCTAGCTATATCGCTCACCGTCGAGAAGTG 20

(SEQ ID NO: 148)
MSNIQNMSLEDIMGERFGRYSKYIIQDRALPDIRDGLKPVQRRILYSMNKDSNTFDKSYRKSAKSVGNIMGNFHPHGDSS
IYDAMVRMSQNWKNREILVEMHGNNGSMDGDPPAAMRYTEARLSEIAGYLLQDIEKKTVPFAWNFDDTEKEPTVLPA
AFPNLLVNGSTGISAGYATDIPPHNLAEVIDAA VYMIDHPTAKIDKLMEFLPGPDFPTGAIIQGRDEIKKAYETGKGRVVV
RSKTEIEKLKGGKEQIVIIEIPYEINKANLVKKIDDVRVNNKVAGIAEVRDESDRDGLRIAIELKKDANTELVLNYLFKYT
DLQINYNFNMVAIDNFTPROVGLFOSCLAISLTVEK

# <u>ID12 684bp</u>

25

30

45

(SEQ ID NO: 150)
MPTLEIAQKKLEFIKKAEEYYNALCTNIQLSGDKLKVISVTSVNPGEGKTTTSINIAWSFARAGYKTLLIDGDTRNSVMLG
VFKSREKITGLTEFLSGTADLSHGLCDTNIENLFVVQSGSVSPNPTALLQSKNFNDMIETLRKYFDYIIIDTPPIGIVIDAAII
TQKCDASILVTATGEANKRDIQKAKQQLKQTGKLFLGVVLNKLDISVNKYGVYGSYGNYGKK

#### ID13 1182bp

(SEQ ID NO: 151) 50 ATGGAGGCAAATATGAAACATCTAAAAACATTTTACAAAAAATGGTTTCAATTATTAGTCGTTATCGTCATTAGCTT AGTACTATTACACAAACTGCCTATAAGAACGAAAATTCAACAACACAGGCTGTTAACAAAGTAAAAGATGCTGTT GTTTCTGTTATTACTTATTCGGCAAACAGACAAAATAGCGTATTTGGCAATGATGATACTGACACAGATTCTCAGCG AATCTCTAGTGAAGGATCTGGAGTTATTTATAAAAAGAATGATAAAGAAGCTTACATCGTCACCAACAATCACGTT 55 ATTAATGGCGCCAGCAAAGTAGATATTCGATTGTCAGATGGGACTAAAGTACCTGGAGAAATTGTCGGAGCTGAC ACTTTCTCTGATATTGCTGTCGTCAAAATCTCTTCAGAAAAAGTGACAACAGTAGCTGAGTTTGGTGATTCTAGTAA GTTAACTGTAGGAGAAACTGCTATTGCCATCGGTAGCCCGTTAGGTTCTGAATATGCAAATACTGTCACTCAAGGT ATCGTATCCAGTCTCAATAGAAATGTATCCTTAAAATCGGAAGATGGACAAGCTATTTCTACAAAAGCCATCCAAA CTGATACTGCTATTAACCCAGGTAACTCTGGCGGCCCACTGATCAATATTCAAGGGCAGGTTATCGGAATTACCTC 60 AAGTAAAATTGCTACAAATGGAGGAACATCTGTAGAAGGTCTTGGTTTCGCAATTCCTGCAAATGATGCTATCAAT ATTATTGAACAGTTAGAAAAAAACGGAAAAGTGACGCGTCCAGCTTTGGGAATCCAGATGGTTAATTTATCTAATG TAATATGCCTGCCAATGGTCACCTTGAAAAATACGATGTAATTACAAAAGTAGATGACAAAGAGATTGCTTCATCA ACAGACTTACAAAGTGCTCTTTACAACCATTCTATCGGAGACACCATTAAGATAACCTACTATCGTAACGGGAAAG 65 AAGAAACTACCTCTATCAAACTTAACAAGAGTTCAGGTGATTTAGAATCTTAA

(SEQ ID NO: 152)

MEANMKHLKTFYKKWFQLLVVIVISFFSGALGSFSITQLTQKSSVNNSNNNSTITQTAYKNENSTTQAVNKVKDAVVSV
ITYSANRQNSVFGNDDTDTDSQRISSEGSGVIYKKNDKEAYIVTNNHVINGASKVDIRLSDGTKVPGEIVGADTFSDIAVV
KISSEKVTTVAEFGDSSKLTVGETAIAIGSPLGSEYANTVTQGIVSSLNRNVSLKSEDGQAISTKAIQTDTAINPGNSGGPLI
NIQGQVIGITSSKIATNGGTSVEGLGFAIPANDAINIIEQLEKNGKVTRPALGIQMVNLSNVSTSDIRRLNIPSNVTSGVIVR
SVQSNMPANGHLEKYDVITKVDDKEIASSTDLQSALYNHSIGDTIKITYYRNGKEETTSIKLNKSSGDLES

# ID15 939bp

10 (SEQ ID NO: 153)

- CTCTATCTATCAACAAGGGAATGACCGTGGTCGCCAATATCGAACTGGGATTTATTATCAGGATGAAGCAGA
  TTTGCCAGCTATCTACACAGTGGTGCAGGAGCAGGAACGCATGCTGGGTCGAAAGATTGCAGTAGAAGTGGAGCA
  ATTACGCCACTACATTCTGGCTGAAGACTACCACCAAGACTATCTCAGGAAGAATCCTTCAGGTTACTGTCATATC
  GATGTGACCGATGCTGATAAGCCATTGATTGATGCAGCAAACTATGAAAAGCCTAGTCAAGAGGTGTTGAAGGCC
  AGTCTATCTGAAGAGTCTTATCGTGTCACACAAGAAGCTGCTACAGAGGCTCCATTTACCAATGCCTATGACCAAA
- 20 CCTTTGAAGAGGGGATTTATGTAGATATTACGACAGGTGAGCCACTCTTTTTTTGCCAAGGATAAGTTTGCTTCAGGT
  TGTGGTTGGCCAAGTTTTAGCCGTCCGATTTCCAAAGAGTTGATTCATTATTACAAGGATCTGAGCCATGGAATGG
  AGCGAATTGAAGTTCGTTCTCGTTCAGGCAGTGCTCACTTGGGTCATGTTTTCACAGATGGACCGCGGGAGTTAGG
  CGGCCTCCGTTACTGTATCAATTCTGCTTCTTTACGCTTTGTGGCCAAGGATGAGATGGAAAAAGCAGGATATGGCT
  ATCTATTGCCTTACTTAAACAAATAA
- 25 (SEQ ID NO: 154)

MAEIYLAGGCFWGLEEYFSRISGVLETSVGYANGQVETTNYQLLKETDHAETVQVIYDEKEVSLREILLYYFRVIDPLSIN QQGNDRGRQYRTGIYYQDEADLPAIYTVVQEQERMLGRKIAVEVEQLRHYILAEDYHQDYLRKNPSGYCHIDVTDADK PLIDAANYEKPSQEVLKASLSEESYRVTQEAATEAPFTNAYDQTFEEGIYVDITTGEPLFFAKDKFASGCGWPSFSRPISKE LIHYYKDLSHGMERIEVRSRSGSAHLGHVFTDGPRELGGLRYCINSASLRFVAKDEMEKAGYGYLLPYLNK

30

5

#### ID17 870bp

(SEQ ID NO: 155)

- 40 TGATTTTCTAGCTTACATTCCAAACTATGAATTACGTACTCGCGACAGCCGTAGTGTCTTGCCTAAAAAATTGTCTT
  ATAAGGAAGCTGTTGCTGCAAGTTCTATCGCCAATGTAGCGGTTGCTGCTGCAGGAGACATGTGCTGC
  TGGGCAAGCAATCGAGGGAGACCTCTTCCATGAGCGCTATCGTCAGGACTTTGGTAAGAGAATTTGCGATGATTAAG
  CAAGTGACCAAAGAAAATGGGGCCTATGCAACCTACCTTTCTGGTGCTGGGCCGACAGTTATGGTTCTGGCTTCTC
  ATGACAAGATGCCAACAATTAAGGCAGAATTGGAAAAGCAACCTTTCAAAGGAAAACTGCATGACTTGAGAGTTG
- 45 ATACCCAAGGTGTCCGTGTAGAAGCAAAATAA

(SEQ ID NO: 156)

MKIIVPATSANIGPGFDSVGVAVTKYLQIEVCEERDEWLIEHQIGKWIPHDERNLLLKIALQIVPDLQPRRLKMTSDVPLA RGLGSSSSVIVAGIELANQLGQLNLSDHEKLQLATKIEGHPDNVAPAIYGNLVIASSVEGQVSAIVADFPECDFLAYIPNY ELRTRDSRSVLPKKLSYKEAVAASSIANVAVAALLAGDMVTAGQAIEGDLFHERYRQDLVREFAMIKQVTKENGAYAT YLSGAGPTVMVLASHDKMPTIKAELEKQPFKGKLHDLRVDTQGVRVEAK

# ID20 564bp

55 (SEQ ID NO: 157)

ATGAAATATCACGATTACATCTGGGATTTAGGTGGAACTTTACTGGATAATTATGAAACTTCAACAGCTGCATTTGT
TGAAACATTGGCACTGTATGGTATCACACAAGACCATGACAGTGTCTATCAAGCTTTAAAGGTTTCTACTCCTTTTG
CGATTGAGACATTCGCTCCCAATTTAGAGAATTTTTTAGAAAAGTACAAGGAAAATGAAGCCAGAGAGCTTGAAC
ACCCGATTTTATTTGAAGGAGTTTCTGACCTATTGGAAGACATTTCAAATCAAGGTGGCCGTCATTTTTTTGGTCTCT

- 65 (SEO ID NO: 158)

MKYHDYIWDLGGTLLDNYETSTAAFVETLALYGITQDHDSVYQALKVSTPFAIETFAPNLENFLEKYKENEARELEHPIL FEGVSDLLEDISNOGGRHFLVSHRNDOVLEILEKTSIAAYFTEVVTSSSGFKRKPNPESMLYLREKYQISSGLVIGDRPIDIE AGQAAGLDTHLFTSIVNLRQVLDI

#### 5 ID21 1875bp

15

45

(SEQ ID NO: 159) ATGACAGAAGAAATCAAAAATCTGCAGGCACAGGATTATGATGCCAGTCAAATTCAAGTTTTAGAGGGCTTAGAG GCTGTTCGTATGCGTCCAGGGATGTACATTGGATCAACCTCAAAAGAAGGTCTTCACCATCTAGTCTGGGAAATTG 10 ACTGTTGTGGATGATGGGCGTGGTATCCCAGTCGATATTCAGGAAAAAACAGGCCGTCCTGCTGTTGAGACCGTCT TTACAGTCCTTCACGCTGGAGGAAAGTTCGGCGGTGGTGGATACAAGGTTTCAGGTGGTCTTCACGGGGTGGGGTC

GTCAGTAGTTAATGCCCTTTCCACTCAATTAGACGTTCATGTTCACAAAAATGGTAAGATTCATTACCAAGAATACC GTCGTCGTCATGTTGTCGCAGATCTTGAAATAGTTGGAGATACGGATAAAACAGGAACAACTGTTCACTTCACACC CTAAATCGCGGTCTTCAAATTTCAATTACAGATAAGCGCCAAGGTTTGGAACAAACCAAGCATTATCATTATGAAG GTGGGATTGCTAGTTACGTTGAATATATCAACGAGAACAAGGATGTAATCTTTGATACACCAATCTATACAGACGG

TGAGATGGATGATATCACAGTTGAGGTAGCCATGCAGTACACAACTGGTTACCATGAAAATGTCATGAGTTTCGCC AATAATATTCATACCCATGAAGGTGGAACACATGAACAAGGTTTCCGTACAGCCTTGACACGTGTTATCAACGATT 20 ATGCTCGTAAAAATAAGTTACTGAAAGACAATGAAGATAATTTAACAGGGGAAGATGTTCGCGAAGGCTTAACTG CAGTTATCTCAGTTAAACACCCAAATCCACAGTTTGAAGGACAAACCAAGACCAAATTGGGAAATAGCGAAGTGG TCAAGATTACCAATCGCCTCTTCAGTGAAGCTTTCTCCGATTTCCTCATGGAAAATCCACAGATTGCCAAACGTATC

GTAGAAAAAGGAATTTTGGCTGCCAAGGCTCGTGTGGCTGCCAAGCGTGCGCGTGAAGTCACACGTAAAAAATCT GGTTTGGAAATTTCCAACCTTCCAGGGAAACTAGCAGACTGTTCTTCTAATAACCCTGCTGAAACAGAACTCTTCAT 25 CGTCGAAGGAGACTCAGCTGGTGGATCAGCCAAATCTGGTCGTAACCGTGAGTTTCAGGCTATCCTTCCAATTCGC GGTAAGATTTTGAACGTTGAAAAAGCAAGTATGGATAAGATTCTAGCCAACGAAGAAATTCGTAGTCTTTTCACAG CCATGGGAACAGGATTTGGCGCAGAATTTGATGTTTCGAAAGCCCGTTACCAAAAACTCGTTTTGATGACCGATGC CGATGTCGATGGAGCCCACATTCGTACCCTTCTTTTAACCTTGATTTATCGTTATATGAAACCAATCCTAGAAGCTG

GTTATGTTTATATTGCCCAACCACCAATCTATGGTGTCAAGGTTGGAAGCGAGATTAAAGAATATATCCAGCCGGG 30 TGCAGATCAAGAATCAAACTCCAAGAAGCTTTAGCCCGTTATAGTGAAGGTCGTACCAAACCGACTATTCAGCGT TATAAGGGGCTAGGTGAAATGGACGATCATCAGCTGTGGGAAACAACCATGGATCCCGAACATCGCTTGATGGCT AGAGTTTCTGTAGATGATGTGCAGAAGCAGATAAAATCTTTGATATGTTGA

(SEQ ID NO: 160)

35 MTEEIKNLQAQDYDASQIQVLEGLEAVRMRPGMYIGSTSKEGLHHLVWEIVDNSIDEALAGFASHIQVFIEPDDSITVVD DGRGIPVDIQEKTGRPAVETVFTVLHAGGKFGGGGYKVSGGLHGVGSSVVNALSTQLDVHVHKNGKIHYQEYRRGHV VADLEIVGDTDKTGTTVHFTPDPKIFTETTIFDFDKLNKRIQELAFLNRGLQISITDKRQGLEQTKHYHYEGGIASYVEYIN ENKDVIFDTPIYTDGEMDDITVEVAMOYTTGYHENVMSFANNIHTHEGGTHEOGFRTALTRVINDYARKNKLLKDNED NLTGEDVREGLTAVISVKHPNPQFEGQTKTKLGNSEVVKITNRLFSEAFSDFLMENPQIAKRIVEKGILAAKARVAAKRA 40

REVTRKKSGLEISNLPGKLADCSSNNPAETELFIVEGDSAGGSAKSGRNREFQAILPIRGKILNVEKASMDKILANEEIRSL FTAMGTGFGAEFDVSKARYQKLVLMTDADVDGAHIRTLLLTLIYRYMKPILEAGYVYIAQPPIYGVKVGSEIKEYIQPGA DQEIKLQEALARYSEGRTKPTIQRYKGLGEMDDHQLWETTMDPEHRLMARVSVDDVQKQIKSLIC

# ID54 1446bp

ATTGTTAGTTTGTTTTTTATTGTTCTTAATCTTTAAGTACAATATCCTTGCTTTTAGATATCTTAATCTAGTGGTAACT GCGTTAGTCCTACTAGTTGCCTTGGTAGGGCTACTCTTGATTATCTATAAAAAAAGCTGAAAAGTTTACTATTTTTCT 50 GTTGGTGTTCTCTATCCTTGTCAGCTCTGTGTCGCTCTTTGCAGTACAGCAGTTTGTTGGACTGACCAATCGTTTAAA TGCGACTTCTAATTACTCAGAATATTCAATCAGTGTCGCTGTTTTTAGCAGATAGTGAGATCGAAAATGTTACGCAAC TGACGAGTGTGACAGCACCGACTGGGACTAATAATGAAAATATTCAGAAATTACTAGCTGATATCAAGTCAAGTCA GAATACCGATTTGACGGTCAACCAGAGTTCGTCTTACTTGGCAGCTTACAAGAGTTTGATTGCAGGGGAGACTAAG GCCATTGTCCTAAATAGTGTCTTTGAAAACATCATCGAGTCAGAGTATCCAGACTACGCATCGAAGATAAAAAAGA 55 GGAATTGACACCTATGGTCCTATTAGTTCGGTGTCGCGATCAGATGTCAACATCCTGATGACTGTCAATCGAGATA CCAAGAAAATCCTCTTGACCACAACGCCACGTGATGCCTATGTACCAATCGCAGATGGTGGAAATAATCAAAAAG ATAAATTGACTCATGCGGGCATTTATGGAGTTGATTCGTCCATTCACACCTTAGAAAATCTCTATGGAGTGGATATC 60 CAAGAATTTACTGCCCATACGAATGGAAAGTATTACCCTGCAGGCAATGTTCATCTTGATTCAGAACAGGCTCTCG

GTTTTGTTCGTGAGCGCTACTCCCTAGCAGATGGCGATCGTGACCGCGGGCGCCATCAACAAAAGGTGATTGTGGC TATCCTTCAAAAATTAACGTCAACCGAAGTGCTGAAAAATTATAGTACGATCATTAATAGCTTGCAAGATTCTATC CAAACAAATATGCCACTTGAGACCATGATAAATTTGGTCAATGCTCAGTTAGAAAGTGGAGGGAATTATAAAGTA TGGAAATAGATGATAGTAGTTTAGCTGTAGTTAAAGCAGCTATACAGGATGTGATGGAGGGTAGATGA

- YYTPDVLDKLEKKRIPTLNDSRYALIEFSMNTPYRDIHSALSKILMLGITPVIAHIERYDALENNEKRVRELIDMGCYTQV 25 NSSHVLKPKLFGERYKFMKKRAQYFLEQDLVHVIASDMHNLDGRPPHMAEAYDLVTQKYGEAKAQELFIDNPRKIVM DQLI ID58 3990bp 30 (SEO ID NO: 165) TTGATTTATATAATCGCTATCAATATAACAATGCAATCAGGAGGTTTTGCAATGAAAACATGAAAAAACAACAGCGTT TTTCTATTCGTAAATACGCTGTAGGAGCAGCTTCTGTTCTAATTGGATTTGCCTTCCAAGCACAGACTGTTGCAGCC 35 ATCGGACTGAGGAAACACCTAAAGCAGTGCTTCAACCAGAAGCTCCAAAAAACTGTAGAAACAGAAACTCCAGCTA CAGAAGTGGTAACTCCAACTTCTGCTGAAAAAGAAACTGCTAATAAAAAGGCAGAAGAAGCTAGCCCTAAAAAGG AAGAAGCGAAAGAGTTGATTCTAAAGAGTCAAATACAGACAAGACTGACAAGGATAAACCAGCTAAAAAAGAT GAAGCGAAAGCAGAGGCTGACAAACCGGCAACAGAGGCAGGAAAGGAACGTGCTGCAACTGTAAATGAAAAACT 40 AGCGAAAAAGAAATTGTTTCTATTGATGCTGGACGTAAATATTTCTCACCAGAACAGCTCAAGGAAATCATCGAT AAAGCGAAACATTATGGCTACACTGATTTACACCTATTAGTCGGAAATGATGGACTCCGTTTCATGTTGGACGATA TGAGCATCACAGCTAACGGCAAGACCTATGCCAGTGACGATGTCAAACGCGCCATTGAAAAAGGTACAAATGATT ATTACAACGATCCAAACGGCAATCACTTAACAGAAAGTCAAATGACAGATCTGATTAACTATGCCAAAGATAAAG GTATCGGTCTCATTCCGACAGTAAATAGTCCTGGACACATGGATGCGATTCTCAATGCCATGAAAGAATTGGGAAT 45 CCAAAACCCTAACTTTAGCTATTTTGGGAAGAAATCAGCCCGTACTGTCGATCTTGACAACGAACAAGCTGTCGCT TTTACAAAAGCCCTTATCGACAAGTATGCTGCTTATTTCGCGAAAAAGACTGAAATCTTCAACATCGGACTTGATG AATATGCCAATGATGCGACAGATGCTAAAGGTTGGAGTGTGCTTCAAGCTGATAAATACTATCCAAACGAAGGCTA CCAATGGCTTTTAACGACGGTATCTACTACAATAGCGACACAAGCTTTGGTAGTTTTGACAAAGACATCATCGTTTC 50 TATGTGGACTGGTGGTTGGGGAGGCTACGATGTCGCTTCTTCTAAACTACTAGCTGAAAAAAGGTCACCAAATCCTT AATACCAATGATGCTTGGTACTACGTTCTTGGACGAAACGCTGATGGCCAAGGCTGGTACAATCTCGATCAGGGGC TCAATGGTATTAAAAACACACCAATCACTTCTGTACCAAAAACAGAAGGAGCTGATATCCCAATCATCGGTGGTAT GGTAGCTGCTTGGGCTGACACTCCATCTGCACGTTATTCACCATCACGCCTCTTCAAACTCATGCGTCATTTTGCAA 55 ACCGTTATACTGCAGAAAGCGTCACGGCCGTAAAAGAAGCTGAAAAAGCTATTCGCTCTCTCGATAGCAACCTTAG CCGTGCCCAACAAGATACGATTGATCAAGCCATTGCTAAACTTCAAGAAACTGTCAACAACTTGACCCTCACGCCT GAAGCTCAAAAAGAAGAAGAAGCTAAACGTGAGGTTGAAAAACTTGCCAAAAACAAGGTAATCTCAATCGATGCT GGACGCAAATACTTTACTCTGAACCAGCTCAAACGCATCGTAGACAAGGCCAGTGAGCTCGGATATTCTGATGTCC ATCTCCTTCTAGGAAATGACGGACTTCGCTTTCTACTCGATGATATGACCATTACTGCCAACGGAAAAACCTATGCT 60 AGTGATGACGTTAAAAAAGCTATTATCGAAGGAACTAAAGCTTACTACGACGATCCAAACGGTACTGCACTAACA CAGGCAGAAGTAACAGAGCTAATTGAATACGCTAAATCTAAGGACATCGGTCTCATCCCAGCTATTAACAGTCCAG GTCACATGGATGCTATGCTGGTTGCCATGGAAAAATTAGGTATTAAAAAATCCTCAAGCCCACTTTGATAAAGTTTC AAAAACAACTATGGACTTGAAAAACGAAGAAGCGATGAACTTTGTAAAAGCCCTCATCGGTAAATACATGGACTT CTTTGCAGGTAAAACAAAGATTTTCAACTTTGGTACTGACGAATACGCCAACGATGCGACTAGTGCCCAAGGCTGG 65 TACTACCTCAAGTGGTATCAACTCTATGGCAAATTTGCCGAATATGCCAACACCCTCGCAGCTATGGCCAAAGAAA GAGGGCTTCAACCAATGGCCTTCAACGATGGCTTCTACTATGAAGACAAGGACGATGTTCAGTTTGACAAAGATGT
- (SEQ ID NO: 164) MIDIHSHIVFDVDDGPKSREESKALLAESYROGVRTIVSTSHRRKGMFETPEEKIAENFLOVREIAKEVASDLVIAYGAEI
- AGTCGTTATGCCTTGATAGAGTTTAGTATGAACACTCCTTATCGCGATATTCATAGCGCCTTGAGCAAGATCTTGAT GTTGGGAATTACTCCAGTCATTGCCCACATTGAGCGCTATGATGCTCTTGAAAATAATGAAAAACGCGTTCGAGAA CTGATCGATATGGGCTGTTACACGCAAGTAAATAGTTCACATGTCCTCAAACCCAAACTTTTTTGGCGAACGTTATA AATTCATGAAAAAAGGGCTCAGTATTTTTTAGAGCAGGATTTGGTTCATGTCATTGCAAGTGATATGCACAATCT 20 AGACGGTAGACCTCCTCATATGGCAGAAGCATATGACCTTGTTACCCAAAAATACGGAGAAGCGAAGGCTCAGGA ACTITITATAGACAATCCTCGAAAAATTGTAATGGATCAACTAATITAG
- TGGCAGAATCCTACAGACAGGGGGTGCGAACCATTGTTTCTACCTCTCACCGTCGCAAGGGCATGTTTGAAACTCC GGAAGAGAAGATAGCAGAAAACTTTCTTCAGGTTCGGGAAATAGCTAAGGAAGTGGCGAGTGACTTGGTCATTGC 15 TTACGGGGCTGAAATTTATTACACACCAGATGTTCTGGATAAGCTGGAAAAAAAGCGGATTCCGACCCTCAATGAT
- ID55 732bp 10

(SEQ ID NO: 163)

(SEQ ID NO: 162) MSRRFKKSRSQKVKRSVNIVLLTIYLLLVCFLLFLIFKYNILAFRYLNLVVTALVLLVALVGLLLIIYKKAEKFTIFLLVFSI LVSSVSLFAVOOFVGLTNRLNATSNYSEYSISVAVLADSEIENVTOLTSVTAPTGTNNENIOKLLADIKSSONTDLTVNOS SSYLAAYKSLIAGETKAIVLNSVFENIIESEYPDYASKIKKIYTKGFTKKVEAPKTSKSQSFNIYVSGIDTYGPISSVSRSDV 5 NILMTVNRDTKKILLTTTPRDAYVPIADGGNNQKDKLTHAGIYGVDSSIHTLENLYGVDINYYVRLNFTSFLKLIDLLGGI DVYNDQEFTAHTNGKYYPAGNVHLDSEOALGFVRERYSLADGDRDRGRHQQKVIVAILQKLTSTEVLKNYSTIINSLQD SIQTNMPLETMINLVNAQLESGGNYKVNSQDLKGTGRMDLPSYAMPDSNLYVMEIDDSSLAVVKAAIQDVMEGR

AAATTCTTGAATACCAACGGTGACTGGTACTACATTCTTGGTCAAAAACCAGAAGATGGTGGTGGTTTCCTCAAGA AAGCTATTGAGAATACTGGAAAAACACCATTCAATCAACTAGCTTCTACCAAATATCCTGAAGTAGATCTTCCAAC AGTCGGAAGTATGCTTTCAATCTGGGCAGATAGACCAAGCGCTGAATACAAGGAAGAGGAAATCTTTGAACTCAT 5 GACTGCCTTTGCAGACCACAACAAGACTACTTTCGTGCTAATTATAATGCTCTCCGCGAAGAATTAGCTAAAATT CCTACAAACTTAGAAGGATATAGTAAAGAAAGTCTTGAGGCCCTTGACGCAGCTAAAACAGCTCTAAATTACAACC TCAACCGTAATAAACAAGCTGAGCTTGACACGCTTGTAGCCAACCTAAAAGCCGCTCTTCAAGGCCTCAAACCAGC TGTAACTCATTCAGGAAGCCTAGATGAAAATGAAGTGGCTGCCAATGTTGAAACCAGACCAGAACTCATCACAAG AACTGAAGAAATTCCATTTGAAGTTATCAAGAAAGAAAATCCTAACCTCCCAGCCGGTCAGGAAAATATTATCACA 10 GCAGGAGTCAAAGGTGAACGAACTCATTACATCTCTGTACTCACTGAAAAATGGAAAAACAACAGAAACAGTCCTT GATAGCCAGGTAACCAAAGAAGTTATAAACCAAGTGGTTGAAGTTGGCGCTCCTGTAACTCACAAGGGTGATGAA AGTGGTCTTGCACCAACTACTGAGGTAAAACCTAGACTGGATATCCAAGAAGAAGAAAATTCCATTTACCACAGTGA CTTGTGAAAATCCACTCTTACTCAAAGGAAAAACACAAGTCATTACTAAGGGCGTCAATGGACATCGTAGCAACTT CTACTCTGTGAGCACTTCTGCCGATGGTAAGGAAGTGAAAACACTTGTAAATAGTGTCGTAGCACAGGAAGCCGTT 15 ACTCAAATAGTCGAAGTCGGAACTATGGTAACACATGTAGGCGATGAAAACGGACAAGCCGCTATTGCTGAAGAA AAACCAAAACTAGAAATCCCAAGCCAACCAGCTCCATCAACTGCTCCTGCTGAGGAAAGCAAAGTTCTTCCTCAAG ATCCAGCTCCTGTGGTAACAGAGAAAAACTTCCTGAAACAGGAACTCACGATTCTGCAGGACTAGTAGTCGCAG GACTCATGTCCACACTAGCAGCCTATGGACTCACTAAAAGAAAAGAAGACTAA

20 (SEO ID NO: 166) MIYIIAINITMQSGGFAMKHEKQQRFSIRKYAVGAASVLIGFAFQAQTVAADGVTPTTTENQPTIHTVSDSPQSSENRTEE TPKAVLQPEAPKTVETETPATDKVASLPKTEEKPQEEVSSTPSDKAEVVTPTSAEKETANKKAEEASPKKEEAKEVDSKE SNTDKTDKDKPAKKDEAKAEADKPATEAGKERAATVNEKLAKKKIVSIDAGRKYFSPEOLKEIIDKAKHYGYTDLHLL VGNDGLRFMLDDMSITANGKTYASDDVKRAIEKGTNDYYNDPNGNHLTESQMTDLINYAKDKGIGLIPTVNSPGHMDA 25 ILNAMKELGIQNPNFSYFGKKSARTVDLDNEQAVAFTKALIDKYAAYFAKKTEIFNIGLDEYANDATDAKGWSVLQAD KYYPNEGYPVKGYEKFIAYANDLARIVKSHGLKPMAFNDGIYYNSDTSFGSFDKDIIVSMWTGGWGGYDVASSKLLAE KGHOILNTNDAWYYVLGRNADGQGWYNLDQGLNGIKNTPITSVPKTEGADIPIIGGMVAAWADTPSARYSPSRLFKLM RHFANANAEYFAADYESAEQALNEVPKDLNRYTAESVTAVKEAEKAIRSLDSNLSRAQQDTIDQAIAKLQETVNNLTLT PEAQKEEEAKREVEKLAKNKVISIDAGRKYFTLNQLKRIVDKASELGYSDVHLLLGNDGLRFLLDDMTITANGKTYASD 30 DVKKAIIEGTKAYYDDPNGTALTQAEVTELIEYAKSKDIGLIPAINSPGHMDAMLVAMEKLGIKNPQAHFDKVSKTTMD LKNEEAMNFVKALIGKYMDFFAGKTKIFNFGTDEYANDATSAQGWYYLKWYQLYGKFAEYANTLAAMAKERGLOPM AFNDGFYYEDKDDVQFDKDVLISYWSKGWWGYNLASPQYLASKGYKFLNTNGDWYYILGQKPEDGGGFLKKAIENT GKTPFNQLASTKYPEVDLPTVGSMLSIWADRPSAEYKEEEIFELMTAFADHNKDYFRANYNALREELAKIPTNLEGYSK ESLEALDAAKTALNYNLNRNKQAELDTLVANLKAALOGLKPAVTHSGSLDENEVAANVETRPELITRTEEIPFEVIKKEN PNLPAGQENIITAGVKGERTHYISVLTENGKTTETVLDSQVTKEVINQVVEVGAPVTHKGDESGLAPTTEVKPRLDIQEE EIPFTTVTCENPLLLKGKTQVITKGVNGHRSNFYSVSTSADGKEVKTLVNSVVAQEAVTQIVEVGTMVTHVGDENGQA 35 AIAEEKPKLEIPSQPAPSTAPAEESKVLPQDPAPVVTEKKLPETGTHDSAGLVVAGLMSTLAAYGLTKRKED

# ID122 825bp

40

45

50

65

(SEO ID NO: 167)

(SEO ID NO: 168)

55 MNKKTRQTLIGLLVLLLLSTGSYYIKQMPSAPNSPKTNLSQKKQASEAPSQALAESVLTDAVKSQIKGSLEWNGSGAFIV NGNKTNLDAKVSSKPYADNKTKTVGKETVPTVANALLSKATRQYKNRKETGNGSTSWTPPGWHQVKNLKGSYTHAV DRGHLLGYALIGGLDGFDASTSNPKNIAVQTAWANQAQAEYSTGQNYYESKVRKALDQNKRVRYRVTLYYASNEDLV PSASQIEAKSSDGELEFNVLVPNVQKGLQLDYRTGEVTVTQ

# 60 <u>ID123 225bp</u>

(SEQ ID NO: 169)

GTGCTAAGATTCAGCGGATTGAGGCAAGTGATGAAGATGAATAAGAAATCAAGCTACGTAGTCAAGCGTTTACTTT
TAGTCATCATAGTACTGATTTTAGGTACTCTGGCTCTAGGAATCGGTTTAATGGTAGGTTATGGAATCTTGGGCAAG
GGTCAAGATCCATGGGCTATCCTGTCTCCAGCAAAATGGCAGGAATTGATTCATAAATTTACAGGAAATTAG

(SEQ ID NO: 170) VLRFSGLRQVMKMNKKSSYVVKRLLLVIIVLILGTLALGIGLMVGYGILGKGQDPWAILSPAKWQELIHKFTGN